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Pressure ulcers (PUs) are serious secondary complications occurring in individuals with spinal 
cord injury (SCI). PUs not only decrease quality of life, but can adversely affect physical, 
psychological, emotional and financial status. Although studies have investigated general risk 
factors for PUs, few have focused on the time period immediately following SCI when the 
inflammation associated with SCI may influence the body’s ability to tolerate secondary tissue 
damage leading to occurrence of PUs. Biomarkers obtained from plasma and urine biofluids are 
commonly used to characterize inflammation. 
The Rehabilitation Engineering Research Center on SCI (RERC on SCI) recruited 
individuals with new traumatic SCI (TSCI). Data were collected at predetermined time points in 
acute care, inpatient rehabilitation and after discharge on the risk factors and incidence of PUs, 
and on plasma and urine inflammatory mediators. A secondary analysis was performed on data 
obtained from the 104 individuals with TSCI. 
The purpose of this study was to investigate the association of clinical, demographic and 
inflammatory factors with the formation of PUs following TSCI during acute care hospitalization 
and inpatient rehabilitation. Severity of SCI (ASIA A) and presence of pneumonia were 
determined to predict PU incidence. Plasma concentrations of IL-1RA, GM-CSF, MIP-1α, IFN- 
γ, IL-5, IL-17, MIG and MIP-1β; and urine concentrations of IL-6, IL-8, IL-13, IP-10, MCP-1, 
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IFN-γ, IL-5, IL-17, MIG and TNF-α were associated with formation of PU, immediately after 
SCI. An increase in the plasma concentrations of IP-10 and a decrease in the urine concentrations 
of IFN-α were observed just before formation of the first PU. A significant association between 
presence of pneumonia and formation of PU was observed as compared to no pneumonia. This 
association between PU and pneumonia could be linked through inflammation. Increased plasma 
synthesis of IFN-α and urine synthesis of IL-1RA were associated with formation of PU in 
individuals with pneumonia.  
The findings of this study suggest that an imbalance in the inflammatory response after 
SCI may be associated with formation of PUs. The findings also suggest an association between 
the presence of pneumonia and formation of PU, which could be linked through inflammation.  
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1.0  INTRODUCTION 
Pressure ulcers (PUs) are the most frequent secondary complication in individuals with spinal 
cord injury (SCI) that affects their quality of life, length of stay during hospitalization and 
increases the mortality and morbidity [1]. Although numerous risk factors are associated with the 
occurrence of PUs, there is limited evidence for the increased incidence of PUs and factors 
associated with the same in individuals with newly traumatic SCI during hospitalization. In 
addition, an acute inflammatory response by the immune system is inherent after traumatic SCI 
due to increased synthesis of inflammatory factors that spills into the systemic circulation. The 
effects of this response can be both beneficial and detrimental [2]. Studies also report an increase 
in the inflammatory biomarkers in individuals with SCI having comorbidities such as pneumonia 
[3], urinary tract infections (UTIs) [4] and PUs [4, 5]. The complex cascade of secondary 
complications after traumatic SCI can be attributed to this intrinsic inflammatory response after 
SCI. Thus, identifying the clinical and inflammatory factors associated with the development of 
PUs in this population during acute care hospitalization and inpatient rehabilitation may help 
prevent this secondary complication and may reduce the risk of rehospitalization and improve 
the quality of life.  
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1.1 OBJECTIVE AND SPECIFIC AIMS 
The objective of this study was to identify the clinical factors and inflammatory biomarkers that 
are associated with the risk of developing pressure ulcers during acute care and inpatient 
rehabilitation. The specific aims of this dissertation were:  
1. To identify the clinical and demographic risk factors that predict the formation of PUs in 
individuals with traumatic SCI; 
2. To identify the inflammatory mediators in plasma and urine immediately after traumatic 
SCI that may predict future PU incidence; 
3. To identify changes in the inflammatory mediators in plasma and urine that can detect 
pressure ulcers just before clinical diagnosis in individuals with traumatic SCI; and  
4. (A) To investigate an association between presence of pneumonia and PU incidence in 
individuals with traumatic SCI in the Rehabilitation Engineering Research Center on SCI 
(RERC on SCI) and Spinal Cord Injury Model Systems (SCIMS) database; and 
(B) To identify a change in the inflammatory mediators in urine and plasma before and 
after occurrence of pneumonia; that predict formation of PUs in subjects having 
pneumonia preceding or coinciding with PU as compared to subjects having pneumonia 
who do not develop PU.    
1.1.1 Hypothesis and Rationale for Specific Aim 1 
Despite a large amount of evidence recommending preventive strategies, pressure ulcers remain 
the most common secondary complication in individuals with SCI that increases the risk of 
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rehospitalization [6, 7]. The extrinsic environment plays an important role in the development of 
PUs. A majority of studies focus on the risk factors associated with the development of PUs in 
community care in individuals with SCI [8-15], however only a few address the risk factors 
during hospitalization or acute care [16].  Hence, identifying the predictors for development of 
PUs in high-risk settings (e.g., during hospitalization) is essential. Most studies on risk factors 
associated with PUs used self-report or retrospective chart review methods [8, 10]. This may 
result in underreporting of the data due to recall bias or insufficient data. Those who are likely to 
develop PUs are individuals who have SCI of traumatic origin [17], males [18], have a history of 
smoking, alcohol or drug use [10], have medical comorbidities such as diabetes mellitus [19, 20], 
decreased oxygenation or hypotension [16], infections such as pneumonia, urinary tract 
infections, osteomyelitis, and other bacterial infections[8, 21], those on mechanical ventilators 
[22] and use of steroids [16]. The current study is a prospective longitudinal cohort and focused 
on identifying the clinical and demographic risk factors associated with the occurrence of PUs in 
individuals with traumatic SCI during the time of initial hospitalization- acute care and inpatient 
rehabilitation.  
Hypothesis 1: Pneumonia, urinary tract infection, use of steroids, gender, age, and ASIA 
score will indicate increased risk for the formation of PUs in individuals with traumatic SCI. 
1.1.2 Hypothesis and Rationale for Specific Aim 2 
Activation of an inflammatory response by the immune system is inherent after traumatic SCI 
(TSCI). After the initial SCI; damage to the axonal and neuronal cells is followed by a complex 
secondary cascade of events [4, 23, 24]. The disruption of the blood spinal cord barrier (BSCB) 
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after SCI increases the synthesis of the pro-inflammatory and anti-inflammatory cytokines and 
other inflammatory mediators. This disrupted BSCB further increases the passage of these 
inflammatory markers into the circulation. The inflammatory response after SCI can be 
detrimental and predispose the individuals to secondary complications and tissue damage [25, 
26]; on the other hand, inflammatory response after SCI also helps reduce injury by activating 
the process of wound healing, thus initiating repair [27]. Hence, inflammation after SCI is 
described as a “double-edged sword”, and early inflammatory response may be detrimental 
whereas the late inflammatory response is likely beneficial [2]. Inflammatory response may be 
beneficial by maintaining finely tuned balance between the pro-inflammatory and the anti-
inflammatory mediators [28]. Pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α increase 
immediately after injury until 5 hours post injury [29]. The inflammatory response can be 
explained by the early expression of the pro-inflammatory mediators from 24 hours until 4 days 
after injury [30]. The synthesis of pro-inflammatory cytokines such as TNF-α increased after 
subjecting mice to SCI in the lumbar region due to the disruption of the BSCB [24]. Increased 
serum concentrations of pro-inflammatory cytokines such as TNF-α, IL-2, and IL-1RA were 
found in individuals with SCI as compared to able-bodied individuals [4]. The synthesis of anti-
inflammatory cytokines such as IL-10 suppresses the microglial activity and helps to decrease 
inflammation after SCI [27]. Hence, the purpose of this aim was to identify the inflammatory 
mediators in urine and plasma immediately (within four days) following SCI associated with 
subsequent risk for formation of PUs during acute care and inpatient rehabilitation. 
Hypothesis 2(a): Levels of TNF-α, IL-1β, IL-2, IL-6, IL-10 and IL-1RA measured within 
four days after traumatic SCI will indicate increased risk for formation of PUs.  
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Hypothesis 2(b): Inflammatory markers in urine that predict occurrence of PUs will be 
similar to those in plasma.   
1.1.3 Hypotheses and Rationale for Specific Aim 3  
In vitro studies have shown increased synthesis and proliferation of inflammatory cytokines such 
as IL-1, IL-6, IL-8, GM-CSF and TNF-α after loading the tissue before the tissue damage is 
barely visible [31]. Hence, the tissue damage due to inflammation can be termed as a sub-clinical 
disease that is not visible on the skin. Increase in the plasma concentrations of pro-inflammatory 
mediators such as interleukin 2 receptor (IL-2R), and intercellular adhesion molecule 1 (ICAM-
1) were noted in individuals with SCI having PUs or slow healing PUs as compared to able-
bodied subjects or subjects with SCI having no PUs [32]. Pro-inflammatory cytokines and 
chemokines such as IL-8, IL-1β and TNF-α are increased in subjects having slow healing or 
Stage III and IV PUs when compared to able-bodied individuals or individuals with healing 
ulcers [5, 33].  Clinically it is not known why certain individuals with SCI develop PUs and 
some do not despite having similar risk factors that predispose them to develop PU. However, 
this could be attributed to the differences in the intrinsic inflammatory state in the individual, 
since evidence supports an increase in serum concentrations of pro-inflammatory cytokines in 
individuals with PUs, [34]. A multidisciplinary expert panel sponsored by SCI Quality 
Enhancement Research Initiative (SCI QUERI) identified “research on biomarkers” for the 
development of PUs in individuals with SCI as “highest priority risk factor research” [34]. There 
are only a few objective tools to measure the risk assessment for PUs and studies have shown 
that there is an increase in the concentration of these serum biomarkers during skeletal muscle 
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damage in response to a deep tissue injury (DTI) induced by pressure on a chronic SCI rat model 
[35]. Also, serum protein alterations were found in subjects with PUs that were not specific for 
individuals with SCI. These alterations also tend to disappear with the healing of the PU [36].  It 
is therefore essential to identify the inflammatory biomarkers that may alter before the tissue 
damage is visible. This can aid in earlier diagnosis and treatment measures for PUs. The intrinsic 
risk factors can be identified by analyzing the plasma and urine levels of these inflammatory 
mediators just before the individuals develop PUs. Hence, aim of this study was to identify the 
inflammatory mediators in plasma and urine, associated with formation of PU, before the PU is 
clinically diagnosed and is in its incipient stage, in individuals with TSCI and PUs, during acute 
care through inpatient rehabilitation.  
Hypothesis 3(a): A change in the level of TNF-α, IL-1β, IL-8, IL-6 and GM-CSF 
measured immediately after SCI and just before clinical diagnosis of PU will indicate increased 
risk for the formation of PUs.  
Hypothesis 3(b): Inflammatory markers in urine that predict imminent occurrence of PUs 
will be similar to those in plasma.   
1.1.4 Hypotheses and Rationale for Specific Aim 4(A) 
Approximately 200 risk factors have been associated with the formation of PUs in individuals 
with SCI [8].  As reported by the SCI QUERI panel in 2011, the identification of all risk factors 
in individuals with SCI and implementing corresponding preventive techniques can be 
challenging in the clinical practice. Hence, it is essential to identify dependent and independent 
risk factors associated with development of PUs  in this population [34]. Significant correlations 
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between individuals having PUs and pneumonia (or atelectasis) were observed after 1, 2 and 5 
years of injury in the SCI population [37]. Subjects with high-level traumatic SCI are dependent 
on mechanical ventilation, and report an increase in incidence of pneumonia within days of 
intubation [22]. A preliminary study of 91 subjects from the RERC on SCI database showed that 
the subjects were twice as likely to develop PUs when the ulcer was preceded by or coincided 
with the presence of pneumonia as compared to subjects who did not have pneumonia Hence, the 
presence of pneumonia could indicate possible future pressure ulcer development, in individuals 
with SCI during acute care hospitalization and inpatient rehabilitation [38]. It was worthwhile to 
explore the data of the SCI Model Systems to investigate if this association holds true in a larger 
population. Hence, the first part of this aim investigated the association between the presence of 
pneumonia and occurrence of pressure ulcers in the SCIMS database population. The study was 
intended to confirm the RERC SCI study’s results. 
Hypothesis 4(a):  Individuals having pneumonia will have a higher incidence or presence 
of pressure ulcers than individuals who do not have pneumonia. 
1.1.5 Hypotheses and Rationale for Specific Aim 4(B) 
The synthesis of the inflammatory biomarkers increases in individuals with the presence of PUs 
[5], and also in individuals having respiratory infections such as pneumonia [39].  However, an 
apparent association linked through inflammation has not yet been explored. Presence of 
pneumonia activates an acute inflammatory response to counteract the infection, which when not 
in balance, may result in secondary complications such as PUs (Figure 1). TNF-α is one of the 
early mediators in the inflammatory process and induces activation of pro- and anti-
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inflammatory mediators and is responsible for the protective response in pneumonia. Cytokines 
such as IL-1β, IL-6, and IL-8 were correlated with TNF-α in subjects having pneumonia [40]. 
The inflammatory response in individuals with SCI may be different during the inception of 
pneumonia and days after the onset of pneumonia; as previous studies have shown significant 
impact of time from onset of pneumonia on inflammatory response [40]. Increased 
concentrations of IL-1β and IL-10 were also found to be associated in individuals with 
pneumonia [3, 39]. The differences in the inflammatory response before and after the presence of 
pneumonia may explain the formation of PUs in these individuals. The aim of this study was to 
identify the inflammatory cytokines and chemokines in urine and plasma, before and after the 
presence of pneumonia that will indicate increased risk for formation of PUs in acute care and 
inpatient rehabilitation.  
Hypothesis 4(b):  Differences in inflammatory mediators measured before and after the 
presence of pneumonia of TNF-α, IL-1β, IL-6, IL-8 and IL-10 will indicate increased risk for the 
formation of PUs. 
 
1.2 BACKGROUND 
Every year, more than 2.5 million individuals in the United States develop pressure ulcers (PUs). 
In 2006, the total cost of hospitalization in an adult diagnosed with PUs was around $11.0 
billion. Cost of individual patient care ranges from $20,900 to $151,700 per PU depending upon 
the stage, severity or extent of the PU [41, 42]. Overall prevalence of PUs during hospitalizations 
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from 2006-2011 ranged from 11.2% to 13.8%. Long-term acute care had the highest prevalence 
of PUs (29.2%), acute care setting had an overall prevalence of 10.8% to 13.3% and the acute 
care facility-acquired prevalence of PUs was 4.5% to 6.4%. Rehabilitation facilities showed an 
overall prevalence of 13.3% to 19.4% and facility-acquired prevalence of 3.7% to 6.6% from the 
years 2006 to 2011 [43]. In hospitals, the mortality rate in individuals with PUs as a secondary 
diagnosis was five times higher than individuals with no PUs [42]. 
Spinal Cord Injury (SCI) is a devastating neurologic disorder and has profound impact on 
physical, psychological and socioeconomic status [44]. Increase in age and severity of injury are 
associated with rise in long-term complications after traumatic SCI. Pneumonia accounts for 
approximately 67% of respiratory complications, and is the most frequent secondary 
complication causing mortality and morbidity in individuals with SCI [45]. Respiratory condition 
accounts for 50% of mortality rate during the first year post SCI [46, 47].The second leading 
cause of death in individuals with SCI is septicemia (88.6%); usually associated with urinary 
tract infections (UTI’s), pneumonia, and presence of PUs [45]. 
1.2.1 Pressure Ulcers in Individuals with Spinal Cord Injury 
Individuals with SCI are at a great risk for the formation of PUs from the time of acute 
hospitalization throughout their life [7, 12]. PUs are the most frequent secondary complication 
occurring after SCI that decrease the quality of life and life expectancy of these individuals [48]. 
They also increase the length of stay, cases of re-hospitalization, and admission to long-term care 
[49]. Studies indicate that around 47% of individuals with SCI develop at least one PU during 
the period of acute care hospitalization and rehabilitation [50]. The prevalence of PUs following 
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TSCI increases after every annual follow-up [37]. The 2011 annual statistical report for the 
Spinal Cord Injury Model Systems (SCIMS) reported PUs to be the second most frequent 
complication and third leading cause of death following SCI. Around 34% of individuals with 
SCI develop PUs in acute care or rehabilitation. The report also indicated that 53.4% of subjects 
with neurologically complete tetraplegia develop PUs [45]. The prevalence rate of PUs in 
veterans with SCI was reported to be 39% during a period of 3 years [13].   
1.2.2 Risk Factors for Pressure Ulcers 
There are several risk factors that contribute to the formation of PUs. Individuals with SCI with 
traumatic origin have higher occurrence of PUs when compared to other etiologies [37]. Males 
and subjects with complete tetraplegics are at a higher risk to develop PUs than females and 
complete paraplegics [18]. Smoking, alcohol or drug use, were also reported to be associated 
with presence of PUs. [10].  
 Numerous intrinsic and extrinsic characteristics were related to the risk for developing a 
PU. Moisture and/or urinary, fecal incontinence and type of bowel management [8, 16], 
temperature (hypo/hyperthermia), friction, shear, are some of the extrinsic risk factors associated 
with the formation of PUs in individuals with SCI during acute care and intensive care unit 
(ICU) [19, 51-55]. Decreased nutrition or low serum albumin levels, decreased mobility and 
sensation, medical comorbidities such as diabetes mellitus, cardiac, pulmonary, renal disease and 
impaired cognitive function contribute towards the intrinsic risk factors for the development of 
PUs in individuals with SCI [19, 20].  A retrospective study in a surgical intensive care unit 
(ICU), reported 9.6% individuals with SCI developed PUs. Hypotension and decreased 
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oxygenation were found to be the primary risk factors for the development of PUs. Additionally 
medications such as use of steroids were also associated with the development of PU. [16].  
Infections such as septicemia, pneumonia, urinary tract infections (UTIs), osteomyelitis, 
and bacterial or any other skin infection were found to increase the risk of development of 
pressure ulcers. [8, 21]. Of the other clinical risk factors for development of PUs after SCI, 
strong evidence was reported for individuals with pneumonia and deep vein thrombosis (DVT) 
[11]. Three cohort studies found pneumonia as a significant risk factor for the formation of PUs 
in individuals with SCI [15, 19, 37].  Pneumonia was the only medical complication that was a 
predictor for occurrence of PUs during primary inpatient rehabilitation in individuals with SCI, 
and the other predictors that were significant were completeness of injury, mobility status and 
previous PU [56]. The individuals on mechanical ventilation are at a risk of developing PUs, and 
the risk increases with length of time of using mechanical ventilation.  A study reported an 
incidence of 13.4% for occurrence of PUs, in individuals on mechanical ventilators [22].  
1.2.3 Pneumonia in Individuals with Spinal Cord Injury 
Pneumonia is an inflammatory condition of the lung, specifically inflammation of the alveoli 
(microscopic air sacs in the lungs). Although there are many causes of pneumonia, infection is 
the most common etiology. The infecting agents can be bacteria, viruses, fungi, or parasites [57, 
58]. Pneumonia is the most frequent respiratory complication (66.9% cases) that occurs weeks 
after the SCI [45, 59, 60]. Around 30% of individuals with SCI develop pneumonia during the 
time of hospitalization [50]. Of all the secondary conditions following SCI, pneumonia is one of 
the most frequent causes of death [46, 47].  
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The diaphragm is the main inspiratory muscle of respiration and is supplied by the 
phrenic nerve that originates from third and extends to fifth cervical nerve (C3-C5). The muscles 
of respiration such as the diaphragm, abdominals and intercostal are affected with progressively 
higher level of SCIs, resulting in a higher incidence of pneumonia in individuals with tetraplegia 
than paraplegia [61]. Individuals with complete tetraplegia have altered lung volumes and 
ineffective cough, and present with a restrictive ventilatory pattern. The alteration in lung 
volumes decreases the lung compliance and increases the cost of energy, predisposing the 
individual to respiratory fatigue. Therefore, higher-level SCIs (tetraplegics at C3-C5) may 
produce complete respiratory paralysis [7, 37, 59, 62].  
Overall 5% to 20% of individuals with SCI develop pneumonia during initial 
rehabilitation. Pneumonia was found to be associated with atelectasis in these subjects that alters 
the pattern of respiration. Studies have shown that prior anesthesia increases the risk of 
developing pneumonia [61]. Studies also indicated that the incidence of pneumonia increases 
within days of intubation for individuals who are on mechanical ventilation [63]. Hence, 
critically ill subjects on prolonged mechanical ventilation are predisposed to ventilator-
associated pneumonia. These subjects who are on mechanical ventilators in either supine or semi 
recumbent positions also had incidence of PUs in the heel and sacral regions [63, 64].  
1.2.4 Inflammation 
Inflammation involves a complex process of cellular activation resulting in release of pro-
inflammatory mediators such as cytokines, activation of neutrophils, monocytes and 
microvascular endothelial cells, involvement of neuroendocrine reflexes, and activation of the 
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complement, coagulation, and fibrinolytic system [65].  Inflammation is a necessary process by 
which the body restores its baseline function after tissue insult like trauma or sepsis, at the same 
time it can be destructive to otherwise healthy tissue resulting in tissue injury and further 
stimulating inflammatory response. Thus, finely tuned balance between pro-inflammatory and 
anti-inflammatory cytokines is necessary for the host [28] (Figure 1). 
 
 
Figure 1. Inflammatory response post trauma (Source: Vodovotz, 2012) 
    Cytokines and Chemokines 1.2.4.1
The human immune system is complex and a large array of pro and anti-inflammatory cytokines 
are produced at the time of inflammation. The balance and the net interaction effect between 
these cytokines determine the nature of this immune response. [28]. The human body is capable 
of producing innate immune response, which is a pre-programmed activity independent of the 
antibodies produced by the body. This innate response acts as the first line of defense during 
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trauma or infection. The adaptive immune response usually acts or follows after the innate 
immune response [66].  
    Pro-Inflammatory Cytokines and Chemokines 1.2.4.2
Pro-inflammatory cytokines are important in maintaining both acquired and innate immunity and 
are released in response to stress or trauma. At the time of injury the outcome of the 
inflammatory response depends upon the extent and duration of these cytokines released. The 
interleukin-1 (IL)-1, IL-2, IL-6, tumor necrosis factor-α (TNF- α), and interferon gamma (IFN-γ) 
are included in the family of these cytokines. The interferons are mainly concerned with innate 
and acquired immunity. The pro-inflammatory cytokines, TNF-α, IL-1, IL-6, IL-12, IL-15, IL-18 
and chemokines such as IL-8, monocyte chemotactic protein-1 (MCP-1), and interferons, are 
produced by local and circulating macrophages. In response to injury the lymphocytes and 
macrophages are activated at the site of injury to reduce the excess inflammation and decrease 
the damage cells. Too little or not enough response (maladaptive response) delays the healing 
process. Thus, inflammation is the process by which body tries to restore hemostasis following 
an insult [67]. On the other hand, excess activation of these cells can lead to tissue destruction 
[2].   
    Anti-Inflammatory Cytokines and Chemokines 1.2.4.3
The anti-inflammatory cytokines or the cytokine inhibitors such as IL-10 and IL-1RA are one of 
the most important mediators of this immune system. These cytokines limit the deleterious 
effects of excessive inflammation caused by the pro-inflammatory mediators after an injury. 
Studies report that therapeutic administrations of the anti-inflammatory cytokines are known to 
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have clinical benefits [28].  During a traumatic event the synthesis of the anti-inflammatory 
cytokines may be beneficial as they help combat the excessive effects of the pro-inflammatory 
mediators, thus reducing the pathology.  On the other hand, excessive synthesis of these anti-
inflammatory cytokines can over compensate the state of pathology, leading to systemic damage. 
The anti-inflammatory cytokines such as IL-6 sometimes have properties of pro-inflammatory 
cytokines depending upon the timing they are released and the sensitivity of the tissue that 
responds. [28, 68].  
    Inflammatory response to trauma 1.2.4.4
Traumatic injury induces an early inflammatory immune response that further releases pro-
inflammatory cytokines such as IL-1, IL-2, IL-6, and TNF-α, predisposing the body to infection 
and increased mortality. The release of these cytokines depends upon the severity of the 
traumatic injury. It was initially believed that with initial pro-inflammatory response there is 
release of compensatory anti-inflammatory cytokines. At present, research suggests that there is 
rapid and simultaneous alterations in the pro-inflammatory and anti-inflammatory mediators 
after trauma [69]. Anti-inflammatory responses help attenuate the infection and induce healing 
and, when excessive, may lead to immunosuppression further aggravating the infection injury 
and increased mortality. Immediately following trauma, the inflammatory response starts locally. 
Gradual increase in inflammation may spill the inflammatory mediators into the systemic 
circulation, causing multiple organ damage including soft tissue injuries (Figure 2) [70]. 
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Figure 2. Inflammatory response post trauma (Moore, 1995) 
 
    Inflammation in Individuals with Spinal Cord Injury 1.2.4.5
In individuals who sustain traumatic SCI, production of cytokines and chemokines results in 
developing a robust inflammatory response that is characterized by neutrophil infiltration (being 
the first inflammatory cells to arrive) at the site of injury followed by macrophages [23]. The 
resident macrophages also known as resting microglia are diffusely spread in the central nervous 
system (CNS). These macrophages that are activated post-SCI, results in secretion of cytotoxic 
substances and pro-inflammatory mediators such as TNF-α, IL-1, IL-6, nitric oxide, reactive free 
radicles and oxygen free radicals. Post-traumatic SCI, inflammatory response further leads to 
deterioration in the functional outcome and predisposes the host to secondary complications such 
as tissue damage and other infections [25, 26]. These cytotoxic substances can lead to destruction 
resulting in secondary complications or production of growth factors essential for tissue repair. 
The anti-inflammatory mediators such as the IL-10 suppress most of the microglial activity. The 
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beneficial role of this inflammatory process can be attributed to the dual nature of the post 
inflammatory process [27].  
Most of the cytokines such as IL-1α, IL-1β, IL-1ra, IL-6, and TNF-α pass freely through 
the blood brain barrier (BBB). Traumatic SCI elicits up-regulation of this transport due to the 
disruption of the blood-spinal cord barrier (BSCB). Studies have shown that the secondary 
complications and infections after SCI can be associated with the increase in the serum 
concentrations of mediators such as TNF-α and IL-2 [4, 24]. The pro-inflammatory mediators 
such as IL-1β, IL-6, TNF-α increase immediately after injury until 5 hours post injury, and from 
the second day post injury the expression of these cytokines declines to baseline [29]. Previous 
studies showed that the pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α and circulating 
levels of antibodies and immunoglobulins such as IgG and IgM were increased in individuals 
with SCI and were further increased in this population with complications such as UTIs and PUs 
as compared to able bodied subjects [4]. This suggests an increase in the active inflammatory 
process in individuals with SCI and other medical complications such as PUs and UTI’s.  
    Inflammation in Individuals with Pressure Ulcers 1.2.4.6
Increase in the local inflammatory process at the PU site is observed in individuals with PUs. 
Keratinocytes present in the epidermis play an important role in the immune system. Upon 
mechanical skin injury in vitro via a loading device these keratinocytes lead to increase in 
production of pro-inflammatory cytokines such as IL-1 and granulocyte macrophage stimulating 
factor (GM-CSF). The IL-1 further produces the production of other cytokines and chemokines 
such TNF-α, IL-6, IL-8 [71]. Elevated levels of IL-8 were found in the tissue biopsies of the 
slow healing wounds as compared to healed wounds or skin and suggested that IL-8 retards 
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keratinocyte replication and thus delays the process of wound healing [33].  Moreover increase 
in pro-inflammatory cytokines such as TNF-α and IL-1β have been observed in stage III and IV 
PUs. [5]. These pro-inflammatory cytokines were increased in response to low mechanical 
loading when the tissue damage is barely visible. There was a threefold increase in these 
cytokines in vitro after a short loading with high pressure [31]. In addition, an in vivo study 
indicated morphological signs of inflammation in stage I PUs. [72]. Hence, these inflammatory 
markers can play an important role in the early detection of occurrence of PUs. 
The cytokines such as IL-1α, IL-1ra and IL-8 were found to be significantly increased 
after 1 hour of mechanical loading of tissue-engineered epidermal equivalents (in vitro), whereas 
TNF-α was reported to be released after 4 hours of epidermal loading and remains constant for 
16 hours of loading as compared to the unloaded group. These pro-inflammatory cytokines 
released within four hours of epidermal loading, was much before the tissue damage was visible. 
Thus, measuring pro-inflammatory cytokines may help as an objective measure to determine risk 
for formation of PUs [73].  
Some researchers reported systemic elevation of inflammatory mediators in individuals 
with PUs. Segal et al., found an increase in plasma concentrations of interleukin 2 receptor (IL-
2R), IL-6 and ICAM-1 following SCI, in individuals with slow healing PUs as compared to able-
bodied subjects or healthy subjects with SCI without PUs [32]. The increase in pro-inflammatory 
cytokines in individuals with SCI having formation of PUs and presence of other infections 
inhibits the wound health and are associated with slow healing of these ulcers [4]. A recent study 
compared the variations in the plasma biomarkers in three groups, individuals with SCI, PU in 
individuals with SCI and able-bodied subjects, and the results indicated decrease in the trend of 
creatine kinase (CK) in the individuals with SCI with PU as compared to the other groups. 
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Increased trend was noted in in the C-reactive protein; marker of inflammation and tissue 
damage, and heart type fatty acid binding protein (H-FABP) in subjects with SCI with PU as 
compared to the other two groups. The biomarkers analyzed in this study were the biomarkers 
associated with skeletal muscle damage and cardiac muscle damage [74]. Thus, increase in 
concentration of the inflammatory mediators in individuals with SCI and PUs. The synthesis of 
these inflammatory mediators was increased both locally at the tissue level and systemically. The 
initial inflammatory response increases the blood flow to heal the injured tissue. Prolonged 
activation and synthesis of this inflammatory response predisposes the body to chronic 
inflammation, and upturns the concentrations of these mediators systemically. 
   Inflammation in Individuals with Pneumonia 1.2.4.7
The complex and dynamic network of pro and anti-inflammatory mediators contributes to the 
initiation and resolution of the infectious process involved with presence of pneumonia. On one 
hand, the local synthesis of pro-inflammatory cytokines is essential to fight against the pathogens 
in pneumonia; on the other hand the synthesis of the anti-inflammatory cytokines if in excess 
impairs the host defense. Although the inflammatory response is essential to eliminate the 
pathogen in pneumonia this response in excess may worsen the damage to the lung and may 
make it difficult to eliminate the pathogens. Any bacteria or other pathogen entering the lung is 
killed by the alveolar macrophages before the pathogens reach the alveoli. These macrophages 
activate the synthesis of the pro-inflammatory cytokines and neutrophils and further increase the 
response of the pro-inflammatory cytokines such as the TNF-α and IL-1. Plasma levels of IL-1β 
and TNF were found to be elevated in subjects with local pneumonia irrespective of the etiology 
[39]. Experimental studies show that TNF-α eliminates the pathogens by inhibiting the 
 20 
 
outgrowth of bacteria. Administrating anti-TNF in experimental animals was found to decrease 
their survival rate [75]. Hence, the synthesis of TNF-α is essential to maintain the host defense 
against different microorganisms. Excess of IL-10 was found to impair the host defense, and 
increases the pathogen production in subjects with pneumonia. Treatment with anti-IL-10 
improves the host defense to eliminate the pathogens by increasing the production of the pro-
inflammatory cytokines. At the same time inhibition of IL-10 seemed to be lethal since it is 
essential to control the excessive inflammation. Hence, the effect of IL-10 in infections such as 
pneumonia seems to be complex and is dependent upon the source of infection and is based on 
the balance in the dynamic network of the pro and anti-inflammatory cytokines [3].  
  
 21 
 
1.3 SIGNIFICANCE OF THE STUDY 
Pressure ulcers are the most frequent secondary complication and are one of the leading causes 
of death after Spinal Cord Injury (SCI) [8]. Individuals with PUs experience increased pain, 
discomfort and distress that increase the hospital stay and the ongoing treatment time [76]. Loss 
of independence, body image, and burden to others were some of the concerns expressed by 
these individuals further contributing towards anxiety emotional and psychological 
complications. These individuals avoid moving their body parts due to the pain and continue to 
stay in one position. This further increases conflicts with their healthcare professionals and 
interfere with their rehabilitation care [77]. A recent literature review discusses the lack of 
evidence in the medical risk factors during hospitalization associated with developing PUs as 
compared to the care related risk factors [6]. This study investigated and determined the 
demographic and clinical risk factors in newly injured individuals following traumatic SCI 
associated with the formation of PUs during hospitalization. Individuals with TSCI having PUs 
and pneumonia possibly will have an imbalance in the inflammatory response. Reduced life 
expectancy and decreased quality of life was reported in individuals with SCI having secondary 
complications such as pneumonia and septicemia [78]. This study identified the inflammatory 
mediators associated with the formation of PUs, following SCI and just before the formation of 
PUs was visible. Although studies indicate pneumonia to be correlated with the occurrence of 
PUs in individuals with SCI [37, 42], none of them explore the mechanism of the presence of 
pneumonia that may be a risk factor for the formation of PUs in this population. This study 
highlighted the relationship between presence of pneumonia and incidence of PU linked through 
inflammation.  
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1.4 DISSERTATION STRUCTURE 
Chapter 2 investigates the demographic and medical risk factors associated with the formation of 
pressure ulcers in individuals with traumatic spinal cord injury (TSCI). In Chapter 3, we 
explored and investigated whether the concentrations of the inflammatory mediators measured in 
both plasma and urine biofluids immediately following TSCI, could predict the occurrence of 
pressure ulcers, by building a stepwise multivariate logistic regression model. Chapter 4 
investigates whether there are changes in the concentrations of the inflammatory mediators in 
both plasma and urine biofluids from immediately after spinal cord injury to just before 
formation of pressure ulcer. In Chapter 5, the association between pneumonia and occurrence of 
pressure ulcer was investigated in the Rehabilitation Engineering Research Center on SCI and 
Spinal Cord Injury Model Systems populations. Chapter 6 explored and investigated whether 
changes in the concentrations of inflammatory mediators before and after formation of 
pneumonia, in both plasma and urine biofluids could predict the occurrence of pressure ulcers. 
Chapter 7 summarizes the results and conclusions obtained from this dissertation study and 
venues for future work.  
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2.0  DEMOGRAPHIC FACTORS AND CLINICAL COMORBIDITIES ASSOCIATED 
WITH FORMATION OF PRESSURE ULCERS IN INDIVIDUALS WITH TRAUMATIC 
SPINAL CORD INJURY 
2.1 INTRODUCTION 
Spinal cord injury (SCI) is a devastating neurologic disorder that has profound impact from 
physical, psychological and socioeconomic perspectives [44]. Increase in age and severity of 
injury are associated with rise in long-term complications after traumatic SCI [79]. The second 
leading cause of death in individuals with SCI is septicemia (88.6%); usually associated with 
urinary tract infections (UTI’s), pneumonia, and/ or presence of PUs [45]. Pressure ulcers (PUs) 
are the most frequent secondary complication in individuals with SCI from the time of acute 
hospitalization through community reintegration PUs affect quality of life, length of stay during 
hospitalization and increases the mortality and morbidity [1, 7, 12, 48, 49]. The 2011 annual 
statistical report for the Spinal Cord Injury Model Systems (SCIMS) identify PUs as the second 
most frequent complication and third leading cause of death for people with SCI [45].  
Many risk factors have been associated with the formation of pressure ulcers. Medical 
complications such as cardiac or renal disease were associated with the risk of developing PUs 
[8]. Individuals likely to develop PUs were those who have SCI of traumatic origin [17], males 
[18], have a history of smoking, alcohol or drug use [10], have medical comorbidities such as 
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diabetes mellitus [19, 20], decreased oxygenation or hypotension [16], infections such as 
pneumonia, urinary tract infections, osteomyelitis, and other bacterial infections [8, 21], those on 
mechanical ventilators [22] and use of steroids [16]. Moisture and/or urinary and fecal 
incontinence, hypo/hyperthermia, friction, shear, were reported to be the extrinsic risk factors for 
the formation of PUs in individuals in acute care and intensive care unit (ICU) [16, 19, 51-55]. 
Decreased nutrition or low serum albumin levels, decreased mobility and sensation, and impaired 
cognitive function contribute towards the intrinsic risk factors for the development of PUs in 
individuals with SCI [19, 20].   
The extrinsic environment plays an important role for the development of PUs. A 
majority of studies focus on the risk factors associated with the development of PUs in 
community care in individuals with SCI [8-15], however only a few address the risk factors in 
this population during hospitalization or acute care [16].  Hence, identifying the factors for 
development of PUs in high-risk settings (e.g., during hospitalization) is essential. Studies on 
risk factors associated with PUs mostly used self-report or retrospective chart review methods [8, 
10]. This may result in underreporting of the data due to recall bias or misclassification of the 
data. Although numerous risk factors are associated with the occurrence of PUs, the increased 
incidence of PUs for newly injured individuals with SCI during hospitalization have not been 
similarly determined.  
Thus, identifying the clinical factors associated with the development of PUs during 
acute care hospitalization and inpatient rehabilitation may help prevent this secondary 
complication and may reduce the risk of re-hospitalization and improve the quality of life. Since 
this study is a secondary analysis few factors were included to predict the formation of first PU 
due to limited availability of data. 
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We hypothesized medical factors such as presence of pneumonia, urinary tract infection 
(UTI), use of steroids, and demographic factors such as gender, age, and severity of injury 
measured by ASIA score will be associated with increased risk for the formation of PUs in 
individuals with traumatic SCI during acute care hospitalization and inpatient rehabilitation. 
2.2 METHODS 
2.2.1 Research Design 
The study was conducted at the Rehabilitation Engineering Research Center on Spinal Cord 
Injury (RERC on SCI). The RERC on SCI serves individuals with SCI by research and 
development of new technologies to improve treatment and thus help with reintegration into 
society. This protocol received approval from the University of Pittsburgh Institutional Review 
Board (IRB). The Clinical Core of the Center enrolled acute patients with SCI to collect blood, 
urine, demographic information and medical information during their acute and inpatient stay 
through their rehabilitation stay at UPMC and post discharge. The focus of the RERC project 
was to obtain information related to the incidence of pressure ulcers in the SCI population, the 
occurrence of urinary tract infections and data associated with depression and pain status, and 
develop a protocol was developed generate data needed to develop a model of inflammation and 
healing in PU development following SCI 
 Once informed consent was obtained, clinical data, plasma and urine samples were 
collected three times per week when the subject was in acute care, weekly in inpatient 
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rehabilitation and annually after discharge to outpatient care until the duration of study; that 
occurred for 5 years (2008-2012). The RERC on SCI was funded by the National Institute for 
Disability and Rehabilitation Research (NIDRR), grant #H133E070024. The RERC database 
was used in this study in a secondary analysis to explore and examine the relationship among the 
clinical and demographic variables and PU outcome [80]. 
2.2.2 Inclusion and Exclusion Criteria 
The individuals with SCI were recruited within 24-72 hours of admission into the University of 
Pittsburgh Medical Center, neurotrauma centers. The subjects were eligible for the study if they 
met the following inclusion criteria:  
1. Received acute medical and surgical treatment at UPMC hospitals 
2. Received acute rehabilitation at Institute for Rehabilitation and Research (IRR) South 
Side / UPMC Mercy after acute medical/surgical treatment 
3. Were 18 years and older 
4. Presented with acute newly traumatic SCI (such as motor vehicle accident, fall or sport 
injury) 
The subjects were excluded if they had the following comorbidities: 
1. Pre-existing diseases (such as autoimmune or demyelinating diseases) that affected the 
inflammatory response to SCI 
2. Previous SCI or other neurological diseases that affected the motor and sensory 
function 
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Individuals with any pre-existing disease (e.g. diabetes) were initially excluded from the 
study but later included after a year in an effort to increase recruitment rate. 
2.2.3 Data Collection 
The Clinical Core of the RERC on SCI collaborated with the University of Pittsburgh Medical 
Center (UPMC) and UPMC Model System on SCI to recruit, screen and retain subjects. Data 
related to risk and incidence of PUs and UTIs were recorded. PU risk variables included age, 
gender, and level of injury, other injury associated with trauma, ASIA grade, smoking, alcohol 
use and comorbidities [12, 81]. The American Spinal Cord Impairment scale (AIS) was used to 
grade severity of motor and sensory impairment [82]. Injury severity score (ISS), (Table 3) was 
used to record the combined severity of the possible multiple other traumatic injuries [83]. The 
AIS and ISS were noted from the UPMC electronic health records by the research staff. The 
extent of the injury that was recorded for this study in listed in Table 1. Comorbidities in all 
systems for individuals with TSCI were noted by the research staff. The research staff measured 
the intensity of pain using the pain scale [84]. The severity of depression was assessed by the 
research staff using the patient health questionnaire (PHQ)-9 [85]. If a subject developed PU, the 
research coordinators recorded the severity, size, shape and progression of the wound healing. 
Severity was determined using National Pressure Ulcer Advisory Panel (NPUAP) staging 
system, Table 2. Shape and size was recorded by the research staff using digital photograph and 
quantified using length, width and depth measurement technique [86]. The characteristics of the 
PU such as site, shape, necrotic tissue, amount, wound base, ulcer edges, drainage, surrounding 
tissue, and steroid protocol were also recorded by the recorded. The medications such as steroids, 
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NSAIDs, pain, anti-inflammatory and any other mediation these individuals were on were noted 
from their UPMC electronic health records. The data collected is summarized in (Table 1). 
 
Table 1. Data Collected for the RERC on SCI 
Variables Specifics 
Demographics Admission date, Consent date, Date of Injury, Age Sex, Marital Status, 
Ethnicity, Height, Weight, past medical history (PMH) of smoking. 
 
Injury  
 
Cause of Injury, Level of Injury: Cervical / thoracic/ Lumbar/ Sacral/ Coccyx; 
Also Bilateral v/s left and right, Complete v/s Incomplete, American Spinal 
Injury Classification (ASIA) score, Lower Extremity Score (This is a subset of 
ASIA score, where the motor score of the individual is tested by manual Muscle 
test), Injury Severity Score (ISS- This is a score which asses the severity of 
injury). 
 
Medical 
Information 
 
• Alcohol use & tobacco use, musculoskeletal pain, PHQ scale (Scale to assess 
depression; 1-4 – Minimal depression, 5-9 – Mild depression, 10-14 – 
Moderate Depression, 15-19 – Moderately severe depression, 20-27- Severe 
Depression) 
• Medical Co Morbidities such as cardiovascular, hematopoietic, respiratory, 
ENT, gastrointestinal, rheumatologic, musculoskeletal, neurologic, 
endometric/metabolic, immunological, psychiatric, malignancy, substance 
Abuse, UTI, integumentary. 
• Number of PUs, Braden Score (pressure ulcer risk score) 
• Bladder and Bowel Management 
• Medications: Pain, Non-steroidal anti-inflammatory drugs (NSAIDs), 
Steroids, Antibiotics and Others. 
• Ambulation Status were recorded only at the time of inpatient discharge and 
Outpatient phases 
 
Pressure Ulcer 
Information 
Size, shape, severity and progression of the PU are recorded. Severity was 
recorded using the National Pressure Ulcer Advisory Panel (NPUAP) staging 
system 
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Table 2. Stages of Pressure Ulcer[87] 
Category/ Stage Description 
I 
“Non-blanchable 
erythema” 
“Intact skin with non-blanchable redness of a localized area usually 
over a bony prominence. Darkly pigmented skin may not have 
visible blanching; its color may differ from the surrounding area. 
The area may be painful, firm, soft, warmer or cooler as compared 
to adjacent tissue. Category I may be difficult to detect 
in individuals with dark skin tones. May indicate “at risk” persons”. 
 
II 
“Partial thickness” 
“Partial thickness loss of dermis presenting as a shallow open ulcer 
with a red pink wound bed, without slough. May also present as an 
intact or open/ruptured serum-filled or sero-sanginous filled blister”. 
 
III 
“Full thickness skin loss” 
“Subcutaneous fat may be visible but bone, tendon or muscle 
are not exposed. Slough may be present but does not obscure the 
depth of tissue loss. May include undermining and tunneling. 
Bone/tendon is not visible or directly palpable”. 
 
IV 
“Full thickness tissue 
loss” 
“Full thickness tissue loss with exposed bone, tendon or muscle. 
Slough or eschar may be present. Often includes undermining and 
tunneling. Exposed bone/muscle is visible or directly palpable”. 
 
“Unstageable: Full 
thickness skin or tissue 
loss– depth unknown” 
“Full thickness tissue loss in which actual depth of the ulcer is 
completely obscured by slough (yellow, tan, gray, green or brown) 
and/or eschar (tan, brown or black) in the wound bed. Until enough 
slough and/or eschar are removed to expose the base of the wound, 
the true depth cannot be determined; but it will be either a 
Category/Stage III or IV”. 
 
“Suspected Deep Tissue 
Injury – depth unknown” 
“Purple or maroon localized area of discolored intact skin or blood-
filled blister due to damage of underlying soft tissue from pressure 
and/or shear. The area may be preceded by tissue that is painful, 
firm, mushy, boggy, warmer or cooler as compared to adjacent 
tissue”. 
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Table 3. ISS Scale Score 
ISS Score Severity 
1-9 Minor 
10-15 Moderate 
16-24 Moderate/Severe 
≥25 Severe/Critical 
2.2.4 Procedure  
The primary outcome is occurrence of first PU. All stages of PUs (Stage I- IV, deep tissue injury 
and Unstageable) were considered. Through expert opinion of a group of therapists and 
clinicians, and review of the literature, the list of possible variables was reduced to the following 
for analysis:  
1. Age  
2. ASIA Impairment Scale (AIS) Score 
3. Gender 
4. Use of Steroids 
5. Urinary Tract Infection diagnosis 
6. Pneumonia diagnosis 
7. Diabetes 
2.2.5 Data Analysis 
All data were analyzed using Statistical Package for Social Sciences (SPSS) version 20.0. 
Descriptive statistics using means, frequencies, and standard error of mean were computed.  
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    Logistic Regression 2.2.5.1
Univariate Logistic Regression 
A univariate logistic regression analysis was conducted to assess individual risk factors ability to 
predict the probability of the outcome (PU, yes/no). The model is[88]: 
𝐥𝐨𝐠𝐢𝐭 (𝐘) = 𝟏
𝟏 + 𝒆−(𝜷𝟎+𝜷𝟏𝑿𝟏) =  𝛃𝟎 +  𝛃𝟏𝐗𝟏 
• β0 is a constant 
• β1 is the coefficient of the individual predictor variable. 
• X1 is the clinical (predictors) variable in question 
Our hypotheses are:  
H0 (Null Hypothesis): β1 = 0  
H1 (Alternate Hypothesis): β1 ≠ 0 
The significance level was set at α = 0.05.  
Multivariate Logistic Regression  
A multivariate logistic regression was conducted with the independent variables selected from 
univariate analysis and by reviewing the literature that previously identified these risk factors. 
The outcome for the model was occurrence pressure ulcer (yes/no). The model is: [88] 
𝐥𝐨𝐠𝐢𝐭 (𝐘) = 𝟏
𝟏 + 𝒆−(𝜷𝟎+𝜷𝟏𝑿𝟏+𝛃𝟐𝐗𝟐+⋯.𝛃𝐤𝐗𝐤) =  𝛃𝟎 + 𝛃𝟏𝐗𝟏 + 𝛃𝟐𝐗𝟐 + ⋯… + 𝛃𝐤𝐗𝒌 
• β1, β2…. βk are the regression coefficients for the independent variables of the regression 
equation.  
• X1, X2…Xk are the independent variables (risk factors in question).  
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Our hypotheses are:  
H0 (Null Hypothesis): β1= β2=…. = βk (or) βi = 0  
H1 (Alternate Hypothesis): β1 ≠ 0 (or) βi ≠ 0 
The significance level was set at α = 0.05. 
    Logistic Regression Coefficients and Wald statistic  2.2.5.2
The logistic regression coefficients,?̂?0, ?̂?1..., ?̂?𝑘 β�0and their standard errors are estimated using 
maximum likelihood methods. These values, in turn, are used to evaluate the fit of one or more 
models. Maximum likelihood estimation provides estimates of regression coefficients that make 
a sample as likely as possible, given values on the predictors and the outcome. The computed 
likelihood of a sample given the maximum likelihood estimates is termed the maximum 
likelihood of the sample, typically denoted by L. If an acceptable model is found, the statistical 
significance of each of the coefficients is evaluated using the Wald test where the squared 
coefficient is divided by the squared standard error. The Wald statistic is a χ2 statistic with one 
degree of freedom. Wald statistic has different forms and can be defined as in Equation 1 and 
Equation 2, and it has standard normal (z) distribution [89].  
Equation 1. Wald Statistic  
𝑊𝑖 = 𝛽�𝑖2𝑠𝛽�𝑖2  
Equation 2. Different form of Wald statistic 
𝑊𝑖 = 𝛽�𝑖𝑠𝛽�𝑖 
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    Interpretation of β’s 2.2.5.3
β’s cannot be interpreted directly.  ?̂?𝑗 is the amount of change in logit for each unit 
increase in 𝑋𝑗. 𝑒𝛽𝑗  is equal to odds ratio; change in odds between a baseline group and 
a single unit increase in  𝑋𝑗 . 𝑒𝛽𝑗 can be interpreted [88] (Table 4).  
 
Table 4. Interpretation of Odds Ratio 
Odds Ratio( 𝑒𝛽𝑗) Interpretation 
𝑒𝛽𝑗 = 1   No change in odds ratio 
 
𝑒𝛽𝑗 < 1   Odds ratio decrease  
𝑒𝛽𝑗 > 1 Odds ratio increase 
 
The sample sizes were not estimated by using power analysis to obtain a desired power 
prior to data collection. Since this study was a secondary analysis, to have a good model fit and a 
good power the general “rule of thumb” to have 10 cases per predictor variable was considered 
[90]. The assumptions of logistic regression such as multicollinearity, linearity and outliers were 
checked to minimize the number of predictors and include the best set of variables to maximize 
the strength of prediction.  
    Hosmer-Lemeshow goodness of fit  2.2.5.4
The Hosmer-Lemeshow goodness of fit was computed. This evaluates the goodness of fit by 
comparing the observed model by creating ten groups of subjects (based on estimated 
probability) to the predicted logistic regression model. When there are one or more continuous 
predictors in the model, Hosmer-Lemeshow statistic can be used to assess goodness of fit. 
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Subjects are first put in order by their estimated probability on the outcome variable. Then 
subjects are divided into 10 groups according to their estimated probability: those with estimated 
probability below .1 (in the lowest decile) form one group, and so on, up to those with estimated 
probability 0.9 or higher (in the highest decile). The next step is to further divide the subjects 
into two groups on the outcome variable to form a 2×10 matrix of observed frequencies. If the 
logistic regression model is good, then most of the subjects with outcome 1 are in the higher 
deciles of risk and most with outcome 0 in the lower deciles of risk. If the model is not good, 
then subjects are roughly evenly spread among the deciles of risk for both outcomes 1 and 0. A 
nonsignificant Hosmer-Lemeshow chi-square statistic indicates a good model. The test statistic 
of Hosmer-Lemeshow is given in Equation 3 [91].  
Equation 3. Hosmer-Lemeshow test statistic 
𝜒𝐻𝐿
2 = � (𝑜𝑘 − 𝑛𝑘𝜋𝑘)2
𝑛𝑘𝜋𝑘(1− 𝑛𝑘𝜋𝑘)𝑔𝑘=1  
• g is the number of groups 
• 𝑜𝑘is the total frequency of event outcomes in the kth group 
• 𝜋𝑘 is the average estimated predicted probability of an event outcome for the kth group 
• 𝑛𝑘 is the frequency of subjects in the kth group 
• degrees of freedom = g – 2 
    Area under the Receiver Operating Characteristic (ROC) curve 2.2.5.5
The ROC curve was plotted for the multivariate logistic regression model. The ROC curve 
analysis allows us to evaluate the multivariate logistic regression model. It plots the probability 
of detecting true signal (sensitivity) and false signal (1 - specificity) for an entire range of 
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possible cutoff values. The area under the ROC curve, which ranges from 0 to 1, provides a 
measure of discrimination (classification). The ROC analysis thus helps to determine the power 
of the model’s predicted values to discriminate between those with and without the disease 
(pressure ulcer). A complete description of ROC classification accuracy is given by the area 
under the receiver operating characteristic (ROC) curve (AUC). The area under the ROC curve 
(AUC) helps us to quantify the power and evaluate the accuracy of the multivariate logistic 
regression model. An area under the curve varies from 0.5 (represents discriminating power not 
better than chance) to 1.0 (represents a perfect discriminating power). A guide for classifying the 
accuracy of a diagnostic test is given in Table 5 [92].  
 
Table 5. Area under the Receiver Operating Characteristic (ROC) curve classification 
Area under ROC Accuracy 
0.90-1   excellent  
0.80-0.90 good  
0.70 -0.80  fair  
0.60 -0.70 poor  
0.50 -0.60  fail  
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2.3 RESULTS 
2.3.1 Baseline Characteristics 
One hundred and four individuals were included and enrolled in the RERC on SCI study. The 
demographics, characteristics, location of the subjects and medical comorbidities are shown in 
Table 6. Majority of SCIs were due to falls (38%) or due to motor vehicle accident (32%). 
Thirty-five percent of the individuals were followed from acute care through discharge, while the 
other individuals were either withdrawn by the study team, withdrew themselves from the study, 
or were discharged at different time points. Eighty-one percent of the individuals in the 
population were Caucasians. Almost 93% of individuals in acute care and 83% of individuals’ in 
inpatient rehabilitation used catheters for their bladder management. 
2.3.2 Pressure Ulcers 
Forty-four individuals (42%) with traumatic spinal cord developed at least one pressure ulcer. 
The demographics, characteristics, location of subjects and medical comorbidities of these 
subjects are shown in Table 6. The severity of first pressure ulcer for most of the individuals in 
this population was Stage II (67%). The mean number of days from the time of injury until onset 
of the first PU was 19.2 ± 1.8. 42% of males and 29% of females developed pressure ulcers. 45% 
of individuals between the ages 18-30 years developed PUs. 
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2.3.3 Risk factors for the Formation of Pressure Ulcer 
    Univariate analysis 2.3.3.1
A univariate logistic regression was performed for age, gender, ASIA, pneumonia, UTI, steroids 
and diabetes (Table 7). The analysis was significant for individuals with pneumonia; p=0.014 
and for injury severity (ASIA scale score); p=0.011. The univariate analysis was not significant 
for any other variables. The average number of days from the time of injury to develop 
pneumonia in subjects with PUs in this study was 11 days (Table 6). The receiver operator 
characteristic (ROC) curve was plotted for all the individual predictors (Figure 3) and the area 
under the curve (AUC) was computed (Table 8). The AUC for individuals who had pneumonia is 
0.626 and significant p= 0.035. The AUC was not significant for any other variables.  
    Multivariate Logistic Regression Model 2.3.3.2
A multivariate logistic regression was performed with pressure ulcer as the outcome and six 
predictors: Age, ASIA classification, gender, steroid use, pneumonia, and urinary tract infection. 
The PU outcome was dichotomized into 2 levels (PU present (1) or not PU (0)). There were 2 
levels in UTI, steroids, and pneumonia (yes (1), no (0)), 2 levels in gender (male and female) and 
4 levels in ASIA (ASIA A (1), ASIA B (2), ASIA C (3) and ASIA D (4)). (Table 9) shows the 
results of the multivariate logistic regression. All assumptions were met. There was a significant 
prediction of PU outcome by the clinical and demographic factors that were included in the 
multivariate model, χ2 (8) = 17.925, p=0.022. The odds of formation of a first PU in individuals 
with ASIA A was 4.7 times greater individuals with ASIA B, p=0.04 and the odds of formation 
of a PU in individuals with ASIA A was 5.5 times greater individuals with ASIA C, p= 0.01. 
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There were no significant prediction of pressure ulcer occurrence by medical factors such as 
pneumonia (p=0.25), urinary tract infection (p=0.25), use of steroids (p=0.36), and demographic 
factors such as age (p= 0.94) and gender, (p= 0.411).  
    Hosmer-Lemeshow goodness of fit 2.3.3.3
In this study, there was no significant difference between the observed and predicted group 
membership, Hosmer-Lemeshow χ2 (8) = 9.912, p= 0.271. This means that there is a good 
overall fit of the logistic regression model and that there is no misspecification of the predictors.  
    Area under the Receiver Operating Characteristic (ROC) curve 2.3.3.4
In this study, the area under the ROC curve is 0.735 with 95% confidence interval (0.636, 0.835). 
Also, the area under the curve is significantly different from 0.5 since p value = 0.000 (Table 
10). This means that the variables in the multivariate logistic regression model significantly 
classifies formation of PU the RERC on SCI population.  
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Table 6. Baseline Characteristics of Individuals in the RERC on SCI during acute care and inpatient rehab 
Variables 
All subjects 
(n=104) 
#of subjects (%) 
Subjects with PUs  
(n=39) 
Subjects without PU 
(n=65) P value 
Gender     0.65 
Male 83 (80%) 32 (82%) 51 (79%)  
Female 21 (20%) 7 (18%) 14 (22%)  
Age – years  (Mean ± SEM) 40.9 ± 1.7 38.1±2.7 42.5±2.2 0.19 
18-30 40 (38%) 16 (41%)   
31-50 28 (27%) 10 (27%)   
51-65 25 (24%) 10 (27%)   
>65 11 (11%) 3 (8%)   
Level of Injury    0.49 
C2-C7 51 (49%) 19 (49%) 32 (49%)  
T1- T6 14(14%) 6 (12%) 8(12%)  
T6-T12 21 (20%) 9 (23%) 12 (19%)  
L1-L5 13 (13%) 2 (5%) 11 (17%)  
Other 3 (3%) 2 (5%) 1 (2%)  
Unknown 2 (2%) 1 (3%) 1 (2%)  
ASIA Score    < 0.001 
A 42 (40%) 25 (64%) 17 (26%)  
B 13 (13%) 3 (8%) 10 (15%)  
C 24 (23%) 5 (13%) 19 (29%)  
D 21 (20%) 5 (13%) 15 (23%)  
E 1 (1%) 0 (0%) 1 (2%)  
Unknown 5 (5%) 1 (3%) 3 (5%)  
Education    0.48 
High School 75 (72%) 30 (77%) 45 (69%)  
4 year College 10 (10%) 2 (5%) 8 (12%)  
Post-Graduate 3 (3%) 0 (0%) 3 (5%)  
Tech/2year degree 11 (11%) 4 (10%) 7 (11%)  
In High School 2 (2%) 1 (3%) 1(2%)  
Unknown 3 (3%) 2 (5%) 1 (2%)  
Marital Status     
Single 55 (53%) 19 (49%) 36 (55%) 0.77 
Married 37 (36%) 16 (41%) 21 (32%)  
Divorced 10 (10%) 3 (8%) 7 (11%)  
Widowed 2 (2%) 1 (3%) 1 (2%)  
Ethnicity    0.18 
African-American 19 (18%) 4 (10%) 15 (23%)  
Asian-American 1 (1%) 0 (0%) 1 (2%)  
Caucasian/White 84 (81%) 35 (90%) 49 (75%)  
Past Medical History of Smoking 43 (41%) 16 (41%) 27 (42%) 0.85 
Diabetes 15 (14%) 7 (18%) 8 (12.3%) 0.4 
Secondary Conditions      
UTI 53 (51%) 24 (63%) 29 (44%) 0.06 
Onset of UTI 
 (Mean no. of days ± SEM) 26.1 ± 3.3 34.4 ± 6.6 19.2±1.5 0.15 
Pneumonia 40 (39%) 20 (51%) 20 (31%) 0.03 
Onset of Pneumonia 
 (Mean no. of days ± SEM) 8.9 ± 1.04 11.2 ± 1.8 6.3±0.6 0.02 
At least 1 Pressure Ulcer 39 (42%) 39 N/A  
Use of Catheters 97 (93%) 38 (97%) 59 (91%) 0.18 
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Table 7. Univariate Logistic Regression of clinical and demographic factors (n=104). 
Variables Individuals with at least 
1 PU in acute care 
through inpatient 
rehabilitation 
N=39 
Individuals with no PU 
in acute care through 
inpatient rehabilitation 
N=65 
Sig (p) 
Age  (mean) 38.12 y 42.50 y 0.22 
Gender (N) M= 32 
F= 7 
 
M= 51 
F=14 
0.79 
ASIA (N) 
 
A= 25 
B= 3 
C= 5 
D= 5 
A= 17 
B=10 
C= 19 
D= 15 
 
0.01* 
Pneumonia (N) 
 
Y= 21 Y= 19 0.01* 
UTI (N) 
 
Y= 24 Y= 29 0.09 
Steroids (N) 
 
Y=13 Y= 20 0.78 
 (N) Y=7 Y= 8 0.43 
*p < 0.05,  
 
 41 
 
 
Figure 3. ROC curve for individual variables 
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Table 8. Area under the Curve for all Variables 
 
Variables 
 
Area 
 
Std. Error 
 
Sig(p) 
Asymptotic 95% Confidence 
Interval 
Upper 
Bound 
Lower Bound 
ASIA A – ASIA 
B 
0.459 0.059 0.491 0.344 0.574 
ASIA A – ASIA 
C 
0.413 0.057 0.143 0.300 0.525 
ASIA A – ASIA 
D 
0.445 0.058 0.356 0.330 0.559 
Age 0.423 0.059 0.197 0.306 0.540 
Gender 0.474 0.059 0.665 0.358 0.590 
Pneumonia 0.626 0.059 0.035* 0.511 0.741 
UTI 0.569 0.059 0.250 0.453 0.685 
Steroids 0.505 0.060 0.938 0.387 0.622 
 
  
*p<0.05 
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Table 9. Multivariate Logistic Regression of Clinical and Demographic Factors, RERC on SCI 
Independent 
Variables 
B SE Wald Sig (p) Exp(B) 
Age 
 
-0.001 0.014 0.005 0.943 0.99 
Gender 
 
0.486 0.592 0.675 0.411 1.63 
ASIA A – ASIA B 
 
1.548 0.772 4.023 0.045* 4.7 
ASIA A –ASIA C 
 
1.701 0.658 6.678 0.01* 5.47 
ASIA A – ASIA D 
 
1.090 0.719 2.3 0.129 2.98 
Pneumonia 
 
-0.592 0.515 1.319 0.251 0.55 
Urinary tract infection  
 
-0.552 0.484 1.301 0.254 0.576 
Steroids 
 
-0.468 0.511 0.839 0.360 0.626 
Constant 
 
-3.482 1.809 3.703 0.054 0.031 
 
Model χ2    = 17.925, p < 0.05 
Pseudo R2   = 0.223 
n               = 104 
 
 
  
Note: The dependent variable in this analysis is formation of pressure ulcer in acute care or inpatient 
rehabilitation, so that 0= did not have pressure ulcer and 1= had a formation of pressure ulcer  
**p<0.01, *p< 0.05 
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Figure 4. ROC curve for Multivariate Logistic Regression Model for clinical predictors in RERC on SCI 
population  
 
 
Table 10. Area under the Curve for Multivariate Logistic Regression Model 
 
Area 
 
Std. Error  
 
Sig  
Asymptotic 95% Confidence Interval 
Upper Bound Lower Bound 
0.735 0.051 0.000** 0.636 0.835 
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2.4 DISCUSSION 
The results of this study investigated factors associated with the development of pressure ulcers 
(PUs) in acute care and inpatient rehabilitation in individuals with newly traumatic SCI (TSCI). 
Individuals with TSCI are at a risk for developing PUs and other secondary complications [17, 
93]. This may be because of the clinical, epidemiological and functional changes following 
TSCI. Using the univariate and multivariate logistic regression model, severity of SCI (ASIA A) 
and pneumonia were identified to be associated with formation of first PU in this population.  
The overall incidence rate of formation of at least one PU in the RERC on SCI population 
was 42%. Prior studies have found that approximately 47% of individuals with SCI develop at 
least one PU during the period of acute care hospitalization and rehabilitation [50].  Most of the 
PUs occur in the acute care as compared to the rehabilitation units [94, 95], these findings are 
comparable to this study. The incidence of pressure ulcers in the RERC on SCI population in the 
acute care setting and inpatient rehabilitation was 28% and 12% respectively. Thirty-nine percent 
of individuals in this study population developed at least one PU in acute care and inpatient 
rehabilitation, which is similar to 34% reported by the 2011 Model Spinal Cord Injury Care 
Systems [45].  
A factor determined to predict first PU occurrence in this study was severity of injury 
measured by the ASIA scale score. In this study, individuals with ASIA A were more at risk to 
develop PUs than ASIA B, and C, similar to previous studies [96]. A prospective cohort study in 
individuals with SCI found completeness of injury a significant risk factor for the formation of 
PUs. The odds of forming a PU with AIS A were much higher than AIS C or D [97]. A complete 
motor and sensory lesion (ASIA A) severely limits mobility not allowing them perform the 
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activities of daily living and other activities that may require mobilizations. [15, 96, 98, 99]. 
Also, individuals with higher severity of injury (ASIA A) complete injury are usually on 
anesthesia and mechanical ventilation. This decreases their awareness to the pressure and shear 
forces on their bony prominences. Also, individuals with complete neurological injuries are more 
prone to urinary and or fecal incontinence that increases moisture and maceration around the skin 
[100]. This coupled with lack of sensory and motor supply increases their risk to develop 
pressure ulcers.  
Pneumonia was another factor that predicted pressure ulcer outcome (from the results of 
the univariate analysis) in this study. Individuals in this study were diagnosed with pneumonia 
within eleven days (on average) following injury. The area under the receiver operator 
characteristic (ROC) determined that individuals with pneumonia have greater occurrence of 
PUs than individuals with no pneumonia.  Hence, presence of pneumonia was significantly 
associated with the formation of PU in the RERC on SCI population, indicating a relationship 
between pulmonary disease and formation of PUs. Pneumonia was the only medical comorbidity 
that predicted occurrence of PU in the univariate logistic regression analysis, but was not 
significant in presence of other variables that were included in the multivariate logistic 
regression model. Increased severity of injury and complete loss of motor control predisposes 
them to pneumonia due to ventilatory incompliance. Hence, individuals with higher level and 
complete of SCI are dependent on mechanical ventilation. Lack of movement in individuals 
dependent on mechanical ventilators, may predispose them to form PUs. Correlation between 
pneumonia and the formation of PUs has been indicated in previous studies [11, 15, 19, 37]. The 
pathogenesis between the formation of PUs and presence of pneumonia is not known and has to 
be further explored. 
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Demographics such as age and gender were not significant predictors of first PU 
formation in this study. Although some studies have identified age [79] and gender [18] 
associated with PU formation, a recent study by Wilczweski and colleagues, determined 
demographics not to be a significant predictor for the occurrence of PUs [16]. In this study, all 
the individuals with SCI developed UTI within twenty-six days from injury, whereas individuals 
with PUs developed UTI within thirty-four days from the day of injury. Diagnosis with urinary 
tract infection (UTI) was not a significant predictor of PU development in this study. Studies 
have indicated urinary tract infections (UTIs), to be associated with the risk of development of 
PUs in acute care hospitals [21]. Most of the individuals (80%) in hospitals are predisposed to 
UTI’s because if the use of catheters for bladder management and improper maintenance and 
insertion of catheters [101, 102]. In this study almost all the individuals (93% in acute care and 
85% in inpatient rehabilitation) were on catheters for bladder management. This may be the 
reason why UTI was not a predictor of PU in the multivariate regression model. Diabetes is also 
known to be associated with the formation of PUs.  [21, 103, 104]. Diabetes was not found to be 
significant predictor of PUs in the RERC on SCI population in the univariate analysis. This may 
have been due to the initial exclusion of people with diabetes in our study since we may have 
missed collecting data on individuals with diabetes who may have had the formation of pressure 
ulcers. The use of steroids was a not significant predictor of PU development in the univariate 
and multivariate analyses. There is not enough evidence regarding the use of steroids and 
formation of PUs. In a previous study the use of steroids was significant in the univariate 
analysis and not significant in the multivariate logistic regression model [16].  
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2.4.1 Limitations and Future Recommendations 
There are potential limitations to this study. The sample size for this study was relatively small. 
Only one hundred and four individuals were recruited in this study. To have a good model fit and 
power for the study the general “rule of thumb” to have ten cases per predictor variable was 
considered [90]. Hence, only six variables were included in the final multivariate logistic 
regression model. Collaborative efforts are necessary to increase sample size and thus maximize 
power. A consensus must be established for the specific data collected to allow cross-comparison 
of findings.  
Also, since the research design for this study was secondary analysis, we need to keep in 
mind the inherent disadvantages. Since the data in RERC on SCI was not collected keeping in 
mind the specific research question, other possible variables such as Braden scale score, 
depression score and pain scale at admission, could not be studied for association with the 
formation of PU. The timing of diagnosis of certain comorbidities such as cardiovascular heart 
disease, nutrition, sepsis, hypotension, and interventions such as dietary protein, and use of 
support surfaces were not specific. Hence these variables were not included in the final 
multivariate model. Only a limited number of factors were identified in this study for the 
occurrence of PU. Hence, it is essential to document additional medical factors from the 
electronic health records or medical records, if the research staff is not able to obtain information 
on risk factors or comorbidities at the time of data collection. It may be interesting to study 
additional risk associated with occurrence of PUs during hospitalization. Also, it may be 
interesting to explore the association between medical and rehabilitation interventions that these 
individuals were on and PU incidence.  
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2.5 CONCLUSION  
Many risk factors have been associated with the formation of pressure ulcers. The individuals 
with SCI are at a higher risk to develop pressure ulcers during the time of hospitalization. This 
study confirmed that individuals with high injury severity are at increased risk to develop PUs. 
This study also suggests that medical co-morbidities such as pneumonia, is also associated with 
the formation of PUs. To further understand the association of presence of pneumonia and 
formation of PU, we investigated the association between the two conditions by noting the 
timing and sequence of formation of the two conditions (Chapter 5.0 ).  
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3.0  EARLY INFLAMMATORY BIOMARKERS ASSOCIATED WITH FUTURE 
PRESSURE ULCER DEVELOPMENT IN INDIVIDUALS WITH SPINAL CORD 
INJURY 
3.1 INTRODUCTION 
Spinal cord injury is a devastating neurologic disorder that has profound impact from physical, 
psychological and socioeconomic perspectives [44]. Increase in age and severity of injury are 
associated with rise in long-term complications after traumatic SCI [79]. The second leading 
cause of death in individuals with SCI is septicemia (88.6%); usually associated with urinary 
tract infections (UTI’s), pneumonia, and presence of PUs [45]. Pressure ulcers (PUs) are the 
most frequent secondary complication in individuals with SCI from the time of acute 
hospitalization through community reintegration that affects their quality of life, length of stay 
during hospitalization and increases the mortality and morbidity in this population [1, 7, 12, 48, 
49]. The 2011 annual statistical report for the Spinal Cord Injury Model Systems (SCIMS) state 
PUs to be the second most frequent complication and third leading cause of death after SCI [45]. 
The etiology of PUs is multifaceted. Many extrinsic and intrinsic factors such as moisture, shear, 
temperature, decreased blood flow and oxygenation to the tissues, decreased mobility and 
sensation after SCI,  lack of nutrition are associated with the formation of PUs.  
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Activation of an inflammatory response by the immune system is inherent after traumatic 
SCI. After initial SCI mechanical damage to the axonal and neuronal cells, is followed by a 
complex secondary cascade of events [4, 23, 24]. The disruption of the blood spinal cord barrier 
(BSCB) after SCI increases the synthesis of the pro-inflammatory and anti-inflammatory 
cytokines and other inflammatory factors. This disrupted BSCB further increases the passage of 
these inflammatory markers into the circulation. The inflammatory response after SCI can be 
detrimental and predispose the individuals to secondary complications and tissue damage [25, 
26]. On the other hand, inflammatory response after SCI also helps reduce injury by activating 
the process of wound healing, thus initiating repair [27]. Hence, inflammation after SCI is 
described as a “double-edged sword”, and early inflammatory response may be detrimental 
whereas the late inflammatory response is likely beneficial [2]. In addition, a finely tuned 
balance between the pro-inflammatory and the anti-inflammatory response is essential for the 
beneficial role of the inflammatory response [28]. Previous studies have indicated that the 
activation of the cytokine and chemokine cascade may be related to the pathogenicity of the 
etiology of PUs [32, 105, 106].  
The pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α increase immediately after 
injury until 5 hours post injury [29]. The inflammatory response can be explained by the early 
expression of the pro-inflammatory cytokines and chemokines from 24 hours until 4 days after 
injury [30]. The synthesis of pro-inflammatory cytokines such as TNF-α increase after subjecting 
mice to SCI in the lumbar region due to the disruption of the BSCB [24]. Increased serum 
concentrations of pro-inflammatory cytokines such as TNF-α, IL-2, and IL-1RA were found in 
individuals with SCI as compared to individuals without SCI [4]. The synthesis of anti-
 52 
 
inflammatory cytokines such as IL-10 suppresses the microglial activity and helps to decrease 
inflammation after SCI [27].  
Previous studies measured the levels of the plasma mediators in individuals with chronic 
SCI having PUs. Out of the 70 individuals with long standing SCI, 19 of them had PUs. The 
inflammatory mediators in these individuals were compared to an able-bodied control group. The 
plasma concentrations of IL-6, IL_2, IL-2R and ICAM-1 were significantly elevated in 
individuals with SCI as compared to the control group. Individuals with slow healing PUs had 
highest increase in concentrations of these mediators when compared to able-bodied individuals 
or individuals with SCI and healing PUs [32]. The production of cytokines such as IL-1β, IL-6 
and TNF-α was studied in elderly individuals with Stage III and Stage IV PUs. This study 
reported poor nutritional status and increase in the serum concentrations of IL-6 in these 
individuals when compared to control group who were not at risk to develop PUs. Thus the 
elevation of cytokines in serum could have aggravate the malnutrition in individuals with PUs 
[107]. 
Although inflammatory mediators in plasma and its association with disease, infection 
and trauma is well established, there are relatively fewer studies describing the contribution of 
these mediators in urine. Studies investigating the inflammatory mediators in various diseases, 
are gradually utilizing urine assays to analyze these mediators. Inflammatory mediators such as 
eosinophil’s in urine was shown to be associated with asthma, [108]. Urine samples can be 
sampled non-invasively, and studies have shown association of urine inflammatory predictors in 
congestive heart failure[109], renal disease[110], lung disease[111]. The urine inflammatory 
mediators have not been explored in individuals with SCI.  
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The purpose of this study was to determine the pattern of inflammatory mediators in 
urine (and plasma) within four days following acute traumatic SCI, which would help predict a 
future pressure ulcer development in individuals during acute care and inpatient rehabilitation. 
We hypothesized that the concentrations of pro-inflammatory mediators such as TNF-α, IL-1β, 
IL-2, IL-6, and anti-inflammatory mediators such as IL-10 and IL-1RA measured within four 
days after traumatic SCI will indicate increased risk for formation of PUs. We also hypothesized 
that the inflammatory mediators in urine that predict occurrence of PUs will be same to those in 
plasma.   
3.2 METHODS 
3.2.1 Research Design 
The research design for this study is a secondary analysis, since the existing database was used to 
examine the variables and to explore the relationship between presence of pneumonia and PU 
outcome [80].  
3.2.2 Inclusion and Exclusion criteria 
The inclusion and exclusion criteria of RERC on SCI are mentioned in Chapter 2, Section 2.2.2. 
For this study, individuals who had plasma and urine samples collected within four days after 
traumatic SCI were included. 54 individuals had plasma samples collected and assayed within 
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four days after TSCI and 53 individuals had urine samples collected and assayed within four 
days after TSCI.  
 
3.2.3 Data Collection  
The data collected for the RERC on SCI are mentioned in Chapter 2, Section 2.2.3. 
3.2.4  Processing of Urine and Plasma Samples 
Plasma and urine samples were collected in the RERC on SCI study thrice a week when the 
subjects are in acute care, and weekly in inpatient rehabilitation. The human inflammatory 
MILLIPLEX ™ MAP Human Cytokine/Chemokine Panel-Premixed 26 Plex (Millipore 
Corporation, Billerica, MA) and Luminex xMAP (Luminex, Austin, TX) were used to measure 
plasma and urine cytokine levels. The Luminex™ system was used in accordance to 
manufacturer’s instructions. Standard curves were established based on various dilutions. NO2-
/NO3- was measured using the nitrate reductase/Griess assay (Cayman Chemical Co., Ann Arbor, 
MI). The plasma and urine samples were centrifuged, and plasma and urine aliquots were stored 
in cryoprecipitate tubes at -80°C for subsequent analysis of cytokine levels. Multiplex analysis 
for plasma cytokines and chemokines levels was performed. All data were stored in de-identified 
fashion in an Oracle™ database. Twenty-three inflammatory mediators in plasma and urine were 
assayed in this study. The inflammatory mediators include Eotaxin, GM-CSF, IFN-γ, IFN-α, IL-
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1RA, IL-1β, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1α, and 
MIP-1β, TNF-α, MIG and NO3-/NO2-.  
3.2.5 Procedure  
Individuals in acute care and inpatient rehabilitation from the RERC on SCI were included for 
this study. The earliest time point of the collection of plasma and urine samples, within the four 
days of SCI, was included to identify inflammatory mediators associated with future 
development of first pressure ulcer. 
3.2.6 Normalization of data 
The outliers (extreme data points) were identified (>3SDs) and were adjusted in the data for each 
inflammatory mediator in both plasma and urine. The data for each inflammatory mediator were 
ranked in descending order. The highest extreme values (>3SDs) were replaced with the highest 
value for that inflammatory mediator.  
The ranges and scales for the concentrations of inflammatory mediators varied among the 
different substances making assessments of their effects difficult using the absolute values. For 
this reason, these adjusted responses for the plasma and urine concentrations of cytokines were 
transformed into percentages of the range for each cytokine. This normalization technique 
allowed comparison between multiple inflammatory mediators on a common scale.  
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3.2.7 Data Analysis 
Two separate analyses were performed to identify the significant cytokines in plasma and urine. 
All data were analyzed using Statistical Package for Social Sciences (SPSS) version 20.0. 
Descriptive statistics using means, frequencies, standard deviations and standard error of mean 
was performed for individuals included in the study to identify plasma and urine inflammatory 
mediators.  
Mann-Whitney U test 
The demographics of the two groups of subjects (those who developed PUs and those who did 
not develop PU) were compared using a two-tailed Mann-Whitney U test (two-tailed); with 
continuous-level variables such as age and ISS[88].  
Mann-Whitney U statistic is for the two groups are  
U𝑃𝑈 = n𝑃𝑈n𝑁𝑂 𝑃𝑈 + n𝑃𝑈 (n𝑃𝑈 + 1)2 − R𝑃𝑈 
• U= Mann-Whitney U statistic 
• nPU is sample size of group 1 (individuals with PU) 
• nNO PU is sample size of group 1 (individuals with no PU) 
• RPU is sum of the ranks for age (or ISS) in PU group 
The Mann-Whitney U statistic (U) is the smaller of the two values calculated for UPU and UNO PU. 
Mann-Whitney U follows a z distribution. 
𝑧 = 𝑈 − 𝑛𝑃𝑈𝑛𝑃𝑈2
𝑛𝑃𝑈𝑛𝑃𝑈(𝑛𝑃𝑈 + 𝑛𝑃𝑈 + 1)12  
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Our hypotheses are:  
H0 (Null Hypothesis): The mean ranks of age (and ISS) between the two groups (individuals with 
PUs and individuals with no PUs) are expected to be the same. (or) Calculated z is between -1.96 
and 1.96 
H1 (Alternate Hypothesis): There is a difference between the ranks of age (and ISS) in the two 
groups (individuals with PUs and individuals with no PUs). (or) z < -1.96 or z > 1.96.  
The significance level was set at α = 0.05.   
Chi-Square Test 
A nonparametric test was performed on the nominal (gender male/female) and ordinal (ASIA 
scale score, A, B, C, D and E) data. The Chi-square statistic (two-tailed) was performed to test 
differences between the level of injury (and gender) in the two groups (those who developed PUs 
and those who did not develop PU). The chi-square statistic is[80, 88]:  
𝜒2 = � (𝑓0−𝑓𝑒)2
𝑓𝑒
 
• fo is observed frequency of ASIA (or gender) 
• fe is expected frequency (or gender) 
Our hypotheses are:  
H0 (Null Hypothesis): The severity of injury measured by ASIA scale score (or gender) and 
individuals who developed PUs are not related. 
H1 (Alternate Hypothesis): The severity of injury measured by ASIA scale score (or gender) and 
individuals who developed PUs are related. 
The significance level was set at α =0.05.  
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    Logistic Regression  3.2.7.1
Univariate Logistic Regression  
A univariate logistic regression analysis was conducted to assess each inflammatory mediator’s 
ability to predict the probability of the outcome (PU, yes/no). The model is[88]: 
𝐥𝐨𝐠𝐢𝐭 (𝐘) = 𝟏
𝟏 + 𝒆−(𝜷𝟎+𝜷𝟏𝑿𝟏) =  𝛃𝟎 +  𝛃𝟏𝐗𝟏 
• β0 is a constant 
• β1 is the coefficient of the individual predictor variable. 
• X1 is the inflammatory mediator (predictor) in question 
Our hypotheses are:  
H0 (Null Hypothesis): β1 = 0  
H1 (Alternate Hypothesis): β1 ≠ 0 
The significance level was set at α =0.05. 
Multivariate Logistic Regression  
The stepwise backward elimination logistic regression technique was used to identify 
inflammatory mediators to predict the outcome (PU yes/no). The model started with all 22 
plasma inflammatory mediators. In this full model the likelihood-ratio test for each mediator was 
examined as if it was the last one to enter given that other mediators are in the model. The 
process, by which the variables were included for the elimination of the model, was the 
likelihood-ratio test. A predictor with lowest likelihood-ratio test statistic was deleted from the 
model one at a time at each step since it won’t contribute to the outcome after other predictors 
are included and the equation is recomputed. The sequence is stopped when there are no more 
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predictors that are not significant on the statistic. The probability to remove a variable was set at 
0.10.  In this model α = 0.05 was selected to be the significance at each step, assuming that any α 
> 0.05 would contribute to noise rather than the predictive ability of the model. This means 
variables with α > 0.05 were neither significant nor a confounding factor. The backward stepwise 
regression model was built similarly for the urine inflammatory mediators. Two-tailed 
significance was set for α = 0.05.  
A multivariate logistic regression was then conducted with the significant plasma 
inflammatory mediators obtained from the stepwise backward elimination logistic regression 
technique. The outcome for the model was occurrence first pressure ulcer (yes/no). The model 
is[88]: 
𝐥𝐨𝐠𝐢𝐭 (𝐘) = 𝟏
𝟏 + 𝒆−(𝜷𝟎+𝜷𝟏𝑿𝟏+𝛃𝟐𝐗𝟐+⋯.𝛃𝐤𝐗𝐤) =  𝛃𝟎 + 𝛃𝟏𝐗𝟏 + 𝛃𝟐𝐗𝟐 + ⋯… + 𝛃𝐤𝐗𝒌 
• β1, β2…. βk are the regression coefficients for the independent variables of the regression 
equation.  
• X1, X2…Xk are the independent variables (risk factors in question).  
Our hypotheses are:  
H0 (Null Hypothesis): β1= β2=…. = βk (or) βi = 0  
H1 (Alternate Hypothesis): β1 ≠ 0 (or) βi ≠ 0 
The significance level was set at α = 0.05 (Two-tailed). 
The logistic regression coefficients, Wald statistic and the interpretation of these are 
described in Section 2.2.5.2 and 2.2.5.3.  
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    Hosmer-Lemeshow goodness of fit 3.2.7.2
The Hosmer-Lemeshow goodness of fit was computed. The Hosmer-Lemeshow test statistic is 
explained in is explained in Section 2.2.5.4. 
    Area under the Receiver Operating Characteristic (ROC) curve 3.2.7.3
The area under the ROC curve was computed and plotted. The area under the ROC curve and 
classification is explained in Section 2.2.5.5.The inflammatory mediators in urine were analyzed 
similarly.  
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3.3 RESULTS 
3.3.1 Plasma Analysis 
 Time course of plasma inflammatory mediators (n = 54) 3.3.1.1
 
 
Figure 5. Time from SCI to measure the plasma mediator and first PU. 
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    Demographics 3.3.1.2
The demographics and characteristics of individuals with PU and no PU in acute care through 
inpatient rehabilitation are listed in Table 11. 
    Age and Gender 3.3.1.3
The individuals with no formation of PU were older (45 years) than the individuals with PU (37 
years). The Mann-Whitney U test produced no significant difference in ages between the two 
groups. A majority of individuals in both the groups were males. The chi-square test produced no 
significant differences in gender distribution between the two groups. 
    Injury Severity 3.3.1.4
The severity of injury for the two groups is listed in Table 11. The chi-square test showed 
significant differences in the severity of injury ASIA and ISS between the two groups, p=0.002 
and p=0.002, respectively. Individuals with PU were mostly ASIA A’s (72%).  
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Table 11. Demographics comparison of PU and no PU groups  
Demographics All subjects 
n=54 
 Subjects with 
PUs 
n= 18 
Subjects with 
no PU  
n=36 
P value 
Age (years) 
Mean ± SEM 
 
42.17±2.39 37±4.19 44.75±2.88 0.088 
Gender M=42(77.8%) 
F=12(22.2%) 
 
M=12(66.7%) 
F=6(33.3%) 
M=30(83.3%)         
F=6(16.7%) 
0.165 
ASIA A=19(35.2%) 
B=9(16.7%) 
C=16(29.6%) 
D=8(14.8%) 
U=2(3.7%) 
A=13(72.2%) 
B=1(5.6%) 
C=2(11.1%) 
D=1(5.6%) 
U=1(5.6%) 
 
 
A=6(16.7%) 
B=8(22.2%) 
C=14(38.9%) 
D=7(19.4%) 
U=1(2.8%) 
0.002** 
Injury Severity 
Score (ISS) 
28.1±2.35  24.09±2.54 36.63±4.4 0.002* 
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Table 12. Means and SEM of Plasma and Urine inflammatory mediators after adjusting for outliers  
Inflammatory 
mediators 
(pg/ml) 
Subjects with 
PU 
Mean ± SEM 
Plasma 
Subjects with 
no PU 
Mean ± SEM 
Plasma 
Subjects with 
PU 
Mean ± SEM 
Urine 
Subjects with no 
PU 
Mean ± SEM 
Urine 
IL-1β 5.03±2 6.8±1.9 4.04±3 1.09±0.5 
IL-1RA 60.51±40.1 78.89±28.4 804.75±236.4 778.6±312.7 
IL-2 7.63±2.7 8.79±1.3 1.39±1.1 1.75±0.5 
IL-6 107.98±35.6 79.62±20.1 30.43±14 11.74±4.4 
IL-10 52.28±16.5 52.75±19.3 31.72±13.7 31.41±9.9 
TNF- α 10.34±4.5 7.34±2 1.49±0.6 5.69±2.9 
Eotaxin 33.82±4.8 44.5±5.4 21.56±11.7 4.3±1.4 
GM-CSF 6.85±4.6 5.47±2.5 26.71±13.9 16.29±4.8 
IFN-α 35.3±20.4 41.49±14.3 36.31±11.5 30.54±7.6 
IFN-γ 30.57±16.6 25.92±8.8 4.72±2.6 8.06±2.7 
IL-4 11±9.2 14.1±6.1 35.68±14.2 33.84±10.9 
IL-5 6.93±4 6.99±2.7 2.87±2.1 5.61±1.6 
IL-7 8.06±3.4 10.04±3.6 0.39±0.2 2.94±1.4 
IL-8 33.82±9.8 23.63±5 108.79±32.1 3.93±17.9 
IL-13 5.97±3 9.01±2.9 0.74±0.5 7.78±2.3 
IL-15 15.12±3.7 11.9±2 30.24±14.1 36.94±10.4 
IL-17 5.8±3.2 7.67±2.5 5.65±5.4 13.21±4.7 
IP-10 503.86±146.9 426.47±80.1 228.79±88.8 112.42±32.7 
MCP-1 515.32±155.6 411.24±76.5 1406.74±478.8 1075.08±289.5 
MIP-1α 60.67±22.6 34.83±7.5 51.15±21.1 38.26±12.3 
MIP-1β 46.15±14.7 47.99±8.4 22.47±5.9 20.16±4.5 
MIG 980.33±337.9 875.86±203 411.07±216.2 90.61±48.7 
NO2-/NO3- 22.54±4.9 19.85±2.4 281.96±43.1 317.62±29.1 
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    Univariate Logistic Regression  3.3.1.5
The means and SEM of the plasma and urine inflammatory mediators for individuals with and 
without PUs, after adjusting for the outliers is listed in Table 12. Table 13 shows the univariate 
logistic regression analysis for the 23 inflammatory mediators in plasma. The baseline 
concentrations of the individual plasma inflammatory mediators could not significantly predict 
the formation of first PU.  
 
Table 13. Univariate Logistic Regression for Plasma and Urine Biomarkers within 4 days after SCI 
Inflammatory 
mediators 
p value  
Plasma 
p value 
Urine 
IL-1β 0.537 0.271 
IL-1RA 0.556 0.958 
IL-2 0.666 0.756 
IL-6 0.289 0.132 
IL-10 0.987 0.985 
TNF- α 0.977 0.516 
Eotaxin 0.221 0.237 
GM-CSF 0.364 0.285 
IFN-α 0.704 0.916 
IFN-γ 0.783 0.469 
IL-4 0.481 0.922 
IL-5 0.990 0.357 
IL-7 0.723 0.421 
IL-8 0.222 0.774 
IL-13 0.514 0.160 
IL-15 0.291 0.713 
IL-17 0.377 0.361 
IP-10 0.612 0.265 
MCP-1 0.296 0.643 
MIP-1α 0.203 0.576 
MIP-1β 0.791 0.766 
MIG 0.335 0.211 
NO2-/NO3- 0.585 0.977 
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    Multivariate Stepwise Logistic Regression  3.3.1.6
A multivariate logistic regression was performed with pressure ulcer as outcome (PU present and 
no PU) and eleven predictors obtained from the stepwise backward logistic regression. The PU 
outcome was dichotomized into 2 levels. Table 14 shows the results of the multivariate logistic 
regression. All assumptions were met. There was a significant prediction of PU outcome by 
inflammatory mediators in plasma included in the final model, χ2 (11) = 24.237, p=0.012.  
There was significant prediction of PU outcome by of plasma inflammatory mediators 
IL-1RA (p=0.02), GM-CSF (p=0.03), IFN-γ (p=0.04), IL-5 (p=0.02), IL-17 (p=0.03), MIP-1α 
(p=0.01), MIP-1β (p=0.03) and MIG (p=0.04). The odds to develop PU increases by 1.3 and 1.2 
times increase in the plasma concentrations of MIP-1α and GMCSF, respectively. There was no 
significant prediction of pressure ulcer occurrence by IL-6 (p=0.08), IL-10 (p=0.2), and IL-8 
(p=0.09).  
    Hosmer-Lemeshow test statistic 3.3.1.7
There was no significant difference between the observed and predicted group membership, 
Hosmer-Lemeshow χ2 (8) =6.987, p= 0.538. This means that there is a good overall fit of the 
multivariate logistic regression model and that there was no misspecification of the predictors.  
    Area under the Receiver Operating Characteristic (ROC) curve 3.3.1.8
The area under the curve for the plasma inflammatory mediators included in the multivariate 
logistic regression model is 0.864 (Figure 6) with 95% confidence interval (0.77, 0.959). Also, 
the area under the curve is significantly different from 0.5 since p value is < 0.001 (Table 15). 
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This means that the plasma factors in the multivariate logistic regression model accurately 
classify individuals with formation of PU in the RERC on SCI population. 
    Adjusted Multivariate Logistic Regression  3.3.1.9
A multivariate logistic regression was performed with pressure ulcer as outcome (PU present and 
no PU) and eleven predictors obtained from the stepwise backward logistic regression. This 
model was adjusted for level of injury measured by ASIA scale score. The PU outcome was 
dichotomized into 2 levels. Table 16 shows the results of the multivariate logistic regression. All 
assumptions were met. There was a significant prediction of PU outcome by inflammatory 
mediators in plasma included in the final model, χ2 (14) = 9.77, p = 0.02. There was no 
significant prediction of pressure ulcer occurrence by the plasma mediators and the level of 
injury.  
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Table 14. Multivariate Logistic Regression of the plasma predictors within 4 days of SCI 
Independent 
Variables 
B SE Wald Sig (p) Exp(B) 
IL-1RA 
 
-0.091 0.040 5.218 0.022* 0.913 
IL-6 
 
0.086 0.050 3.042 0.081 1.09 
IL-10 
 
-0.098 0.068 2.095 0.148 0.907 
GM-CSF 
 
0.221 0.101 4.801 0.028* 1.247 
IFN- γ 
 
-0.414 0.198 4.381 0.036* 0.661 
IL-5 
 
0.338 0.147 5.334 0.021* 1.403 
IL-8 
 
0.063 0.037 2.921 0.087 1.065 
IL-17 
 
-0.157 0.071 4.894 0.027* 0.855 
MIP-1α 
 
0.266 0.107 6.138 0.013* 1.305 
MIP-1β 
 
-0.167 0.075 4.976 0.026* 0.846 
MIG -0.061 0.029 4.451 0.035* 0.941 
      
Constant 0.145 0.704 0.42 0.837 1.156 
 
Model χ2    = 24.237, p < 0.05 
Pseudo R2   = 0.502 
n               = 54 
 
 
 
Note: The dependent variable in this analysis is formation of pressure ulcer in acute care or inpatient 
rehabilitation, so that 0= did not have pressure ulcer and 1= had a formation of pressure ulcer  
**p<0.01, *p< 0.05 
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Figure 6. ROC Curve for Multivariate Logistic Regression Model for plasma biomarkers in RERC on SCI 
population 
 
 
Table 15. Area under the Curve for Multivariate Logistic Regression Model for plasma predictors 
 
Area 
 
Std. Error  
 
Sig  
Asymptotic 95% Confidence Interval 
Upper Bound Lower Bound 
0.864 0.048 0.000** 0.770 0.959 
  Test Variable (s): Predicted probability 
 
**p<0.01 
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Table 16. Multivariate Logistic Regression - Plasma predictors within 4 days of SCI adjusted with level of 
injury 
Independent 
Variables 
B SE Wald Sig (p) Exp(B) 
ASIA   6.46 0.09  
ASIA A – ASIA B 2.2 1.37 2.61 0.1 9.08 
ASIA A– ASIA C -18.86 12.33 0.00 0.99 0.00 
ASIA A– ASIA D -0.51 1.51 0.11 0.73 0.6 
IL-1RA 
 
-0.07 0.05 1.96 0.16 0.93 
IL-6 
 
0.02 0.07 0.11 0.73 1.03 
IL-10 
 
-0.05 0.07 0.48 0.48 0.95 
GM-CSF 
 
0.15 0.1 2.03 0.15 1.16 
IFN- γ 
 
-0.28 0.21 1.86 0.17 0.75 
IL-5 
 
0.22 0.18 1.43 0.23 1.24 
IL-8 
 
0.03 0.04 0.45 0.5 1.03 
IL-17 
 
-0.09 0.1 0.79 0.37 0.91 
MIP-1α 
 
0.18 0.12 2.35 0.12 1.2 
MIP-1β 
 
-0.11 0.06 2.86 0.08 0.9 
MIG 
 
-0.02 0.03 0.39 0.53 0.98 
Constant 
 
-0.67 1.33 0.25 0.62 0.51 
Model χ2    = 9.77, p < 0.05 
Pseudo R2   = 0.66 
n               = 54 
 
 
Note: The dependent variable in this analysis is formation of pressure ulcer in acute care or 
inpatient rehabilitation, so that 0= did not have pressure ulcer and 1= had a formation of pressure 
ulcer  
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 Correlational Analysis 3.3.1.10
In order to see if injury severity or any other demographic variables were related to the 
concentrations of the inflammatory mediators in plasma, a correlational analysis was performed. 
A correlational analysis was performed between the plasma mediators and demographics such as 
age (Spearman’s rank correlation), gender (Point-biserial correlation) and injury severity 
measured by ASIA scale (spearman’s rank correlation). Significant correlations are listed in 
Table 17. The Pearson’s correlational analysis between the plasma inflammatory mediators that 
were included in the multivariate model is listed Table 18. 
 
Table 17. Correlations – Plasma Mediators and Demographics 
Demographics 
 
 
Severity of 
Injury 
(ASIA) 
Inflammatory mediators 
 
Sample Size  (Correlation 
Coefficient) 
Sig. (2-tailed) 
IL-6 52 -.361** 0.009 
IL-10 52 -.380** 0.005 
IL-8 52 -.304* 0.029 
MCP-1 52 -.412** 0.002 
 
Gender IL-1β 54 .270* 0.048 
 
Age IL-6 54 -.290* 0.034 
    
 
 
 
*p<0.05, **p<0.01 
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Table 18.  Correlations between plasma inflammatory mediators 
Mediators 
Pearson 
Correlation 
IL-1RA IL-6 IL-10 GM-CSF IFN-γ IL-5 IL-8 IL-17 MIP-1α MIP-
1β MIG 
IL-1RA 1 0.29* 0.07 0.36** .38** 0.53** 0.24 0.32* -0.05 0.08 -0.13 
IL-6 0.29* 1 0.27* 0 0.20 0.18 0.56** 0.34* 0.28* 0.57** 0.13 
IL-10 0.07 0.27* 1 0.02 0.03 -0.03 0.26* 0.02 0.15 -0.03 -0.08 
GM-CSF 0.36** 0 0.02 1 0.76** 0.61** -0.04 0.64** 0.5** 0.39** -0.18 
IFN-γ 0.38** 0.20 0.03 .76** 1 0.84** 0.01 0.82** 0.67** 0.51** -0.24 
IL-5 0.53** 0.18 -0.03 .61** 0.84** 1 0.07 0.79** 0.29* 0.36** -0.21 
IL-8 0.24 0.56** 0.26* -0.04 0.01 0.07 1 -0.00 0.07 0.22 0.41** 
IL-17 0.32* 0.34* 0.02 0.64** 0.82** 0.79** -0.01 1 0.52** 0.58** -0.22 
MIP-1α -0.05 0.28* 0.15 0.50** 0.6** 0.29* 0.07 0.52** 1 0.63** 0.01 
MIP-1β 0.08 0.57** -0.03 0.39** 0.51** 0.36** 0.22 0.58** 0.63** 1 -0.00 
MIG -0.13 0.13 -0.08 -0.18 -0.24 -0.2 0.40** -0.22 0.01 -0.0 1 
 
 
*p<0.05, **p<0.01 
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3.3.2 Urine Analysis 
    Time course of the data (n = 53) 3.3.2.1
 
 
Figure 7. Time from SCI to measure the urine mediator and first PU. 
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    Demographics 3.3.2.2
The demographics and characteristics of individuals with PU and no PU in acute care through 
inpatient rehabilitation are listed in Table 19. 
    Age and Gender 3.3.2.3
The individuals with no formation of PU were older (45 years) than the individuals with PU (38 
years). The Mann-Whitney U test produced no significant difference in ages between the two 
groups. The Chi-square test produced no significant differences in gender distribution between 
the two groups. 
    Injury Severity 3.3.2.4
The severity of injury for the individuals with PUs and individuals with no PU is listed in Table 
19. There were significant differences in the severity of injury ASIA and ISS between the two 
groups, p < 0.001 and p < 0.01 respectively. Individuals with PUs were mostly ASIA A’s (81%).  
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Table 19. Comparison of Demographics in individuals with and without PUs 
Demographics All subjects 
N=53 
 Subjects with 
PUs 
n=16 
Subjects with 
no PU  
n=37 
p value 
Age (years) 
Mean ± SEM 
 
43.15±2.41 38.31±4.41 45.24±2.85 0.157 
Gender M=43(81.1%) 
F=10(18.9%) 
 
M=12(75%) 
F=4(25%) 
M=31(16.2%) 
F=6(83.8%) 
0.453 
ASIA A=19(35.8%) 
B=8(15.1%) 
C=17(32.1%) 
D=8(15.1%) 
U=1(1.9%) 
 
A=13(81.2%) 
B=0(0%) 
C=2(12.5%) 
D=1(6.2%) 
U=0(0%) 
A=6(16.2%) 
B=8(21.6%) 
C=15(40.5%) 
D=7(18.9%) 
U=1(2.7%) 
<0.001** 
Injury Severity 
Score (ISS) 
26.68±2.15 33.27±3.85 23.86±2.47 0.004** 
    Univariate Logistic Regression 3.3.2.5
Table 13 lists the results of the univariate logistic regression analysis for the 23 inflammatory 
mediators in urine. No individual inflammatory urine mediators were found significant.  
    Multivariate Logistic Regression for Urine Biomarkers 3.3.2.6
Because of differences in scaling of the urine inflammatory mediators, they were standardized to 
their percentage score. A multivariate logistic regression was performed with pressure ulcer as 
outcome (PU present and no PU) and twelve predictors obtained from the stepwise backward 
logistic regression: The PU outcome was dichotomized into 2 levels. Table 20 shows the results 
of the multivariate logistic regression. All assumptions were met. There was a significant 
prediction of PU outcome by all inflammatory mediators in urine included in the final model, χ2 
(12) = 34.650, p=0.001. There was significant prediction for the incidence of pressure ulcer by 
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urine inflammatory mediators IFN-γ (p=0.01), IL-5(p=0.02), IL-6 (p=0.04), IL-8(p=0.02), IL-
13(p=0.01), IL-17(p=0.02), MCP-1(p=0.04), TNF-α (p=0.02), and MIG (p=0.00). The odds to 
develop PU increases by 6.8 times with increased urine concentrations of IL-5, by 1.6 times with 
increased urine concentrations of IFN-γ and by 1.2 times with increase in the urine 
concentrations of MIG, immediately following SCI. There was no significant prediction of 
pressure ulcer occurrence by GMCSF (p=0.1), IP-10 (p=0.08), and NO2-/NO3- (p=0.06) 
    Hosmer-Lemeshow goodness of fit 3.3.2.7
The Hosmer-Lemeshow in this study was χ2 (8) =10.2, p=0.251. This means that there was a 
good overall fit of the multivariate logistic regression model with no misspecification of the 
predictors.  
    Area under the Receiver Operating Characteristic (ROC) curve 3.3.2.8
The area under the curve for the urine inflammatory mediators included in the multivariate 
logistic regression model is 0.932 (Figure 8) with 95% confidence interval (0.852, 1.000). Also, 
the area under the curve is significantly different from 0.5 since p value is < 0.001 (Table 21).  
    Adjusted Multivariate Logistic Regression  3.3.2.9
A multivariate logistic regression was performed with pressure ulcer as outcome (PU present and 
no PU) and twelve predictors obtained from the stepwise backward logistic regression. This 
model was adjusted for level of injury measured by ASIA scale score. The PU outcome was 
dichotomized into 2 levels. Table 22 shows the results of the multivariate logistic regression. All 
assumptions were met. There was a significant prediction of PU outcome by inflammatory 
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mediators in plasma included in the final model, χ2 (15) 15.9, p <0.001. There was no significant 
prediction of pressure ulcer occurrence by the urine mediators and the level of injury.  
 
Table 20. Multivariate Logistic Regression of the urine factors with 4 days of SCI 
Independent 
Variables 
B SE Wald Sig (p) Exp(B) 
GM-CSF 
 
-0.182 0.118 2.366 0.124 0.834 
IFN-γ 0.48 0.178 7.247 0.007** 1.616 
IL-5 
 
1.92 0.827 5.391 0.02* 6.819 
IL-6 
 
0.139 0.068 4.218 0.04* 1.149 
IL-8 
 
-0.127 0.056 5.118 0.024* 0.880 
IL-13 
 
-0.863 0.347 6.175 0.013* 0.422 
IL-17 
 
-1.946 0.802 5.891 0.015* 0.143 
IP-10 
 
0.193 0.108 3.168 0.075* 1.213 
MCP-1 
 
-0.126 0.060 4.371 0.037* 0.882 
TNF-α 
 
-1.797 0.751 5.719 0.017* 0.166 
MIG  
 
0.25 0.087 8.150 0.004** 1.283 
NO2-/ NO3- -0.069 0.036 3.727 0.054 0.933 
      
Constant 0.195 1.443 0.018 0.892 1.216 
 
Model χ2    = 34.65, p < 0.05* 
Pseudo R2   = 0.68 
n               = 53 
 Note: The dependent variable in this analysis is formation of pressure ulcer in acute care or inpatient 
rehabilitation, so that 0= did not have pressure ulcer and 1= had a formation of pressure ulcer 
*p< 0.05, **p<0.01 
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Figure 8. ROC Curve for Multivariate Logistic Regression Model for urine biomarkers in RERC on SCI 
population 
 
Table 21. Area under the Curve for Multivariate Logistic Regression Model for urine predictors 
 
Area 
 
Std. Error  
 
Sig  
Asymptotic 95% Confidence Interval 
Upper Bound Lower Bound 
0.932 0.041 0.000** 0.852 1.000 
 **p<0.01 
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Table 22. Multivariate Logistic Regression - Plasma predictors within 4 days of SCI adjusted with level of 
injury 
Independent 
Variables 
B SE Wald Sig (p) Exp(B) 
ASIA   3.85 0.27  
ASIA A – ASIA B 19.07 15.84 1.43 0.23 17.9 x 107 
ASIA A – ASIA C -42.1 4.7 x 103 0.00 0.99 0.00 
ASIA A – ASIA D 14.18 14.17 1.00 0.31 14.5 x 105 
GM-CSF 
 
0.02 0.49 0.00 0.96 1.02 
IL-13 
 
-1.24 0.86 2.09 0.14 0.28 
IL-6 
 
-0.06 0.13 0.2 0.64 0.93 
IFN-γ 1.19 0.79 2.29 0.13 3.3 
IL-5 
 
1.42 0.18 1.43 0.23 4.14 
IL-8 
 
-0.07 0.13 0.29 0.58 0.93 
IL-17 
 
-2.13 1.62 1.74 0.18 0.11 
IP-10 
 
-0.62 0.37 2.71 0.1 1.86 
MCP-1 
 
0.15 0.2 0.53 0.46 1.16 
TNF-α 
 
-1.45 1.21 1.44 0.23 0.23 
MIG  
 
0.12 0.1 1.3 0.25 1.13 
NO2-/ NO3- 
 
-0.28 0.19 2.17 0.14 0.75 
Constant 
 
-12.43 13.27 0.87 0.34 0.00 
Model χ2    = 15.9, p < 0.01** 
Pseudo R2   = 0.87 
n               = 53 
 
 
Note: The dependent variable in this analysis is formation of pressure ulcer in acute care or inpatient 
rehabilitation, so that 0= did not have pressure ulcer and 1= had a formation of pressure ulcer 
*p< 0.05, **p<0.01 
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 Correlational Analysis 3.3.2.10
A correlational analysis was performed between the urine mediators and demographics such as 
age (spearman’s rank correlation), gender and (Point-biserial correlation) and injury severity 
measured by ASIA scale (spearman’s rank correlation). Significant correlations are listed in. 
Table 23. The Pearson’s correlational analysis between the plasma inflammatory mediators that 
were included in the multivariate model is listed in Table 24. 
 
Table 23. Correlations- Urine Mediators and Demographics 
 
 
 
 
 
Severity of 
Injury 
(ASIA) 
Inflammatory mediators Sample Size  Correlation 
Coefficient 
Sig. (2-tailed) 
GM-CSF 52 -.278* 0.046 
 IL-1Ra 52 -.355** 0.01 
 IL-1b 52 -.391** 0.004 
 MIP-1b 52 -.301* 0.03 
*p<0.05, **p<0.01 
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Table 24. Correlations between urine inflammatory mediators 
 
Mediators 
Pearson  
Correlation 
GM-CSF IFN-γ IL-5 IL-6 IL-8 IL-13 IL-17 IP-10 MCP-1 TNF-α MIG NO2
-/ 
NO3- 
GM-CSF 1 0.19 0.47** 
0.59*
* .44** 0.22 0.39** 0.5** -0.04 0.17 -0.07 0.02 
IFN-γ 0.19 1 .81** 0.08 0.07 0.49** 0.88** -0.14 -0.14 0.32* -0.08 -0.18 
IL-5 0.47** 0.81** 1 0.14 0.21 
0.62*
* 0.90** -0.05 -0.11 0.24 -0.11 -0.23 
IL-6 0.59** 0.08 0.14 1 0.56** 0.07 0.17 0.37** 0.10 -0.02 0.09 0.09 
IL-8 0.44** 0.07 0.21 0.56** 1 0.22 0.13 0.52** 0.29* 0.05 
0.41*
* -0.15 
IL-13 0.22 0.49** 
0.62*
* 0.07 0.22 1 0.65** -0.14 -0.02 -0.06 -0.09 -0.22 
IL-17 0.39** 0.88** 0.9** 0.17 0.13 
0.65*
* 1 -0.16 -0.15 0.24 -0.12 -0.23 
IP-10 0.50** -0.14 -0.05 .37** 0.52** -0.14 -0.16 1 0.27* 0.25 0.29* 0.07 
MCP-1 -0.04 -0.14 -0.11 0.10 0.29* -0.02 -0.15 0.27* 1 -0.09 0.66** 0.06 
TNF-α 0.17 0.32* 0.24 -0.02 0.05 -0.06 0.24 0.25 -0.09 1 -0.00 -0.03 
MIG -0.07 -0.08 -0.11 0.09 0.41** -0.09 -0.12 0.02* 0.66** -0.00 1 0.02 
NO2-/ NO3- 0.02 -0.18 -0.23 0.09 -0.15 -0.22 -0.23 0.07 0.06 -0.03 0.02 1 
*p<0.05, **p<0.01 
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3.4 DISCUSSION 
This is the first study to investigate the inflammatory mediators in both plasma and urine 
biofluids immediately after SCI associated with the formation of the first PU. This study 
identified the plasma and urine inflammatory predictors by using the stepwise backward 
elimination technique [112]. The goal of this study was to explore relationships in the plasma 
(and urine concentrations) of inflammatory mediators associated with the formation of first PU 
following TSCI. The inflammatory mediators associated with formation of first PU in both 
plasma and urine biofluids were IFN-γ, IL-5, IL-17 and MIG. Decreased plasma and urine 
concentrations of IL-17 and increased plasma and urine concentrations of IL-5, increased urine 
concentrations and decreased plasma concentrations of IFN-γ and MIG were associated with the 
formation of first PU immediately after traumatic spinal cord injury. Increased plasma 
concentrations of GM-CSF and MIP-1α, and decreased plasma concentrations of IL-1RA and 
MIP-1β, but no changes in the urine concentrations; and increased urine concentrations of IL-6 
and IP-10; and decreased urine concentrations of IL-8, IL-13, MCP-1 and TNF-α, but no changes 
in plasma concentrations were shown to be associated with formation of first PU in this study. 
The concentrations of some inflammatory mediators in urine, immediately after SCI that predict 
formation of the first PU, were not similar as compared to the plasma concentrations. Previous 
studies comparing the inflammatory cytokines in both plasma and urine after exercise [113] and 
renal disease [110], also reported different plasma and urine mediators associated with exercise 
and renal disease.  
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The inflammatory mediators in plasma and urine, which correlated with severity of 
injury, were not similar to the mediators that were associated with the formation of first PU. 
Hence, the inflammatory mediators that were significant were specific to the formation of PUs.  
3.4.1 Interferon-gamma (IFN-γ) 
We found increased plasma concentrations and decreased urine concentrations of IFN-γ 
following initial injury associated with later development of first pressure ulcer in individuals 
with traumatic SCI. IFN-γ is a cytokine that belongs to type II interferon family [114]. It is 
activated by natural killer cells and T lymphocytes and is known to stimulate macrophages and 
immune cells. The macrophages at the site of wound tissue in turn stimulate the synthesis of 
chemical mediators such as the IFN-γ that participates in the fibroblast proliferation and 
migration.  [115, 116]. It has both anti-tumor and anti-proliferative activities [117]. It is a 
chemoattractant and increases during infections [118] and bronchial asthma [119]. 
Therapeutically it is used as a treatment protocol for idiopathic pulmonary fibrosis [120] and 
systemic sclerosis [121]. IFN-γ plays an essential role in innate immunity by participating in the 
first line of defense against infection and also contributes towards the activation of adaptive 
immunity [122]. IFN-γ thus regulates the immune system and participates in the process of 
wound healing [116]. It is known to increase during the late phase of inflammation [123]. 
Although IFN-γ is known to have an important role in initial stages of infection and participates 
in the process of wound healing it can also predispose the body to a pathological state [122]. This 
can explain the imbalance in IFN-γ in urine and plasma that is associated with development of 
PUs in this population.  It is still unclear as to why there were differences in concentrations of 
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IFN-γ in the urine and plasma bio fluids associated with the formation of first PU in this 
population.  
3.4.2 Interleukin-5 (IL-5) 
We found increased plasma and urine concentrations of IL-5 following initial injury associated 
with later development of first pressure ulcer in individuals with traumatic SCI. IL-5 is a 
cytokine that belongs to the hematopoietic family produced by mast cells [124]. It stimulates 
macrophages and immune cells [115]. Imbalance in the concentrations of IL-5 is known to be 
associated with allergic conditions such as asthma [125], eosinophilia due to increased 
concentrations of eosinophils in blood, bone marrow and spleen [126, 127]. Eosinophils in turn 
plays a role in tissue damage [126]. Administration with anti-IL-5 decreased the development of 
eosinophilia [126], infections [128] and asthma [129]. Increased synthesis of IL-5 is associated 
with delay in the process of wound healing since it enhances the inflammatory process and 
inhibits the process of re-epithelialization [130]. The increase in the plasma and urine 
concentrations of IL-5 increases the overall pro-inflammatory response that may be associated 
with the development of first PU in this population.  
3.4.3 Interleukin-17 (IL-17) 
We found decreased plasma and urine concentrations of IL-17 following initial injury associated 
with later development of first pressure ulcer in individuals with traumatic SCI. IL-17 is a pro-
inflammatory cytokine [131]. During the initial stages of immune response, IL-17 signals the 
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neutrophils to accumulate at the site of inflammation [123]. IL-17 stimulates the production of 
other cytokines and chemokines such as GM-CSF, IL-8, IL-1RA, TNF-α, IL-6 and IL-10; and 
thus up regulates the immune system [123, 132]. The synthesis of IL-17 increases in a variety of 
inflammatory conditions such as psoriasis [133], multiple sclerosis [134], arthritis [135], 
amyotrophic lateral sclerosis [136] and neuropathic pain [137].  IL-17 further directs the 
neutrophils and macrophages to the site of injury. The protein and mRNA expression levels of 
IL-17 were increased in mice with pressure ulcers as compared to the no PUs. This indicates the 
association of IL-17 in formation and development of PUs [123]. Imbalance in the inflammatory 
response due to decreased secretions of IL-17 may be associated with the formation of PU in this 
population.  
3.4.4 Monokine induced by gamma interferon (MIG) 
We found increased urine concentrations and decreased plasma concentrations of MIG following 
initial injury associated with later development of first pressure ulcer in individuals with 
traumatic SCI. MIG belongs to the CXC chemokine family is chemoattractant induced by IFN-γ 
is also called CXCL9. It is functionally related to IP-10 and is involved in recruitment of 
lymphocytes [138]. It is elevated during ocular sarcoidosis [139], meliodosis [140], rheumatoid 
arthritis [141] and is known to have anti-tumor activity [142]. It is one of the dermal mediators 
expressed during skin inflammation, various skin diseases [143] and venous leg ulcers [144]. 
The imbalance in concentrations of MIG in urine and plasma may be attributed to PU formation 
in this population. It is unclear as to why there are differences in concentrations of MIG in the 
urine and plasma bio fluids associated with the formation of first PU in this population.  
 86 
 
3.4.5 Granulocyte-macrophage colony-stimulating factor (GM-CSF) 
We found increased plasma concentrations of GM-CSF following initial injury associated with 
later development of first pressure ulcer in individuals with SCI. GM-CSF is a cytokine that is 
stimulated by T cells, fibroblasts and endothelial cells [145]. Although the mechanism of GM-
CSF is not well understood during inflammation, it is known to function systemically [146]. 
Studies have shown increased concentrations of GM-CSF in inflammatory and autoimmune 
diseases and host protection [146, 147] such as rheumatoid arthritis [148], renal and lung 
disorders [149] suggesting its pro-inflammatory response. Some studies also suggested its anti-
inflammatory response playing a beneficial role in pulmonary fibrosis [150]. Studies have 
indicated difficulty in detecting the GM-CSF levels in human serum in individuals with sepsis 
[151]. GM-CSF is known to increase the secretion of other pro-inflammatory cytokines such as 
TNF-α, interleukin-1 (IL-1) and interleukin-8 (IL-8) [152]. Since GM-CSF leads to synthesis of 
the pro-inflammatory mediators, blockage of GM-CSF is therapeutic since it decreases the 
adverse inflammatory effects caused by this cytokine [153]. Local injections of GM-CSF are 
known to heal sacral PUs. It also promotes the formation of granulation tissue by enhancing 
tissue proliferation and thus increases the fibroblast activation [154, 155]. Increase in GM-CSF 
activity was found in wound fluids and tissues in individuals with chronic leg venous ulcers. This 
indicates the role of this cytokine in the regulation of the immune system during the process of 
wound healing [156]. Studies have shown that the production of GM-CSF is essential for 
communication between the local tissue cells during an inflammatory reaction that takes place 
after SCI [146]. In this study the increase in plasma concentrations of GM-CSF immediately 
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after SCI associated with for development of PUs can be attributed to its increased pro-
inflammatory activity.  
3.4.6 Macrophage inflammatory protein-1α (MIP-1α) 
We found increased plasma concentrations of MIP-1α following initial injury associated with 
later development of first pressure ulcer in individuals with SCI. MIP-1α also called CCL3, is 
responsible for the synthesis and secretion of many pro-inflammatory cytokines such as IL-6 and 
TNF-α as it induces the recruitment of lymphocytes at the site of inflammation [157]. MIP-1α is 
known to have variety of pro-inflammatory properties, and there is evidence of increased MIP-
1α in subjects with rheumatoid arthritis, and osteoarthritis [158], acute lung injury [159], early 
after spinal cord injury at the level of lesion and is further elevated as the days since injury 
increases [160]. Previous studies have shown increase in synthesis of MIP-1α in the injured 
spinal cord immediately after SCI and eventually decreases days after the injury [161, 162]. 
MIP-1α alters the overall process of wound healing by decreasing fibrosis [163]. Deficiency in 
synthesis of MIP-1α in the brain of mice decreased the pro-inflammatory responses [164]. 
Previous studies have shown the importance of the inflammatory process in the prevention of 
PUs [72]. In this study the increase in plasma concentrations of MIP-1α immediately after SCI 
was associated with development of PUs. We hypothesize that the increase in plasma 
concentrations of MIP-1α immediately after SCI may decrease the overall anti-inflammatory 
response essential for the repair and regeneration process to prevent secondary complications 
after SCI such as PUs.  
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3.4.7 Interleukin-1 receptor antagonist (IL-1RA) 
We found decreased plasma concentrations of IL1-RA following initial injury associated with 
later development of first pressure ulcer in individuals with SCI. IL-1RA belongs to the 
interleukin 1 cytokine family, secreted by neutrophils is involved in wound healing and 
inflammation[115]. It is an anti-inflammatory cytokine and inhibits the synthesis of IL-1 [165]. 
Increased plasma and/or urine levels of IL-1RA were associated with sepsis [166], rheumatic 
diseases and osteoporotic fractures [167, 168], and schizophrenia [169]. IL-1RA is an acute 
phase protein and previous literature shows increase in the plasma concentrations of IL-1RA 
when individuals were subjected to trauma and during infections [165]. IL-1RA had been used as 
a therapeutic intervention is individuals, cancer [170]  and neuropathy [171]. IL-1RA was 
identified as one of the early markers for mechanically induced epidermal damage along with IL-
8 and TNF- α [71]. Although the role of IL-1RA in individuals with SCI and PUs needs to be 
clarified, it is known to maintain homeostasis throughout the acute inflammatory response after 
SCI, by maintaining a balance between IL-1 and IL-1RA, thus influencing the host immune 
response to the traumatic event [172]. 
3.4.8 Macrophage inflammatory protein-1β (MIP-1β) 
We found decreased plasma concentrations of MIP-1β following initial injury associated with 
later development of first pressure ulcer in individuals with SCI. MIP-1β also called CCL4 is a 
chemoattractant especially leukocyte attractant. Although this can be beneficial since it 
accumulates leukocytes to inhibit infection and contributes to repair, excess accumulation of 
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leukocytes due to the synthesis of MIP-1β could be pathological [173]. Its secretion increases in 
multiple sclerosis [174], osteoarthritis [175, 176], myositis [177], bronchitis [178] and 
rheumatoid arthritis [176]. The expression of MIP-1β was increased in ulcerative tissues as 
compared to healthy individuals [179]. Imbalance in the MIP-1β activity was found in wound 
fluids and tissues in individuals with chronic leg venous ulcers. This indicates the role of this 
cytokine in the regulation of the immune system during the process of wound healing [156]. The 
lack of leucocyte infiltration to inhibit the infection, due to decreased synthesis of MIP-1β could 
contribute to the development of PUs in this population.  
3.4.9 Interleukin-6 (IL-6) 
We found increased urine concentrations of IL-6 following initial injury associated with later 
development of first pressure ulcer in individuals with SCI. IL-6 is a pro-inflammatory cytokine 
and takes part in anti-microbial function and tissue repair. It is stimulated by macrophages, mast 
cells, lymphocytes and immune cells [115]. It is associated with diseases such as rheumatoid 
arthritis [180], cancer [181], diabetes [182], renal disease [183], immunosuppression [184], 
cardiovascular disease [185] and psoriasis [186]. Increase in IL-6 activity was found in wound 
fluids, tissues in individuals with chronic leg venous ulcers [156] and cutaneous ischemic 
reperfusion cutaneous injury [187]. There were increased concentrations of IL-6 observed in 
both human and rodents with SCI [162]. Previous studies indicated increased plasma 
concentrations of IL-6 associated with individuals with SCI, and their concentrations was further 
increased in individuals with SCI having PUs as compared to able-bodied individuals [32]. The 
blood levels of IL-6 were increased in individuals with malnutrition and aggravated the catabolic 
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activity in these individuals predisposing them with PUs [107]. The levels of IL-6 remain low 
during physiological conditions, but a slight increase in stress, injury or infection increased the 
levels of IL-6 since their source is not only the immune cells but also the muscles, keratinocytes, 
hepatocytes, adipose tissue and fibroblasts [184]. Although the urine concentrations of IL-6 
increases after SCI in this study is associated with the incidence of first pressure ulcer it may not 
be a true marker of formation of PUs given a varied number of co-morbidities among individuals 
with SCI and IL-6 increases in slight stress and inflammation.  
3.4.10 Interferon gamma induced protein (IP-10) 
We found increased urine concentrations of IP-10 following initial injury associated with later 
development of first pressure ulcer in individuals with SCI. Previous studies have shown the 
increased synthesis of IP-10 in pulmonary disease, tuberculosis, diabetes mellitus, autoimmune 
and thyroid diseases [188-195]. IP-10 was one of the macrophage/monocyte-associated 
inflammatory mediators associated with non-healing of diabetic foot ulcers in both wound fluid 
and plasma samples [196, 197]. This connects the presence of systemic inflammatory biomarkers 
in diabetic foot ulcers manifested with infection.  Nevertheless, the role of IP-10 in pressure 
ulcers in individuals with SCI remains obscure. This is the first study to find significant increase 
in the urine concentrations of IP-10 in individuals immediately after SCI (within four days) in 
the RERC on SCI population. IP-10 is a chemokine secreted by the CXCL10 gene. As a 
chemoattractant it activates the T cells towards sites of tissue inflammation [118, 198].  IP-10 is 
known to have both pro-inflammatory and anti-angiogenic properties. As a pro-inflammatory 
chemokine, IP-10 inhibits and limits the fibroblast recruitment and motility in individuals with 
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chronic wounds [199]. During physiologic conditions the process of angiogenesis is finely 
regulated associated with formation of new blood vessels that supply oxygen and nutrients to the 
tissue and aid in the formation of granulation tissue. The process of angiogenesis is important for 
the wound healing process [200]. IP-10, as an angiogenic inhibitor prevents the growth of the 
new blood vessels from pre-existing vessels [201]. This probably explains the increase in the 
urine levels of IP-10 immediately after SCI in this study since there is no growth of new vessels 
to participate in tissue regeneration process. This increase in the pro-inflammatory cells 
precipitates a complex inflammatory cascade of events that predisposes the individuals to form 
PU. Intervention with an antibody to neutralize the inflammatory effects of IP-10 in mice 
subjected to SCI reduced tissue injury by neutralizing the inflammation and thus improving 
functional recovery by angiogenesis [202, 203]. This increased urine secretion of IP-10 
following SCI during the process of regeneration and repair may spill over in systemic 
circulation thus causing secondary complications such as PUs. This clarifies the role of IP-10 in 
the pathogenesis of PUs in individuals with SCI. 
3.4.11 Interleukin-8 (IL-8) 
We found decreased urine concentrations of IL-8 following initial injury associated with later 
development of first pressure ulcer in individuals with SCI. IL-8 is a pro-inflammatory cytokine 
that is stimulated by macrophages, lymphocytes and mast cells [115]. It promotes angiogenesis 
and signals the feed-forward mechanisms that in turn increases the secretion of IL-8 from 
neutrophils [115]. During physiologic conditions the process of angiogenesis is finely regulated 
associated with formation of new blood vessels that supply oxygen and nutrients to the tissue and 
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aid in the formation of granulation tissue. The process of angiogenesis is important for the 
wound healing process [115, 200]. IL-8 is associated with diseases such as rheumatoid arthritis 
[204] and psoriasis [205]. Imbalance in the IL-8 activity was found in wound fluids and tissues 
in individuals with chronic leg venous ulcers [156]. There were increased concentrations of IL-8 
observed in both human and rodents with SCI [162]. IL-8 was identified as one of the early 
markers for mechanically induced epidermal damage along with IL-1RA and TNF- α [71]. In 
this study the urine concentrations of IL-8 decreases after SCI that is associated with the 
incidence of first pressure ulcer. Increased levels of IL-8 is seen in healing wounds since it 
participates in regeneration and repair process [206]. Lack of angiogenesis due to decreased IL-8 
synthesis on this study after SCI can probably explain the association to the formation of 
pressure ulcer.  
3.4.12 Interleukin-13 (IL-13) 
We found decreased urine concentrations of IL-13 following initial injury associated with later 
development of first pressure ulcer in individuals with SCI.IL-13 has both pro-inflammatory and 
anti-inflammatory properties [28]. The synthesis of IL-13 increases in when there is allergic 
inflammation [207], lung disease and asthma [208], pulmonary fibrosis [209] and sclerosis [210]. 
There were increased concentrations of IL-13 observed in rodents with SCI [162]. IL-13 also 
induces tissue fibrosis, as it stimulates fibroblast proliferation and collagen synthesis [209]. It 
affects the process of wound healing and lung function [211]. It mainly has anti-inflammatory 
and suppresses the production and synthesis of pro-inflammatory cytokines such as IL-6, IL-1, 
IL-10, IL-12, TNF-α and GM-CSF; and chemokines such as IL-8, and MIP [207]. In this study 
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the urine concentrations of IL-13 decreases after traumatic SCI that is associated with the 
incidence of first pressure ulcer. The decrease in the anti-inflammatory activity due to decrease 
in the urine excretions of IL-13 may not be sufficient to inhibit or control the inflammatory 
response after SCI predisposing the individuals to PUs.  
3.4.13 Monocyte chemotactic protein-1 (MCP-1) 
We found decreased urine concentrations of MCP-1 following initial injury associated with later 
development of first pressure ulcer in individuals with SCI. MCP-1 is a chemokine and attracts 
monocytes, participates is host defense and inflammatory response. Macrophages, lymphocytes, 
endothelial cells and fibroblasts secrete MCP-1. It contributes towards ischemic reperfusion 
injury in myocardium and kidney [212]. The concentration of MCP-1 increases in individuals 
with coronary artery disease since it is a chemoattractant and activates monocytes and 
macrophages to the site of inflammation [213]. Its synthesis increases during inflammatory 
diseases such as psoriasis [214], arthrosclerosis [215], rheumatoid arthritis [216], and during 
neurological conditions such as epilepsy [217], ischemia [218], and traumatic brain injury [219]. 
Previous studies have shown that the plasma concentrations of MCP-1 also increase in 
individuals with diabetes [220] and diabetic foot ulcers [212]. In this study the urine excretions 
of MCP-1 decreases immediately after SCI that is associated with the development of first 
pressure ulcer. There were increased concentrations of MCP-1 observed in both human and 
rodents with SCI [161, 162]. The protein levels of MCP-1 increase during the compressed phase 
of ischemic reperfusion cycles. Also, the healing of the wounds was significantly more during 
MCP-1 deficiency since it reduces the ischemia reperfusion injury. Also, there is reduction in 
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number of skin infiltrating cells such as macrophages, and the activation of pro-inflammatory 
mediators such as iNOS and TNF-α were inhibited, following IR cycles in MCP-1 deficient mice 
[187]. In this study the urine concentrations of MCP-1 decreases after traumatic SCI that is 
associated with the incidence of first pressure ulcer. Insufficient inflammatory response may 
contribute towards formation of the PU in this population.   
3.4.14 Tumor necrosis factor-alpha (TNF-α) 
We found decreased urine concentrations of TNF-α following initial injury associated with later 
development of first pressure ulcer in individuals with SCI. In this study the urine excretions of 
TNF-α decreases immediately after SCI that is associated with the incidence of first pressure 
ulcer. TNF-α, a pro-inflammatory cytokine is synthetized after activation of neutrophils. It is 
stimulated by macrophages and neutrophils and thus participates in the process of wound healing 
and inflammation [115]. It is a chemoattractant and increased synthesis of TNF-α cause infection 
such as fever and granulocytosis. It also induces angiogenesis [115]. During physiological state 
TNF-α is not detected in human serum and tissue [221]. Its concentration increases during 
inflammatory conditions such as asthma [119], rheumatoid arthritis, inflammatory lung diseases 
and traumatic brain injury[221]. During physiologic conditions the process of angiogenesis is 
finely regulated associated with formation of new blood vessels that supply oxygen and nutrients 
to the tissue and aid in the formation of granulation tissue. The process of angiogenesis is 
important for the wound healing process [200]. TNF- α was identified as one of the early 
markers for mechanically induced epidermal damage along with IL-8 and IL-1RA [71]. It was 
increased during cutaneous ischemic reperfusion cutaneous injury [187]. There are increased 
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proportions of TNF-α in the wound fluids in individuals with chronic venous ulcers. Also, 
increased serum proportions of TNF-α were related to non-healing ulcers as compared to healing 
ulcers [222]. TNF-α is also known to stimulate the synthesis of collagen and collagenase[115]. 
Collagenase helps in prevention and treatment of pressure ulcers[223]. This can explain the 
decreased urine concentrations of TNF-α associated with development of PU in this study. 
 
TNF-α, and IFN-γ to contribute towards the inflammatory process during the process of wound 
healing by augmenting the synthesis of nitric oxide (NO) [224]. This affects the infiltration and 
proliferation of the fibroblasts and the collagen gels at the site of the wounds thus helps in 
enhancing overall wound healing process [115]. In this study there was significant decrease in 
the excretion of TNF-α, and IFN-γ in urine that is associated with the formation of first pressure 
ulcer. The decrease production of these cytokines may be associated with the damage to the 
tissue in these individuals. Previous studies have shown elevation of IP-10, IL-6, IL-8 and MCP-
1 in the CSF levels of individuals with SCI [225]. In this study there were increased urine 
concentrations of IP-10, and IL-6; and decreased urine concentrations of IL-8 and MCP-1.  
Hence, the underlying inflammatory factors due to TSCI could contribute towards the imbalance 
in inflammatory mediators associated with development of pressure ulcers in this population.  
Adjusting for the Level of Injury  
To identify the baseline (within 4 days after SCI) concentrations in plasma (and urine), to predict 
first pressure ulcer; the severity of injury (ASIA scale score) was included with the significant 
mediators obtained from the initial analysis of Aim 2. Including ASIA scale score in the final 
model, did decrease the overall degree significance for the individual mediators (plasma and 
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urine) as compared to the initial analysis (since the power decreased by adding more predictors 
in the multivariate logistic regression model) and the ASIA scale score did not turn up to be 
significant. Adding the ASIA scale score does not add much to the original analysis. This is not 
surprising, since the mediators (in plasma and urine) that were significant in original analysis in 
Aim 2 were not correlated with ASIA scale score. The impact of cardiovascular, pulmonary and 
other comorbidities, and medications and other interventions with the inflammatory markers 
were not examined. Future studies should be conducted adjusting for these conditions. 
Additional Analysis 
In an attempt to build a parsimonious model with few inflammatory mediators in urine and 
plasma immediately after SCI, that can explain the occurrence of PU,  the all possible 
regressions was performed as an alternate analysis. The model was built to identify the most 
important plasma and urine predictors that can explain the occurrence of pressure ulcer. The all 
possible regressions model helps to predict well in a new sample and thus is more reliable and is 
a well-known data exploration technique. The model was built with 10 independent variables 
(plasma mediators) and 12 independent variables (urine mediators) obtained from the backward 
logistic regression. Since the models are not nested within each other, an AIC criterion was used 
to compare the model equations with the 10 plasma and 12 urine predictors obtained from the 
stepwise backward logistic regression technique. A restricted model was thus obtained with 
fewer predictors. The best subset model consisted of 9 plasma inflammatory predictors. The 
overall model significantly predicted the pressure ulcer outcome. χ2 (9) = 17.67, p=0.039. 
Decreased plasma concentrations of IL-1RA (p=0.05), and increased plasma concentrations of 
IL-6 (p=0.03), IL-5 (p=0.05) and MIP-1α (p=0.05) were identified as the most important 
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predictors that can explain the occurrence of PU in this population. IFN-γ (0.13), GM-CSF (0.07) 
and MIG (0.16) were not significant. The best subset model consisted of 8 urine inflammatory 
predictors. The overall model significantly predicted the pressure ulcer outcome. χ2 (8) = 24.7, 
p=0.002. Decreased urine concentrations of IL-13 (0.01), and increased plasma concentrations of 
IL-6 (p=0.04), MIG (p=0.03), MIP-1β (p=0.07) and IFN-γ (p=0.02) were identified as the most 
important predictors that can explain the occurrence of PU in this population. TNF-α (p=0.2), IL-
8 (p=0.06), IL-17 (p=0.06) and NO2-/NO3- (p=0.07).  
The significant predictors obtained from the parsimonious model were the best subset of 
predictors that were obtained from the original analysis. This means the parsimonious model 
helps with the significant predictors helps to explain the formation of first PU in individuals with 
SCI using fewer parameters.  
3.4.15 Limitations and Future Work 
The data in this study were analyzed using stepwise logistic regression technique. This method 
has its potential problems while selecting significant predictors since multiple comparisons are 
made [226]. Also, this technique was performed in a small sample size, 54 individuals having 
plasma biomarkers and 53 individuals’ urine biomarkers. The variable selection for the stepwise 
regression may be unstable because of the limited power to select significant variables, in small 
datasets [226]. Although some plasma (and urine) predictors were correlated to one another, 
there was not a high degree of multicollinearity found in the logistic regression model.  Given 
the limited sample size, the data was not cross validated in this study. The significant predictors 
obtained in this study should be verified in a different sample population. The final model 
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retained for significant plasma and urine predictors should be cross validated in future studies. 
Validating the model may be essential to make conclusions of the significant inflammatory 
predictors in the population [227]. The interaction between the inflammatory mediators in 
plasma (and urine) has not been taken into account in this study, and it will be interesting to test 
the interactions in forthcoming studies. In order to study the temporal relationship of the 
inflammatory mediator’s sophisticated techniques such as principal component analysis and 
factor analysis may be useful. 
Although the data were collected prospectively, the timing for the measurements of the 
blood and urine samples for inflammatory mediator analysis was not uniform. Hence, for the 
baseline measure the first time point available within four days after injury was considered. The 
inflammatory mediators that could have contributed for the formation of first PU within hours 
after SCI may have been missed. This study analyzed the mediators at a single time point. We 
may have missed an optimal time point when a specific mediator was associated with formation 
of PU. Forthcoming studies, should investigate a temporal pattern of these mediators. The 
amount of spot urine samples may differ from person to person given the variability in the waste 
products voided. Prior studies adjusted for their creatinine levels, in urine to avoid this variability 
[228]. Future studies should control for this variation before assaying the inflammatory 
mediators in urine. 
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3.5 CONCLUSION 
The concentrations of inflammatory mediators in urine and plasma immediately following TSCI 
is associated with the occurrence of pressure ulcers. A large number of predictors may be 
associated with the formation of pressure ulcer that were either previously identified or may have 
some pathophysiological association with formation of pressure ulcers [4, 24, 27]. The stepwise 
logistic regression using the backward elimination technique is a well-established data reduction 
technique that helps to explore the relationship between the variables associated with the 
formation of pressure ulcer. Inflammatory response after a traumatic injury is essential for the 
repair and regenerative process, but imbalance in the synthesis of the inflammatory mediatory 
predisposes individuals with TSCI to secondary complications such as PUs. Of all the significant 
inflammatory predictors in plasma and urine obtained in this study, prior evidence suggests also 
suggests IL-5, IL-6, IFN- γ and GM-CSF play an active role in cell proliferation and 
differentiation [115]. This may be the reason why imbalance in these inflammatory mediators is 
associated with the formation of pressure ulcers. Further research is essential to investigate 
possible intervention strategies and develop an objective risk prediction tool to identify 
individuals who may be at risk to develop pressure ulcers. The findings of this study imply that a 
complex inflammatory cascade is involved with development of PUs following SCI. This study 
thus can contribute towards hypothesis testing in the future to identify individuals at risk for 
pressure ulcer formation following TSCI. 
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4.0  INFLAMMATORY BIOMARKERS THAT PREDICT IMMINENT PRESSURE 
ULCER DEVELOPMENT IN INDIVIDUALS WITH SPINAL CORD INJURY 
4.1 INTRODUCTION  
Spinal cord injury (SCI) has profound impact from physical, psychological and socioeconomic 
perspectives [44]. The second leading cause of death in individuals with SCI is septicemia 
(88.6%); usually associated with presence of pressure ulcers [45]. Pressure ulcers (PUs) are the 
most frequent secondary complication in individuals with SCI from the time of acute 
hospitalization throughout life that affects their quality of life, length of stay during 
hospitalization and increases the mortality and morbidity [1, 7, 12, 48, 49]. According to the 
2011 annual statistical report for the Spinal Cord Injury Model Systems (SCIMS), PUs are the 
second most frequent complication and third leading cause of death after SCI [45].  
In individuals who sustain traumatic SCI, the production of cytokines and chemokines 
and other inflammatory mediators result in an inflammatory response characterized by neutrophil 
infiltration (the first inflammatory cells to arrive) at the site of injury followed by macrophages 
[23]. The resident macrophages also known as microglia are diffusely spread in the central 
nervous system (CNS). These macrophages are activated post-SCI and result in secretion of the 
cytotoxic substances and pro-inflammatory mediators such as TNF-α, IL-1, IL-6, nitric oxide, 
reactive free radicles and oxygen free radicals. Post-traumatic SCI the inflammatory response 
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further deteriorates the functional outcome and predisposes the host to secondary complications 
such as tissue damage and other infections [25, 26]. Thus, these cytotoxic substances lead to 
secondary complications by damaging the production of growth factors essential for tissue 
repair. Anti-inflammatory mediator such as IL-10 is known to suppress most of the microglial 
activity and helps in attenuating damage and dysfunction. The beneficial role of this 
inflammatory process can be attributed to the dual nature of the inflammatory process [27]. After 
SCI, due to the disrupted blood spinal cord barrier, most of the inflammatory mediators such as 
IL-1α, IL-1β, IL-1RA, IL-6, and TNF-α pass freely through the blood brain barrier (BBB) [24]. 
Increase in the pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α was noted immediately 
after injury until 5 hours post injury, and from the second day post injury the expression of these 
cytokines declines to baseline [29].  
Clinically it is still unknown why certain individuals with SCI develop PUs and some do 
not despite having similar risk factors that predispose them to develop PUs. However, this could 
be attributed to the differences in the intrinsic inflammatory state in the individual, since 
evidence supports an increase in serum concentrations of pro-inflammatory cytokines in 
individuals with PUs [34]. A multidisciplinary expert panel sponsored by SCI Quality 
Enhancement Research Initiative (SCI QUERI) identified “research on biomarkers” for the 
development of PUs in individuals with SCI as “highest priority risk factor research” [34]. There 
are conflicting hypotheses regarding the role of inflammatory mediators in wounds and pressure 
ulcers. Blood and urine samples were collected at baseline and periodically (hours) after DTI 
induced by pressure in a chronic SCI rat model. Increase in serum and urine concentrations of 
biomarkers associated with muscle injury such as myoglobin (MB), heart type fatty acid binding 
protein (H-FABP), were observed in rats with deep tissue injury (DTI) [35]. In vitro studies have 
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shown increased synthesis and proliferation of inflammatory cytokines such as IL-1α after 
prolonged mechanical loading the tissue engineered epidermal equivalents, before the tissue 
damage is barely visible. The elevated levels of IL-1α was an indicator of tissue damage due to 
inflammation before it was visible on the skin [31]. Increase in the plasma concentrations of pro-
inflammatory mediators such as IL-2R), andICAM-1 were noted in individuals with SCI having 
PUs or slow healing PUs as compared to able-bodied subjects or subjects with SCI having no 
PUs [32]. The severity of PUs is thought to be related to the disturbance or imbalance in these 
pro-inflammatory markers. The continued inflammatory stimulus in individuals with pressure 
ulcers could be as a result of the damage to the tissue due to ischemia. Fluid analysis at the site 
of the pressure ulcers have shown elevation of IL-1β and TNF-α [5]. The alterations in serum 
proteins such as C reactive protein, and erythrocyte sedimentation rate, were observed in 
individuals with PUs when compared to individuals with no PUs. These serum alterations 
disappeared with the healing of the PU [36]. IL-8, an acute inflammatory chemokine was 
observed to be elevated in the tissue biopsies of individuals with non-healing thermal wounds. 
The elevated concentration of IL-8 impaired the process of regeneration and repair [33]. 
Systemic evidence of inflammation (TNF-α level) was observed in individuals with long term 
SCI and pressure ulcers when compared to control group [229]. Elevated concentrations of pro-
inflammatory mediators have been observed in individuals with SCI with and without pressure 
ulcers. The serum profile of IL-1β, IL-1RA, IL-6 and TNF-α were compared in individuals with 
SCI without infections, pain and PUs, and in individuals with SCI having these secondary 
complications. These secondary complications after SCI were attributed to the increase in the 
serum concentrations of TNF-α and IL-2 [4]. 
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The inflammatory markers seem to be promising indicators of infection in individuals 
with SCI having PUs. Also, there are no objective tools to measure the risk assessment for PUs 
and it is essential to identify the potential inflammatory markers and discover new markers that 
may increase before the tissue damage is visible that may help prevent formation of PUs. 
Analyzing the concentrations of these mediators in serum just before the clinical diagnosis can 
possibly help identify the intrinsic factors associated with the formation of PUs. Hence, the aim 
of this study was to explore the change in the inflammatory biomarkers in the plasma (and) urine 
from within a week before the development of PU that can predict imminent pressure ulceration 
as compared to immediately after SCI, in individuals with PU and control group (individuals 
with no PU), during acute care and inpatient rehabilitation in this population. We hypothesized 
there will be a change in the concentrations of inflammatory mediators such as TNF-α, IL-1β, 
IL-8, and IL-6 and GM-CSF measured just before clinical diagnosis of PU as compared to 
immediately after SCI for those who developed pressure ulcers when compared to the control 
group. We also hypothesized that the inflammatory markers in urine that predict imminent 
occurrence of PUs will be same to those in plasma. Assaying the inflammatory markers from 
plasma and urine is less invasive than tissue biopsies and assaying at the site of pressure ulcers.  
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4.2 METHODS 
4.2.1 Research Design 
The research design for this study is a secondary analysis, since the existing database was used to 
examine the variables and to explore the relationship between presence of pneumonia and PU 
outcome [80].  
 
4.2.2 Inclusion and Exclusion Criteria 
The inclusion and exclusion criteria of RERC on SCI are mentioned in Chapter 2, Section 2.2.2.  
For this particular study the inclusion criteria were: 
1. Individuals with SCI recruited for the RERC on SCI population until August 2012 from 
acute care through inpatient rehabilitation.  
2. Having inflammatory mediators collected within four days after SCI. 
3. For individuals with PUs, who have inflammatory mediators collected within a week 
before formation of PU. 
4. For individuals with no PUs (in the control group), who have inflammatory mediators 
assayed in plasma (or urine) matched to the plasma (or urine) samples by ±1day in the PU 
group. 
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4.2.3 Data Collection and Processing of Urine and Plasma Samples 
The processing of urine and plasma samples and inflammatory mediator measurement are 
mentioned in Chapter 3, Section 3.2.4.  
4.2.4 Procedure  
The timing (in days) for the formation of the first PU diagnosis was noted. The inflammatory 
mediators in plasma and urine within a week before the clinical diagnosis of the PU were 
analyzed. The time point closest to the clinical diagnosis (pre-PU time point) within a week 
before the clinical diagnosis of the PU was considered. The baseline time point was the earliest 
time point available and within 4 days after SCI. The difference in concentrations of the 
inflammatory mediators in plasma (and urine), between the two time points was analyzed for 
each mediator. The pre-PU time points of plasma and urine assay for individuals with PU were 
matched to the individuals who did not develop PU (control group). 
 
 
Figure 9. Time course for individuals with pressure ulcers 
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Figure 10. Time course for control group 
4.2.5 Data Analysis 
Two separate analyses were performed to identify the significant inflammatory mediators in 
plasma and urine. The same inflammatory mediators for individuals in the control group 
(individuals who did not develop PUs) and the individuals who developed PUs were analyzed. 
All data were analyzed using Statistical Package for Social Sciences (SPSS) version 20.0. Box 
plots and was plotted to subjectively explore the differences in the mediators between the two 
time points.  
Wilcoxon Signed-Ranks Test 
The Wilcoxon Signed-Ranks Test is a version of the dependent samples t-Test that is performed 
on nonparametric data[88]. The two-tailed Wilcoxon signed-rank test was performed to identify 
the difference between the baseline measures (within four days of SCI) and the first time point 
from within a week before the formation of PUs, in subjects who had formation of PUs.  
The Wilcoxon Signed-Ranks test statistic is [88]: 
𝑧 = 𝑇 − 𝑛(𝑛 + 1)4
�𝑛(𝑛 + 1)(2𝑛 + 1)24  
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• z = z score 
• n= sample size of the group 
• T= the lower value obtained from the summation of ranked scores (between positive and 
negative rank scores).  
Our hypotheses were: 
H0 (Null Hypothesis): No difference between the concentrations of the inflammatory mediators 
between the two time points (immediately after SCI and just before formation of first PU), will 
be observed in individuals with PUs and control group, (or) Calculated z is between -1.96 and 
1.96. 
H1 (Alternate Hypothesis): Difference between the concentrations of the inflammatory mediators 
will be observed between the two time points (immediately after SCI and just before formation 
of first PU) in individuals with PUs and control group. 
Bonferroni correction was applied to the level of significance. The significance was set at α = 
0.02 for the plasma inflammatory mediators, (or) z < -1.96 or z > 1.96.  
The inflammatory mediators in urine were analyzed similarly. Bonferroni correction was 
applied to the level of significance. The significance was set at α = 0.1 for the urine 
inflammatory mediators.  
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4.3 RESULTS 
4.3.1 Plasma Analysis 
    Demographics 4.3.1.1
A total of 17 individuals with PUs were included to analyze the plasma inflammatory mediators. 
The demographics of the individuals with PUs are given in Table 25. The mean age of 
individuals in this group was 38 years and most of the individuals were males. Individuals in this 
group had increased severity of SCI, with ASIA scale score A and ISS score of 36. The control 
group of 17 individuals was matched to the PU group by the day (±1day) when the plasma 
samples for the pre-PU time point were assayed. The time course for the plasma inflammatory 
mediators is for the two groups (individuals with PUs and control group) are given in Figure 11.  
The chi-square test produced no significant differences in gender, and the Mann-Whitney 
U statistic produced no significant differences in ages between individuals with PUs and the 
control group. The ASIA scale score and ISS were significantly different between individuals 
with PUs and the control group.  
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Table 25. Demographics of individuals with PUs and Control group – Plasma analysis 
 
 
    Change in the inflammatory mediators in plasma 4.3.1.2
(a) Individuals with Pressure Ulcers  
Since the data for the plasma inflammatory mediators were not normally distributed, box plots 
were plotted for differences between two time points (within four days after injury and just 
before the formation of PU) for each mediator. The change in inflammatory mediators between 
the two time-points was explored with the help of box plots of the differences in the plasma 
concentrations for all the inflammatory mediators between the two time points were plotted 
(Figures 12-14). In these figures, the circles are mild outliers (between inner and outer fence) and 
asterisks are extreme values (beyond outer fences). The mild outliers are values that lie from 1.5 
to 3 interquartile range. Extreme values are those which lay more than 3 interquartile range. 
Demographics  PU  
n= 17 
Control Group (No PUs) 
n=17 
P Value 
Age (years) 
Mean ± SEM 
 
38.12 ± 4.17 40.41±3.83 0.5 
Gender M=12(71%) 
F=5(29%) 
M=14(82%) 
F=3(18%) 
0.42 
ASIA A=13(76%) 
B=0 (0%) 
C=2 (1%) 
D=1 (6%) 
U=1 (6%) 
 
A=6(35%) 
B=6(35%) 
C=3(18%) 
D=2(12%) 
U=0(0%) 
0.04 
Injury Severity Score (ISS) 36.44±4.42 27±4.4 0.03 
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After exploring the boxplots, IP-10 and MIG levels showed differences in the two time points 
subjectively. 
Two-tailed paired t-test, Wilcoxon signed-rank test was performed between the two time 
points for IP-10 and MIP-1α that was identified by exploring the boxplots. Significance was α = 
0.02 after the Bonferroni correction was applied. The test showed a significant increase in 
plasma concentration of IP-10 just before the formation of PU as compared to within four days 
after injury, z= -2.931, p=0.01. There was no statistically significant difference in concentration 
of MIP-1α between the two time points (just before the formation of PU as compared to within 
four days after injury), z= 2-.05, p=0.04 (Figure 15). 
(b) Control Group (Individuals with no Pressure Ulcers)  
For individuals who did not develop PUs, two-tailed paired t-test, Wilcoxon signed-rank test was 
performed between the two time points for IP-10, MIP-1α, GM-CSF and IL-6. There was no 
statistically significant difference in concentration of IP-10 (z = -1.25, p=0.21) and MIP-1α (z= -
0.07, p=0.937), between the two time points (Figure 15).  
 Time course of plasma IP-10 levels in both groups 4.3.1.3
Figure 16 shows the time course of the concentrations of the plasma IP-10 levels in individuals 
with PUs and the control group. Day 0 indicates when the individuals had formation of PU in the 
PU group. Since the control group time points were matched to the PU groups, day 0 in the 
control group is the “expected” PU time point. The plasma inflammatory mediators were 
normalized for plotting.  
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Figure 11. Time course of plasma inflammatory mediators in individuals with PUs and control group
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Figure 12. Box plots for individuals with Pus – differences in plasma inflammatory mediators’ immediately after TSCI and just before formation of PU 
(A) 
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Figure 13.  Box plots for individuals with Pus – differences in plasma inflammatory mediators’ immediately after TSCI and just before formation of PU 
(B) 
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Figure 14. Box plots for individuals with Pus – differences in plasma inflammatory mediators’ immediately after TSCI and just before formation of PU 
(C) 
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Figure 15.  Box plots – Plasma concentrations of IP-10, MIP-1α, GM-CSF and IL-6 immediately after SCI and just before formation of first PU 
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Figure 16. Time course of concentrations of IP-10 in plasma from the days since PU formation  
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4.3.2   Urine Analysis 
A total of 15 individuals with PUs and control group (no PUs), having urine biomarkers were 
included to analyze the change in the urine inflammatory mediators. The control group of 17 
individuals was matched to the PU group by the day (±1day) when the urine samples were 
assayed. 
 Demographics 4.3.2.1
The demographics of the individuals with PUs and the control group are listed in Table 26. The 
mean age of individuals with PUs was 40 years and most of the individuals were males. 
Individuals with PUs had increased severity of SCI, with AIS of A and ISS score of 34. The 
control group of 15 individuals without PUs was matched to the PU group by the day (±1day) 
when the urine samples for the pre-PU time point were assayed. The time course for the urine 
inflammatory mediators is for the two groups (individuals with PUs and control group) are given 
in Figure 17.  
The chi-square test produced no significant differences in gender and ASIA scale score 
distribution between individuals with PUs and the control group. Also, the Mann-Whitney U 
statistic produced no significant differences in age and ISS score between individuals with PUs 
and the control group. 
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Table 26. Demographics of individuals with pressure ulcers and Control group – Urine analysis 
 
 Change in the inflammatory mediators in urine 4.3.2.2
(a) Individuals with Pressure Ulcers  
Since the data for the urine inflammatory mediators for individuals with PUs were not normally 
distributed, box plots were plotted for differences between two time points (within four days 
after injury and just before the formation of PU) for each mediator. To explore the change in 
inflammatory mediators between the two time-points, box plots of the differences in the urine 
concentrations of the inflammatory mediators between the two time points were plotted for all 
the mediators (Figures 18-20). In these figures, the circles are mild outliers (between inner and 
outer fence) and asterisks are extreme values (beyond outer fences). The mild outliers are values 
that lie from 1.5 to 3 interquartile range. Extreme values are those which lay more than 3 
interquartile range. After exploring the boxplots, IP-10 and MIG levels showed differences in the 
Demographics  PU 
 n= 15 
Control Group (No PU) 
n=15 
P value 
Age (years) 
Mean ± SEM 
 
39.53 ± 4.5 35.6 ± 3.61 0.72 
Gender M=11(73%) 
F=4(27%) 
M=12(80%) 
F = 3(20%) 
0.66 
ASIA A=12 (80%) 
B=0 (0%) 
C=1 (7%) 
D=0 (0%) 
U=0 (0%) 
 
A=6(40%) 
B=6(40%) 
C=2(13%) 
D=1(7%) 
0.46 
Injury Severity Score (ISS) 33.57 ± 4.12 31.29 ± 5.26 0.39 
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two time points. After exploring the boxplots, IFN-α, IL-1RA, IL-1β MIP-1α levels showed 
differences in the two time points. 
Two-tailed non-parametric paired test, Wilcoxon Signed Ranks test, between the two 
time points was performed for IFN-α, IL-1RA, IL-1β MIP-1α. Significance was α = 0.01 after 
the Bonferroni correction was applied. The test showed that there was a statistically significant 
decrease in concentration of IFN-α just before the formation of PU as compared to within four 
days after injury, z= -2.346, p=0.01. There was no statistically significant difference in 
concentration of IL-1RA, IL-1β, MIP-1α just before the formation of PU as compared to within 
four days after injury, z= -.402, p=0.68. z= -1.988, p=0.047 z= -2.197, p=0.028 and z= -1.992, 
p=0.046 respectively after Bonferroni correction (Figure 21).  
(b) Control Group (Individuals with no Pressure Ulcers) 
For individuals who did not develop PUs, two-tailed paired t-test, Wilcoxon signed-rank test was 
performed between the two time points for IFN-α, IL-1RA, IL-1β, MIP-1α. There was no 
statistically significant difference in concentration of IFN-α (z = -0.78, p=0.43), IL-1RA (z = -
1.72, p=0.08), IL-1β (z = -0.5, p=0.61) and MIP-1α (z= - 0.07, p=0.937), just before the 
formation of PU as compared to within four days after injury (Figure 21). 
 Time course of urine IFN-α levels in both groups 4.3.2.3
The time course of the urine concentrations of IFN-α in individuals with PUs and the control 
group is shown in Figure 22. Day 0 indicates when the individuals had formation of PU in the 
PU group. Since the control group samplings were matched to the time point of the IFN-α 
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collected in the PU group, the day 0 in the control group was the “expected” PU time point. The 
urine IFN-α levels were normalized for plotting.  
 
 
Figure 17.  Time course of urine inflammatory mediators in individuals with PUs and control group 
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Figure 18. Box plots for individuals with PUs – differences in urine inflammatory mediators’ immediately after TSCI and just before formation of PU 
(A) 
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Figure 19. Box plots for individuals with PUs – differences in urine inflammatory mediators’ immediately after TSCI and just before formation of PU 
(B) 
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Figure 20. Box plots for individuals with PUs – differences in urine inflammatory mediators’ immediately after TSCI and just before formation of PU 
(B) 
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Figure 21. Box plots – Urine concentrations of MIP-1α, IL-1RA, IL-1β and IFN-α 6 immediately after SCI and just before formation of first PU 
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Figure 22. Time course of urine concentrations of IFN-α from the days since formation of first PU 
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4.4 DISCUSSION 
Although pressure ulcer (PU) is a localized injury many systemic consequences such as deep 
vein thrombosis [230], urinary tract infections [231], rheumatoid arthritis [232], diabetes mellitus 
[104] have been associated with formation of PUs. In individuals with SCI these clinical 
manifestations are not only concomitant with formation of pressure ulcers but also associated 
with systemic manifestations such as increase in the inflammatory cells, excessive neutrophils, 
changes in the pro and anti-inflammatory cytokines and chemokines [233, 234]. The current 
study explored the change in the concentration of inflammatory mediators in urine and plasma 
biofluids within four days after SCI and just before the formation of PUs, in individuals with 
PUs.  
Previous studies have shown the changes in synthesis circulating systemic biomarkers 
and tissue concentrations in individuals with SCI and PUs such as such as IL-1α, IL-1β, IL-2, IL-
6, IL-8 and TNF-α [4, 24, 29, 31] indicating the possibility to characterize these individuals with 
PUs using the systemic biomarkers. This is the first study to report the changes in concentration 
between inflammatory mediators in both plasma and urine biofluids immediately after SCI and 
just before formation of the first PU. The changes in the urinary excretions for these 
inflammatory mediators from the baseline measure (immediately after SCI) to just before the 
formation of a PU, was not similar as compared to the plasma concentrations. Previous studies 
accounted for similar differences in the inflammatory cytokines in the plasma and urine after 
exercise [113] and renal disease [110].  
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4.4.1 Inflammatory biomarkers in plasma 
In this study we demonstrated the alterations in the plasma concentrations of IP-10 and MIP-1α 
in individuals with SCI and PUs, in individuals with PUs. 
    Interferon gamma induced protein (IP-10) 4.4.1.1
Previous studies have shown the increased synthesis of interferon gamma induced protein (IP-
10) in pulmonary disease, tuberculosis, diabetes mellitus, autoimmune and thyroid diseases [188-
195]. IP-10 was one of the macrophage/monocyte-associated inflammatory mediators associated 
with non-healing of diabetic foot ulcers in both wound fluid and plasma samples [196, 197]. This 
connects the presence of systemic inflammatory biomarkers in diabetic foot ulcers manifested 
with infection.  Nevertheless, the role of IP-10 in pressure ulcers in individuals with SCI remains 
obscure.  
This is the first study to find significant increase in the plasma concentrations of IP-10 in 
individuals just before the formation of pressure ulcers as compared to their concentrations at 
baseline (within four days after SCI) in the SCI population. The plasma concentrations of IP-10 
did not change significantly in the control group. IP-10 is a chemokine secreted by the CXCL10 
gene. As a chemoattractant it activates the T cells towards sites of tissue inflammation [118, 
198].  
IP-10 is known to have both pro-inflammatory and anti-angiogenic properties. As a pro-
inflammatory chemokine, IP-10 inhibits and limits the fibroblast recruitment and motility in 
individuals with chronic wounds [199]. During physiologic conditions the process of 
angiogenesis is finely regulated associated with formation of new blood vessels that supply 
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oxygen and nutrients to the tissue, and aids in the formation of granulation tissue. The process of 
angiogenesis is important for the wound healing process [200]. IP-10, as an angiogenic inhibitor 
prevents the growth of the new blood vessels from pre-existing vessels [201]. This probably 
explains the increase in the plasma levels of IP-10 just before formation of first pressure ulcer as 
compared to the baseline measure (within four days after SCI) in this study since there is no 
growth of new vessels to participate in tissue regeneration process. This increase in the pro-
inflammatory cells precipitates a complex inflammatory cascade of events that predisposes the 
individuals to form PU. Intervention with an antibody to neutralize the inflammatory effects of 
IP-10 in mice subjected to SCI, reduced tissue injury by neutralizing the inflammation and thus 
improving functional recovery by angiogenesis [202, 203]. 
Interferon-γ (IFN-γ) is recognized to be an inducer of IP-10 [235, 236]. There were no 
significant changes in the plasma secretion of IFN-γ from the baseline measure as compared just 
before formation of PU in this study.  This the increased secretion of IP-10 following SCI during 
the process of regeneration and repair may spill over in systemic circulation thus causing 
secondary complications such as PUs. This clarifies the role of IP-10 in the pathogenesis of PUs 
in individuals with SCI. 
    Macrophage inflammatory protein- 1 alpha (MIP-1α) 4.4.1.2
Although MIP-1α was not significant after application of Bonferroni correction due to multiple 
comparisons of the cytokines between the baseline measure and just before formation of pressure 
ulcer, there was modest decrease in the concentration of MIP-1α in plasma just before the 
formation of pressure ulcer as compared to the baseline measure (with four days after SCI). It is 
still interesting to recognize the systematic inflammatory process associated with the decrease in 
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the plasma levels of MIP-1α in this population. The plasma concentrations of MIP-1α did not 
change significantly in the control group. 
MIP-1α also called CCL3, is responsible for the synthesis and secretion of many pro-
inflammatory cytokines such as IL-6 and TNF-α as it induces the recruitment of lymphocytes at 
the site of inflammation [157]. MIP-1α is known to have variety of pro-inflammatory properties, 
and there is evidence of increased concentrations of MIP-1α in subjects with rheumatoid 
arthritis, and osteoarthritis [158], acute lung injury [159], early after spinal cord injury at the 
level of lesion and is further elevated as the days since injury increases [160]. Previous studies 
have shown increase in synthesis of MIP-1α in the injured spinal cord immediately after SCI and 
eventually decreases days after the injury [161].  
MIP-1α alters the overall process of wound healing by decreasing fibrosis [163]. 
Deficiency in synthesis of MIP-1α in the brain of mice decreased the pro-inflammatory 
responses [164]. Previous studies have shown the importance of the inflammatory process in the 
prevention of PUs [72]. We hypothesize that the decrease in the plasma concentrations of MIP-
1α just before the formation of PU in individuals with SCI and PUs may decrease the overall 
pro-inflammatory effect essential for the repair and regeneration process to prevent formation of 
PUs after SCI.  
    Granulocyte macrophage colony-stimulating factor (GM-CSF) 4.4.1.3
Although the concentrations of GM-CSF did not decrease significantly just before formation of 
pressure ulcer as compared to the baseline measurement in individuals with PUs; there was a 
significant increase in the plasma concentration of GM-CSF just before the pre-pressure ulcer 
time point as compared to the baseline measure (with four days after SCI) in the control group. 
 130 
 
Evidence suggests use of human GM-CSF for the healing of wounds such as postsurgical 
wounds and chronic leg ulcers[237]. In this study the significant increase in plasma 
concentrations of GM-CSF in the control group could be a reason why they didn’t develop a PU 
as compared to individuals with PUs who did not have a significant increase in the plasma 
concentrations just before the formation of the first PU.   
    Interleukin-6 (IL-6) 4.4.1.4
Although the concentrations of IL-6 did not significantly decrease just before formation of 
pressure ulcer as compared to the baseline measurement in individuals with PUs; there was a 
significant decrease in the plasma concentration of GM-CSF just before the pre-pressure ulcer 
time point as compared to the baseline measure (with four days after SCI) in the control group. 
Although there was a significant decrease in the plasma concentrations of IL-6 in the control 
group, this difference was not significant after Bonferroni corrections. It is still interesting to 
understand why there was no significant decrease in the plasma concentrations in individuals 
with PUs. Evidence suggests that individuals with SCI having PUs have significant increase in 
the plasma concentrations of IL-6 as compared to the able-bodied individuals [32]. In this study 
the significant decrease in the plasma concentrations of IL-6 in the control group could be a 
reason why they didn’t develop a PU as compared to individuals with PUs who did not have a 
significant decrease in the plasma concentrations just before the formation of the first PU.   
 
This study thus demonstrates the change in the plasma concentrations of IP-10 and MIP-
1α that contributes to the pathogenesis of the first pressure ulcer formation in individuals with 
SCI. Hence, these inflammatory mediators can be considered to be potential diagnostic markers 
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for identifying individuals at risk for the formation of PUs in this population. It will be 
interesting to further clarify the functional implications of these differences in the expression of 
the cytokines and chemokines in plasma and their pathogenesis of PUs in individuals with PUs.  
4.4.2 Inflammatory biomarkers in urine 
In this study we observed the alterations in the IFN-α urine concentration of specific biomarker 
synthesis in individuals with SCI and PUs, in individuals with PUs. There were no differences in 
the concentrations of IFN-α in the control group. 
    Interferon alpha (IFN-α) 4.4.2.1
In this study the secretion of IFN-α significantly decreases just before the formation of PU as 
compared to immediately after SCI (with four days of SCI). IFN-α belongs to the Type 1 
interferon group. This cytokine activates the immune cells during infection, by stimulating the T 
lymphocytes and macrophages. Interferons are a part of the innate immune system and 
participate in the first line of defense against the pathogens before the specific immune system 
responds. They mainly benefit the host by resisting infection and inflammation initiated after 
trauma. They are produced when the host is subjected to a viral infection or any other pathogen. 
They bind to the viral cell, and induce antiviral state. [238]. Interferon therapy is mainly used to 
stop or slow the growth of tumor cells, leukemia, melanoma, sarcoma, carcinoma [239], hepatitis 
[240], and thus protect the immune system.  
During a physiological response, the timely interactions of the specific cytokine and the 
receptor help to control the inflammation and thus prevent secondary complications that may 
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occur after a traumatic SCI. Interferons also have an ability to up regulate the cytokine responses 
[238]. Although there is not much evidence about the role of IFN-α in individuals with SCI, type 
I interferons have been reported to contribute to promote functional activity after SCI as they 
inhibit the astrocytes that are responsible in the secondary cellular response after SCI [241].  
Although the role of IFN-α in individuals with SCI having pressure ulcers is not elucidated, we 
hypothesize that the decrease in IFN-α secretion just before the formation of PU as compared to 
immediately after SCI indicates an imbalance in the inflammatory response in the immune 
system and thus predispose these individuals with formation of PUs.  
    Interleukin-1 beta (IL-1β) 4.4.2.2
Although the urine concentrations of IL-1β was not significant after application of Bonferroni 
correction due to multiple comparisons of the cytokines between the baseline measure and just 
before formation of pressure ulcer, there was modest decrease in the secretion of IL-1β just 
before the formation of pressure ulcer as compared to the baseline measure (with four days after 
SCI). There were no differences in the concentrations of IL-1β in the control group. It is thus 
interesting to recognize the systematic inflammatory process that is associated with the levels of 
IL-1β in this population. 
IL-1β belongs to the IL-1 family. It is a pro-inflammatory cytokine produced by 
macrophages/monocytes and endothelial cells. The synthesis of IL-1β increases during acute or 
chronic infection [242]. Studies have shown that IL-1β inhibits the synthesis of proteoglycans 
[242]. Proteoglycans are a part of extracellular matrix (ECM) of skin. They are large hydrated 
molecules that help to cushion cells in the ECM and participate in the regulation of the wound 
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healing process by controlling angiogenesis, and granulation tissue formation by preventing scar 
tissue formation  [243].  
IL-1β also stimulates the production and synthesis of other cytokines and chemokines 
such as monocyte chemotactic peptide (MCP-1) and macrophage inflammatory protein (MIP-1α) 
[70]. Numerous studies have found the increase in the peak expression of IL-1β immediately 
after the injury and leads to the apoptotic cell death [244-246]. These increased levels of IL-1β 
may be associated with the formation of PUs that occurs in individuals with SCI. The amount of 
production of IL-1β at the site of lesion is responsible for either the regeneration of the tissues or 
deleterious effect after injury [247]. This study found decrease in the urine levels of IL-1β just 
before the formation of PU in individuals with SCI and we hypothesize the inflammatory process 
necessary for the prevention of tissue destruction may be inadequate.  
    Interleukin-1 receptor antagonist (IL-1RA) 4.4.2.3
Although IL-1RA was not significant after application of Bonferroni correction due to multiple 
comparisons of the cytokines between the baseline measure and just before formation of pressure 
ulcer, there was modest decrease in the secretion of IL-1RA just before the formation of pressure 
ulcer as compared to the baseline measure (with four days after SCI). There were no differences 
in the concentrations of IL-1RAin the control group. It is thus essential to recognize the 
systematic inflammatory process that is associated with the levels of IL-1RA in this population.  
IL-1RA belongs to the interleukin 1 cytokine family, is an anti-inflammatory cytokine 
and inhibits the synthesis of IL-1 [165]. Increased plasma and/or urine levels of IL-1RA were 
associated with sepsis [166], rheumatic diseases and osteoporotic fractures [167, 168], and 
schizophrenia [169]. IL-1RA is an acute phase protein and previous literature shows increase in 
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the plasma concentrations of IL-1RA when individuals were subjected to trauma and during 
infections [165]. IL-1RA had been used as a therapeutic intervention is individuals, cancer [170]  
and neuropathy [171].  
Although the role of IL-1RA in individuals with SCI and PUs needs to be clarified, it is 
known to maintain homeostasis during an acute inflammatory response after SCI, and provides a 
balance between IL-1 and IL-1RA, thus influencing the host immune response to the traumatic 
event [172]. In this study the urine concentrations of IL-1RA decreases just before formation of 
PU that may not be adequate IL-RA to maintain this homeostasis.  
    MIP-1α 4.4.2.4
Although MIP-1α was not significant after application of Bonferroni correction due to multiple 
comparisons of the cytokines between the baseline measure and just before formation of pressure 
ulcer, there was modest decrease in the secretion of MIP-1α just before the formation of pressure 
ulcer as compared to the baseline measure (with four days after SCI). There were no differences 
in the concentrations of IL-1RA in the control group. It is thus essential to recognize the 
systematic inflammatory process that is associated with the levels of MIP-1α in this population.  
Studies have shown IL-1β induces the secretion of MIP-1α [242]. Hence the differences 
in the urine concentrations of MIP-1α may possibly be because of the differences found in the 
urine concentrations of IL-1β found in this study. Also, the plasma concentrations modestly 
decrease just before the formation of PU as compared to immediately after SCI. The plasma 
changes in the MIP-1α levels may partly explain the changes in the urinary concentrations of this 
marker.  Previous studies have shown simultaneous changes in the plasma and urinary markers 
in patients with idiopathic hypercalciuria [248].  
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The immune dysregulation after SCI is associated with the secondary complications such 
as PUs. Previous studies similarly assayed blood and urine samples for ease in data collection in 
individuals [113, 171, 248]. We hypothesized TNF-α, IL-1β, IL-8, and IL-6 and GM-CSF will 
contribute to PU formation by reviewing similar studies [5, 31, 33]. Except for the 
concentrations of IL-1β, the inflammatory mediators detected were not similar to our hypothesis. 
This may be because of the difference in the timing of urine and plasma sample collection and 
assaying these samples during the time course after SCI. It is also essential to note that the 
plasma levels of these inflammatory mediators increases only during serious traumatic event 
because they have a relatively short half-life period, which would have contributed towards the 
variability between the individuals. Most of the prior studies found alterations in tissue 
concentrations of these cytokines in tissues or in vivo associated in formation of PUs. The 
severity of injury as recorded by the ISS and ASIA scale score was significantly different 
between the two groups (PU and control group). A lower degree of injury might be reasonably 
thought to be associated with a lower degree of inflammation; this might have been a 
confounding variable. The values of the plasma (and urine) inflammatory mediators in 
individuals with PUs and the control group had presence of outliers. This may be because the 
sample may not be representative of the population. The Wilcoxon signed rank test is resistant to 
the presence of outliers the test statistic may not be affected to a great extent. This test is known 
to perform well with paired difference with outliers [88].  
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4.4.3 Limitations and Future Work 
This study is a secondary analysis and sample sizes were not estimated for the individual aims by 
using power analysis to obtain a desired power prior to data collection. The number of 
individuals with PUs for this study to analyze the blood and urine samples was relatively small. 
Only 17 individuals with PUs and plasma analysts and 15 individuals with PUs and urine 
analysts were obtained from the RERC on SCI study. Although the data were collected 
prospectively, the timing for the measurements of the blood and urine samples for cytokine 
analysis was not uniform. Hence, for the baseline measure the first time point available within 
four days after injury was considered and the first time point available a week before formation 
of PUs was noted. The inflammatory mediators that could have contributed for the formation of 
first PU within hours after SCI have not been analyzed for the lack of consistency. This study 
analyzed the mediators at a single time point and temporal time points were not studied. We may 
have missed an optimal time point when a specific mediator was associated with a disease 
The amount of spot urine samples may differ from person to person given the variability 
in the void and the waste products that may be excreted. The urine samples used to assay these 
chemokines and cytokines were not adjusted for their creatinine levels, or osmolality [228]. This 
may not take into consideration the inter- and intra-individual variations of the excretions of the 
inflammatory mediators in urine. To successfully use the inflammatory mediator validation for 
the diagnosis of PU the timing for collecting the plasma and urine samples may be essential 
which was not taken into account in this study.  
Further research is necessary to understand the mechanism of these cytokines that are cleared 
from the blood stream and are evident in the urine in individuals with SCI and PUs. 
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Understanding the mechanisms of the plasma synthesis and urine excretion of IP-10 and IFN-α 
may lead to new therapeutic interventions to modulate inflammation in PUs in individuals with 
SCI. It will be interesting to compare the inflammatory mediators and chemokines in healing 
versus non-healing ulcers. This will help us differentiate these inflammatory mediators in plasma 
and urine that may be beneficial and deleterious in this population. Blocking the chemokine or 
cytokine to prevent the incidence of pressure ulcer can be implemented as an effective 
intervention strategy as used in other inflammatory disease states such as infections related to 
HIV [249]. Future studies are required to understand the temporal relationship and interaction 
between these inflammatory responses for these inflammatory mediators from the days since 
SCI.  The cross regulation and interaction between the mediators has not been taken into account 
in this study, and it will be interesting to see the primary regulator if this is taken into 
consideration. 
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4.5 CONCLUSION 
In conclusion, the results of this study show that the localized injury to skin and/or underlying 
tissue in individuals with SCI can be associated with altered biomarker levels in systemic 
circulation and urine. The present study provides evidence that the plasma concentrations differ 
from the urine concentrations of the markers just before formation of PU in this population when 
compared within four days after injury. Changes in the concentrations of the inflammatory 
mediators such as increase in the plasma levels of IP-10, and decrease in urine excretion of IFN-
α, just before the formation of PUs as compared to the baseline measure (within four days after 
SCI) was shown in this study. In the control group, a significant decrease in plasma 
concentrations of GM-CSF was observed. The ease in sampling of plasma and urine and the 
availability and reliability of the multiplex immunoassay technology with Luminex to detect 
different inflammatory mediators simultaneously in body fluids thus provides us with a new 
objective tool to identify the pressure ulcers in individuals with SCI.  
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5.0  ASSOCIATION OF PRESENCE OF PNEUMONIA AND INCIDENCE OF 
PRESSURE ULCERS IN INDIVIDUALS WITH TRAUMATIC SPINAL CORD INJURY 
5.1 INTRODUCTION 
Spinal cord injury (SCI) is a devastating neurologic disorder that has profound impact from 
physical, psychological and socioeconomic perspectives [44]. Increase in age and severity of 
injury are associated with rise in long-term complications after traumatic SCI [79]. The second 
leading cause of death in individuals with SCI is septicemia (88.6%); usually associated with 
urinary tract infections (UTI’s), pneumonia, and/ or presence of PUs [45]. Pressure ulcers (PUs) 
are the most frequent secondary complication in individuals with SCI from the time of acute 
hospitalization through community reintegration PUs affect quality of life, length of stay during 
hospitalization and increases the mortality and morbidity [1, 7, 12, 48, 49]. The 2011 annual 
statistical report for the Spinal Cord Injury Model Systems (SCIMS) identify PUs as the second 
most frequent complication and third leading cause of death for people with SCI [45].  
Many risk factors have been associated with the formation of pressure ulcers. Medical 
complications such as cardiac or renal disease were associated with the risk of developing PUs 
[8]. Individuals likely to develop PUs were those who have SCI of traumatic origin [17], males 
[18], have a history of smoking, alcohol or drug use [10], have medical comorbidities such as 
diabetes mellitus [19, 20], decreased oxygenation or hypotension [16], infections such as 
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pneumonia, urinary tract infections, osteomyelitis, and other bacterial infections [8, 21], those on 
mechanical ventilators [22] and use of steroids [16]. Moisture and/or urinary and fecal 
incontinence, hypo/hyperthermia, friction, shear, were reported to be the extrinsic risk factors for 
the formation of PUs in individuals in acute care and intensive care unit (ICU) [16, 19, 51-55]. 
Decreased nutrition or low serum albumin levels, decreased mobility and sensation, and impaired 
cognitive function contribute towards the intrinsic risk factors for the development of PUs in 
individuals with SCI [19, 20].   
Pneumonia is an inflammatory condition of the lung, specifically inflammation of the 
alveoli (microscopic air sacs in the lungs). Although there are many causes of pneumonia, 
infection is the most common etiology. The infecting agents can be bacteria, viruses, fungi, or 
parasites [57, 58]. Pneumonia is the most frequent respiratory complication (66.9% cases) that 
occurs weeks after the SCI [45, 59, 60]. Around 30% of individuals with SCI develop pneumonia 
during the time of hospitalization [50]. Of all the secondary conditions following SCI, 
pneumonia is one of the most frequent causes of death [46, 47]. The diaphragm is the main 
inspiratory muscle of respiration and is supplied by the phrenic nerve that originates from third 
and extends to fifth cervical nerve (C3-C5). The muscles of respiration such as the diaphragm, 
abdominals and intercostal are affected with progressively higher level of SCIs, resulting in a 
higher incidence of pneumonia in individuals with tetraplegia than paraplegia [61]. Individuals 
with complete tetraplegia have altered lung volumes and ineffective cough, and present with a 
restrictive ventilatory pattern. The alteration in lung volumes decreases the lung compliance and 
increases the cost of energy, predisposing the individual to respiratory fatigue. Therefore, higher-
level SCIs (tetraplegics at C3-C5) may produce complete respiratory paralysis [7, 37, 59, 62]. 
Overall 5% to 20% of individuals with SCI develop pneumonia during initial rehabilitation. 
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Pneumonia was found to be associated with atelectasis in these subjects that alters the pattern of 
respiration. Studies have shown that prior anesthesia increases the risk of developing pneumonia 
[61].  
The SCI Quality Enhancement Research Initiative (QUERI) projects also points out the  
importance and challenge in identification of all the risk factors in individuals with SCI and 
implementing corresponding preventive techniques in the clinical practice [34]. A study 
investigated the association of semirecumbent v/s supine position in individuals on mechanical 
ventilation and pneumonia during their stay in the ICU. As a secondary endpoint the formation 
of PUs in both groups (supine and semirecumbent) was further investigated. An increased 
incidence of pneumonia and PUs in the heel and sacral regions were observed in individuals who 
were in the supine position when compared to the semirecumbent position [63]. The synthesis of 
the inflammatory biomarkers increases in individuals with the presence of PUs [5], and also in 
individuals having respiratory infections such as pneumonia [39]. However, an apparent 
association between them has not yet been explored. Hence, it is essential to identify the 
dependent and independent risk factors such as pneumonia associated with development of PUs 
in this population.  
In order to look at the association between pneumonia and PU formation in individuals 
with SCI, a preliminary study in 86 subjects in the RERC on SCI population was performed. We 
hypothesized that individuals having pneumonia will have a higher risk to develop pressure 
ulcers than individuals who do not have pneumonia in acute care through inpatient rehabilitation 
following TSCI in the RERC on SCI population. The preliminary study in 86 subjects in the 
RERC on SCI population showed that the subjects were twice as likely to develop PUs when the 
PU was preceded by or coincided with the presence of pneumonia as compared to subjects who 
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did not have pneumonia Hence, the presence of pneumonia could indicate possible future 
pressure ulcer development in individuals with SCI during acute care and inpatient rehabilitation 
[38]. It was worthwhile to explore the data of the SCI Model Systems (SCIMS) to see if this 
association holds true in a larger sample size. Hence, this study investigated the association 
between the presence of pneumonia and pressure ulcers in the SCIMS database population. The 
objective of the proposed study was to confirm the RERC SCI study’s results. We hypothesized 
that individuals with presence pneumonia will have a higher presence of pressure ulcers than 
individuals who do not have pneumonia in acute care hospitalization and inpatient rehabilitation 
in the SCIMS population.  
5.2 RERC ON SCI POPULATION 
5.2.1 Methods 
    Research Design 5.2.1.1
The RERC database was used in this study in a secondary analysis to explore and examine the 
relationship among the clinical and demographic variables and PU outcome [80]. 
   Inclusion and Exclusion Criteria 5.2.1.2
The inclusion and exclusion criteria of RERC on SCI are mentioned in Chapter 2, 2.2.2. For this 
particular study the inclusion criteria included individuals with SCI recruited for the RERC on 
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SCI population until August 2012 from acute care through inpatient rehabilitation and subjects 
were excluded if they withdrew from the study in less than three weeks. 
5.2.2 Data Collection 
The data collected for the RERC on SCI are described in Chapter 2, Section 2.2.3. 
    Procedure  5.2.2.1
The presence of pneumonia and first PU were recorded. The subjects were grouped according to 
sequence and timing of presence of pneumonia and PU incidence into four groups. Three weeks 
was chosen to allow the PU ulcer to occur within the time course of resolution of pneumonia 
[250].  
(1) Pneumonia and no PU within three weeks 
(2) PU and no pneumonia preceding the ulcer 
(3) Pneumonia coinciding with or preceding the ulcer within three weeks 
(4) No PU and no pneumonia. 
    Data Analysis 5.2.2.2
The differences in the clinical and demographic data between the four groups of population were 
explored. The data were analyzed using SPSS version 20.0.  
Kruskal-Wallis test 
The Kruskal-Wallis is a version of independent measures (one-way) ANOVA that is performed 
on data that is not normally distributed. The two-tailed, Kruskal-Wallis one-way analysis of 
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variance was performed to test significant differences in ages between the four groups (only 
pneumonia, only PU, with pneumonia and PU; and no pneumonia and no PU). The Kruskal-
Wallis statistic is[88]: 
𝐻 = 12
𝑁(𝑁 + 1)�𝑅𝑖2𝑛𝑖 − 3(𝑁 + 1)𝑘
𝑖=1
 
• N is total sample size 
• k is total number of groups 
• i is to denote the particular group 
• Ri is sum of ranks for each group 
• ni is the sample size of that particular group 
Ho (Null Hypothesis) – The mean ranks from the populations in the four groups (only 
pneumonia, only PU, with pneumonia and PU; and no pneumonia and no PU) is expected to be 
the same. 
H1 (Alternate Hypothesis)- There is difference in the mean ranks of ages between the groups 
(only pneumonia, only PU, with pneumonia and PU; and no pneumonia and no PU).  
The significance level was set at α = 0.05.  
Chi-Square Test 
It is a nonparametric test that is performed on nominal (gender male/female), and ordinal (ASIA 
scale score, A, B, C, D and E) data. The Chi-square statistic (two-tailed) was performed to test 
differences between the level of injury (and gender) in the two groups (those who developed PUs 
and those who did not develop PU). The chi-square statistic is[88]:  
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𝜒2 = � (𝑓0−𝑓𝑒)2
𝑓𝑒
 
• fo is observed frequency of ASIA (or gender) 
• fe is expected frequency (or gender) 
 
Our hypotheses are:  
H0 (Null Hypothesis): The severity of injury measured by ASIA scale score (or gender) and 
individuals who developed PUs are not related. 
H1 (Alternate Hypothesis): The severity of injury measured by ASIA scale score (or gender) and 
individuals who developed PUs are related. 
The significance level was set at α = 0.05.  
A chi-square test was also performed to test the association between presence of 
pneumonia and occurrence of PU as compared to no pneumonia.  
Ho (Null Hypothesis) – The presence of pneumonia and occurrence of PUs are not related. To 
reject the null hypothesis the observed frequency (of individuals with pneumonia having PUs) 
should be closer to the expected frequency. 
H1 (Alternate Hypothesis): The presence of pneumonia and occurrence of PUs are related. 
The significance level was set at α = 0.05.  
Relative Risk Ratio 
The relative risk ratio which is the ratio of the incidence of disease (PU) to the exposed subjects 
(individuals with pneumonia) to the incidence of disease (PU) to the unexposed (no pneumonia) 
was calculated for acute care population and inpatient population with the CI estimates. The 
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relative risk greater than 1.0 will indicate that pneumonia increases risk for the incidence of 
PU[80].  
Relative Risk = CIECIO = a (a + b)⁄c c + d⁄  
• a is subjects who have PU and pneumonia 
• b subjects who did not have PU but had presence of pneumonia 
• c is subjects with PU and no pneumonia 
• d is subjects with no pneumonia and no pressure ulcer 
5.2.3 Results 
Out of the 104 individuals recruited in RERC on SCI, data for 86 individuals were analyzed in 
acute care and inpatient rehabilitation. The rest of the individuals were excluded since they 
withdrew from the study in less than three weeks. 
The demographics and characteristics for the total population included in this study and 
the individual groups are listed in (Table 27) 
    Age and Gender 5.2.3.1
The study population’s mean age was 40 years. The Kruskal-Wallis test produced no significant 
difference in age among the four groups (p= 0.144). Most of the individuals were males (81%). 
A chi-square test revealed no significant differences in gender among the four groups (p=0.644). 
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   Injury Severity 5.2.3.2
A majority of individuals (43%) in this population were classified as AISA A in the AIS scale. A 
chi-square test revealed significant differences in the severity of injury between all four groups in 
this population, p=0.01. Most of the subjects who had pneumonia and PU had ASIA A as their 
severity of injury as compared to subjects who did not have any of the two conditions  
    Pneumonia and Pressure Ulcer  5.2.3.3
The mean onset of pneumonia in the total population was 8.9±1.1 days. There were significant 
differences in the mean onset of pneumonia between individuals who had PUs as compared to 
individuals with no PUs, p=0.02. Individuals with pneumonia and PU had a later onset of 
pneumonia (11.25±1.8 days) as compared to those who had only pneumonia and no PU (6±0.69 
days).  The mean onset of PU in the total population was 19.6±1.8 days. There were no 
significant differences observed in the mean onset of PU between individuals who had 
pneumonia as compared to individuals with no pneumonia, p=0.4 (Table 27). Out of the 86 
individuals in acute care through inpatient rehabilitation, 20 had pneumonia coinciding with or 
preceding the PUs, 16 had only pneumonia but no PUs, 15 had only PUs but no pneumonia and 
35 individuals did not have PUs and pneumonia Table 28. 
The chi-square test produced significant results for the presence of pneumonia coinciding 
with or preceding PU incidence in persons with SCI during acute care through inpatient 
rehabilitation χ2 (1) =5.664, p=.017. The relative risk to develop PUs was found to be 1.9 in 
subjects diagnosed with pneumonia as compared to no pneumonia. The individuals who had 
pneumonia coinciding with or preceding the PU were more likely to be males (90%) with ASIA 
A’s and their mean age is younger (32 years) as compared to the entire population (40 years).  
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Table 27. Demographics (Means and SEM) for the RERC on SCI population 
Demographics Total 
N=86 
Pneumonia 
with PU 
n=20 
PU no 
pneumonia 
n=15 
Pneumonia 
no PU 
n= 16 
No PU & no 
pneumonia 
n=35 
P value 
Age (years) 
 
Mean ± SEM 
39.9 ± 1.9 32.1±3.1 42.4±5 39.9±4.5 43.4±3 0.144 
Gender M=70(81.4%) 
F=16(18.6%) 
 
M=18(90%)             
F=2(10%) 
M=11(73.3%)             
F=4(26.7%) 
M=13(81.2%)             
F=3(18.8%) 
M=28           
F=7 
0.644 
ASIA  A=37(43%) 
B=12(14%) 
C=21(24.4%) 
D=13(15.1%) 
E=1(1.2%) 
U=2(2.3%) 
 
A=15(75%) 
B=1(5%) 
C=3(15%) 
D=0(0%) 
E=0(0%) 
U=1(5%) 
 
A=8(53.3%) 
B=2(13.3%) 
C=1(6.8%) 
D=4(26.7%) 
E=0(0%) 
U=0(0%) 
 
A=8(50%) 
B=3(18.8%) 
C=4(19%) 
D=0(0%) 
E=0(0%) 
U=1(6.2%) 
 
A=6(17.1%) 
B=6(17.1%) 
C=13(37.1%) 
D=9(25.7%) 
E=1(2.9%) 
U=0(0%) 
 
0.01* 
Onset of 
Pneumonia 
(days) 
Mean ± SEM 
 
8.9±1.1 11.25±1.8 - 6±0.69 - 0.017* 
Onset of PU 
(days)   
Mean ± SEM 
 
19.6±1.8 20.4±2.1 18.5 ± 3.4 - - 0.404 
Injury Severity 
Score (ISS) 
24.4 ± 1.9 39.7±4.1 29.5±5 26.8±4.2 20.7±2 <0.01** 
 
 
Table 28. 2 X 2 Contingency table, Frequency distribution in the four groups for the RERC on SCI 
population 
Risk Pressure Ulcer 
Present Absent 
Pneumonia 20 16 
No Pneumonia 15 35 
  
Note: *p< 0.05, **p<0.01 
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5.3 SCIMS POPULATION  
The National Spinal Cord Injury Database (NSCID) has data comprising of individuals with SCI 
who are treated at the Model SCI Systems. The NSCID started in 1973 and has an estimated data 
of 13% of new cases in the US of individuals with SCI. The database has information on 28,711 
as of May 2012. Two sets of data are collected in this System.  Form I data are collected once for 
all individuals that includes demographic data and data and intervention outcomes in acute care 
and rehabilitation. Data on Form II is collected annually for a period of 5 years to reflect changes 
that occurred over the year and also the present status of the individual. The data collection for 
this project is an ongoing process. Data on presence of pneumonia and formation of PUs in 
individuals with spinal cord injury Model Systems (SCIMS) database in the acute care and 
rehabilitation are the variables of interest for this study. These variables were recorded during the 
2000-2005 cycle in Form I. This project is funded by NIDRR and 16 federally funded Model 
SCI Care Systems centers contributed to the data collected during the 2000-2005 cycle. In order 
to get access to the Model Systems data, a proposal was submitted to the Model Systems 
directors via an internal pathway in November 2012. Data on presence of pneumonia and PUs in 
individuals in the SCIMS database in the acute care unit from Form I was requested. The project 
director in Pittsburgh, Dr. Michael Boninger requested the data in writing and the data were 
released to the investigators involved with this project. Analysis on the subjects in the RERC on 
SCI suggested that association exists between presence of pneumonia and incidence of PUs. The 
purpose of this study was to investigate an association between pneumonia and PUs in 
individuals with SCI in the SCIMS population.  
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5.3.1 Methods 
    Research Design 5.3.1.1
Retrospective cohort design 
    Inclusion and Exclusion Criteria 5.3.1.2
Individuals with SCI were eligible in the Model Systems study if they had the following 
inclusion criteria: 
1. All persons must have a clinically discernible degree of neurologic (spinal cord) 
impairment following a traumatic event 
2. All persons must receive System acute inpatient rehabilitation 
3. All persons must be treated at a Model System within 1 year of injury 
4. All persons must not have been previously treated at a Model System post-injury 
5. A signed Informed Consent and HIPAA Authorization 
6. All persons must reside in the geographic catchment area of the Model System at 
the time of the injury. Subjects may be injured outside the catchment area 
7. Must be a citizen of the United States 
    Data Collection 5.3.1.3
Form I included data collected at acute care and acute inpatient rehabilitation. Form II includes 
data collected annually. Form I collected data on demographic information, complete neurologic 
exam at the time of initial admit to system, admit to the system inpatient rehabilitation and 
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during discharge, bladder management and mechanical ventilation during the system inpatient 
rehabilitation and discharge, location and stages of PUs, complication such as pneumonia.  
For this study the following data was requested and retrieved from Form I during the 
term period between 2000 and 2005. Date of birth, age at injury, sex, date of first system 
admission, date of first system Inpatient rehab admission, number of days from injury to first 
system admission, number of days from injury first system Inpatient rehab admission, date of 
injury, date of discharge, number of days hospitalized in acute care and rehab care unit, traumatic 
etiology, external cause of injury, SCI nature of etiology, spinal cord nature of injury, ASIA 
impairment scale, ASIA motor index score, sensory and motor level, level of preserved 
neurological function, number of episodes of pneumonia, utilization of mechanical ventilation, 
number of PUs, location of PUs, grade of PUs, presence of pneumonia and incidence of PUs 
 Procedure  5.3.1.4
The subjects who had missing or no data on the presence of pneumonia or occurrence of pressure 
ulcer were excluded from the study. The presence of pneumonia and PUs was noted in acute care 
setting and inpatient rehabilitation. Subjects were grouped according to the presence of 
pneumonia and PU incidence as: 
1. Pneumonia and PU 
2. Pneumonia and no PU 
3. PU and no Pneumonia  
4. No PU and no Pneumonia 
At the time of measurement and collection of data the severity of injury was changed 
from Frankel’s Scale to AIS. The comparison between the scales is shown in Table 29.  For this 
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study the individuals that have Frankel’s grade was converted to AIS and the severity of injury 
was compared between the four groups. The AIS and Frankel’s grade is similar, just that the AIS 
considers sacral sparing definition on incomplete as compared to Frankel’s scale [251, 252]. 
Data for 24,763 for individuals with SCI was obtained in January 2013. After eliminating all the 
missing or no data collected on the presence of pneumonia and PUs, there were data for 3,887 
subjects during the acute hospitalization and 11,022 individuals during inpatient rehabilitation.   
Since the study is retrospective the sample sizes were not estimated by using power 
analysis to obtain a desired power prior to data collection. We estimated the number of subjects 
needed for each proposed aim with a significance level of α = 0.05, a medium effect size and a 
power of 80%. Medium effect size was selected given the variability is observed in the clinical 
variables and there is no standardization in measuring these variables [253]. A sample size of 88 
was estimated using Gpower3.1. The number of subjects for this study in the existing database 
was >1000. Hence, the sample size was sufficient for the desired power.  
    Data Analysis 5.3.1.5
All data were analyzed using Statistical Package for Social Sciences (SPSS) version 20.0.  
Kruskal-Wallis test 
The Kruskal-Wallis is a version of independent measures (one-way) ANOVA that is performed 
on data that is not normally distributed. The two-tailed, Kruskal-Wallis one-way analysis of 
variance was performed to test significant differences in ages between the four groups (only 
pneumonia, only PU, with pneumonia and PU; and no pneumonia and no PU)[80]. The Kruskal-
Wallis statistic is: 
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𝐻 = 12
𝑁(𝑁 + 1)�𝑅𝑖2𝑛𝑖 − 3(𝑁 + 1)𝑘
𝑖=1
 
• N is total sample size 
• k is total number of groups 
• i is to denote the particular group 
• Ri is sum of ranks for each group 
• ni is the sample size of that particular group 
Ho (Null Hypothesis) – The mean ranks from the populations in the four groups (only 
pneumonia, only PU, with pneumonia and PU; and no pneumonia and no PU) is expected to be 
the same. 
H1 (Alternate Hypothesis)- There is difference in the mean ranks of ages between the groups 
(only pneumonia, only PU, with pneumonia and PU; and no pneumonia and no PU).  
The significance level was set at α = 0.05.  
Chi-Square Test 
It is a nonparametric test that is performed on nominal (gender male/female), mechanical 
ventilation (yes/no) and ordinal (ASIA scale score, A, B, C, D and E) data. The Chi-square 
statistic (two-tailed) was performed to test differences between the level of injury (and gender, 
mechanical ventilation) in the two groups (those who developed PUs and those who did not 
develop PU). The chi-square statistic is[80, 88]:  
𝜒2 = � (𝑓0−𝑓𝑒)2
𝑓𝑒
 
• fo is observed frequency of ASIA (or gender) 
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• fe is expected frequency (or gender) 
Our hypotheses are:  
H0 (Null Hypothesis): The severity of injury measured by ASIA scale score (or gender, 
mechanical ventilation) and individuals who developed PUs are not related. 
H1 (Alternate Hypothesis): The severity of injury measured by ASIA scale score (or gender, 
mechanical ventilation) and occurrence of PUs is related. 
The significance level was set at α = 0.05.  
A chi-square test was also performed to test the association between presence of 
pneumonia and occurrence of PU as compared to no pneumonia across all ASIA scale score 
levels. 
Ho (Null Hypothesis) – The presence of pneumonia and occurrence of PUs are not related. To 
reject the null hypothesis the observed frequency (of individuals with pneumonia having PUs) 
should be closer to the expected frequency. 
H1 (Alternate Hypothesis): The presence of pneumonia and occurrence of PUs are related. 
The significance level was set at α = 0.05.  
Cramer’s V 
To measure the degree of association a correlation coefficient, Cramer’s V was calculated. 
Cramer’s V measures strength of association between two nominal variables, and gives a value 
between ± 1[80]. The Cramer’s V statistic is: 
𝑉 = � 𝜒2
𝑁(𝑞 − 1) 
• Total number of subjects 
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• q is number of rows or columns 
• χ2 is the chi-square statistic obtained from the chi-square test.  
Ho (Null Hypothesis) – The presence of pneumonia and occurrence of PUs are not related.  
H1 (Alternate Hypothesis): The presence of pneumonia and occurrence of PUs are related. 
The significance level was set at α = 0.05.  
Relative Risk Ratio 
For this cohort study the cumulative incidence estimates for exposed (CIE) group that is the 
number of cases having PU among total number of subjects having pneumonia and unexposed 
groups (CI0) that is the number of subjects having PU among the subjects who don’t have 
pneumonia was calculated. The relative risk ratio which is the ratio of the incidence of disease 
(PU) to the exposed subjects (individuals with pneumonia) to the incidence of disease (PU) to 
the unexposed (no pneumonia) was calculated for acute care population and inpatient population 
with the CI estimates. The relative risk greater than 1.0 will indicate that pneumonia increases 
risk for the incidence of PU[80].  
Relative Risk = CIECIO = a (a + b)⁄c c + d⁄  
• CIE=Cumulative incidence estimate for exposed (pneumonia) group 
• CI0= Cumulative incidence estimate for unexposed (no pneumonia)group  
• a is subjects who have PU and pneumonia 
• b subjects who did not have PU but had presence of pneumonia 
• c is subjects with PU and no pneumonia 
• d is subjects with no pneumonia and no pressure ulcer 
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Table 29. Comparison between AIS and Frankel Scale Score [252]. 
 
 
 
Scale 
Grade 
Frankel Scale ASIA Impairment Scale (AIS) 
A Complete- All motor and sensory function is 
absent below the zone of partial preservation 
Complete- No motor or sensory 
function is preserved in the sacral 
segments S4-S5. 
B Incomplete, preserved sensation only- 
preservation of any demonstrable, 
reproducible sensation excluding phantom 
sensation (must be present more than 3 
levels below the injury). Voluntary motor 
functions are absent. 
 
Incomplete- Sensory but not motor 
function is preserved below the 
neurologic level and includes the 
sacral segments S4-S5.  
C Incomplete, preserved motor nonfunctional- 
preservation of voluntary motor function 
that is minimal and performs no useful 
purpose. Minimal is defined as preserved 
voluntary motor ability below the level of 
injury where the majority of the key muscles 
test less than a grade of 3.  
 
Incomplete- Motor function is 
preserved below the neurologic 
level, and at least half of key 
muscles below the neurologic level 
have muscle grade of 3 or more.  
D Incomplete, preserved motor functional-
preservation of voluntary motor function 
which is useful functionally. This is defined 
as preserved voluntary motor ability below 
the level of injury, where the majority of 
key muscles test at least a grade of 3.  
 
Incomplete-Motor function is 
preserved below the below the 
neurologic level, and at least half the 
key muscles below the neurologic 
level have muscle grade of 3 or 
more.  
E Complete return of all motor and sensory 
function, but one may still have abnormal 
reflexes.  
Normal- Motor and sensory function 
is normal. 
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5.3.2 Results 
The demographics and characteristics of individuals in the four groups in acute care setting and 
inpatient rehabilitation are listed in Table 30 and Table 33 respectively. 
    Age and Gender 5.3.2.1
The individuals in the acute care setting were older (38 years) than the individuals in the 
inpatient rehabilitation (34 years). The distribution of ages in the four groups in acute care 
inpatient setting is listed in Table 30 and Table 33 respectively. No significant difference in ages 
between the four groups in acute care setting that was produced by Kruskal-Wallis test. Kruskal-
Wallis produced a significant difference in ages between the four groups in individuals in the 
inpatient setting (p=0.004). Majority of individuals in acute care setting and inpatient 
rehabilitation were males. The distribution of gender in the four groups in acute care setting and 
inpatient rehabilitation is listed in Table 30 and Table 33 respectively. Chi-square test produced 
significant differences in gender distribution between the four groups in acute care setting 
(p=0.017) and inpatient rehabilitation (p=.00). 
    Injury Severity 5.3.2.1
The severity of injury is for all the four groups in acute care and inpatient rehabilitation is listed 
in Table 30 and Table 33 respectively. Chi-square test detected significant differences in the 
severity of injury between the four groups during acute care (p<0.001) and inpatient 
rehabilitation (p<0.001). Individuals in acute care were mostly ASIA A’s (43%). The severity of 
injury for most of the subjects in inpatient rehabilitation was unknown. 
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    Mechanical Ventilation 5.3.2.2
Of the 11,022 individuals in inpatient rehabilitation, 18% of the individuals were on mechanical 
ventilation. Most of the individuals (55%) who had both pneumonia and pressure ulcer were on 
mechanical ventilation. Chi-square test revealed significant differences in all four groups during 
the inpatient rehabilitation with use of mechanical ventilation< 0.001 (Table 33).  
    Pressure Ulcer and Pneumonia in Acute Care 5.3.2.3
The location of PUs in inpatient rehabilitation is listed in Table 31. 1248 PUs were observed in 
individuals during acute care. Most of the PUs were present on sacral region (47%), followed by 
the heel, occiput and the ischium. Out of the 3887 individuals in acute care setting, 451 has 
presence of both pneumonia and PU, 361 had formation of PU and no pneumonia, 739 had 
presence of pneumonia but no PU and 2336 did not have any of the two comorbidities (Table 
32). The chi-square test produced significant results for the presence of pneumonia and 
formation of PUs. χ2 (1, n=3887) = 300.24, p=0.00. Cramer’s V was 0.278, p<0.001. The 
cumulative incidence (CI) of PU for the group exposed to pneumonia is 0.38, and the CI of PU 
for the group not exposed to pneumonia was 0.13. The relative risk to develop PUs was 2.9 in 
individuals with presence of pneumonia as compared to no pneumonia. The individuals with 
pneumonia and PU in acute care were mostly males; ASIA A’s and their mean age was 38 years 
(Table 30) 
Out of the total individuals in acute care hospitalization, 1,671 had ASIA A scale score, 
511 had ASIA B, 599 had ASIA C and 581 had ASIA D (Table 30). The Chi-Square tests were 
performed across all ASIA scale score levels for individuals in acute care hospitalization. The 
chi-square test produced significant results for the presence of pneumonia and formation of PUs; 
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in individuals with ASIA A levels, χ2 (1) = 95.98, p<0.001, ASIA B levels χ2 (1) = 31.35, 
p<0.001, ASIA C levels χ2 (1) = 23.14. The relative risk to develop PUs was 2.2 in individuals 
with presence of pneumonia as compared to no pneumonia with ASIA scale score A. The 
relative risk to develop PUs was 2.6 in individuals with presence of pneumonia as compared to 
no pneumonia with ASIA scale score B and C. Although the chi-square statistic did not reveal 
significant association between the presence of pneumonia and formation of PU, in individuals 
with ASIA scale score D; the relative risk to develop PUs was 1.8 in individuals with presence of 
pneumonia as compared to no pneumonia in these individuals.  
    Pressure Ulcers and Pneumonia in Inpatient Rehabilitation 5.3.2.4
The location of PUs in inpatient rehabilitation is listed in Table 28. 4501 PUs were observed in 
individuals during inpatient rehabilitation. Most of the PUs were present on sacral region (37%), 
followed by the heel, ischium and the occiput. 
Of the 11,022 individuals in inpatient rehabilitation, 875 has presence of both pneumonia 
and PU, 1987 had formation of PU and no pneumonia, 1169 had presence of pneumonia but no 
PU and 6991 did not have any of the two comorbidities (Table 34). The chi-square test produced 
significant results for the presence of pneumonia and formation of PUs. χ2 (1, n=11022) = 
370.261, p=.00. Cramer’s V was 0.183 p<0.001. The cumulative incidence (CI) of PU for the 
group exposed to pneumonia is 0.43, and the CI of PU for the group not exposed to pneumonia 
was 0.22.The relative risk to develop PUs was 1.9 in individuals with presence of pneumonia as 
compared to no pneumonia. The individuals with pneumonia and PU in inpatient rehabilitation 
were males and their mean age was 35 years (Table 33). Individuals with pneumonia and PU and 
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individuals with pneumonia were older than the individuals who did not have presence of 
pneumonia in the inpatient rehabilitation.  
Out of the total individuals in inpatient rehabilitation, 790 had ASIA A scale score, 260 
had ASIA B, 322 had ASIA C and 408 had ASIA D (Table 33). The Chi-Square tests were 
performed across all ASIA scale score levels for individuals in inpatient rehabilitation. The chi-
square test produced significant results for the presence of pneumonia and formation of PUs; in 
individuals with ASIA A levels, χ2 (1) = 4.41, p = 0.03, ASIA B levels χ2 (1) = 3.91, p = 0.048, 
ASIA C levels χ2 (1) = 5.881, p = 0.01; and ASIA D levels χ2 (1) = 6.12, p = 0.01. The relative 
risk to develop PUs in presence of pneumonia was 1.4 in individuals with ASIA scale score A, 
2.1 in individuals with ASIA scale score B,  2.5 in individuals with ASIA scale score C and 7.8 
in individuals with ASIA scale score D, when compared to no pneumonia.  
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Table 30. Demographics (Means and SEM) - SCIMS population- Acute Care 
  
  
Demographics Total 
N=3887(%) 
Pneumonia 
with PU 
n=451(%) 
PU no 
pneumonia 
n=361(%) 
Pneumonia no 
PU 
n= 739(%) 
No PU & no 
pneumonia 
n=2336(%) 
p value 
Age (years) 
Mean ± SEM 
 
37.89±0.28 38.9±0.82 37.7±0.91 38.86±0.65 37.42±0.35 0.162 
ASIA A=1671(43%) 
B=511(13.1%) 
C=599(15.4%) 
D=581(14.9%) 
U=525(13.5%) 
A=255(56.5%) 
B=52(11.5%) 
C=33(7.3%) 
D=7(1.6%) 
U=104(23.1%) 
A=179(49.6%) 
B=50(13.9%) 
C=51(14.1%) 
D=29(8%) 
U=52(14.4%) 
A=397(53.7%) 
B=94(12.4%) 
C=86(11.6%) 
D=59(8%) 
U=103(13.9%) 
A=840 (36%) 
B=315 (13.5%) 
C=429 (18.4%) 
D=486 (20.8%) 
U=266(11.4%) 
 
0.00* 
Gender M=3102(80%)   
F=785(20%) 
M=382             
F=69 
M=289          
F=72 
M=599          
F=140 
M=1832             
F=504 
0.017* 
Note: U=Unknown *p<0.05, **P<0.01 
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Table 31.  Location of PUs in Acute Care and Inpatient Rehabilitation 
PU Location Acute Care  
3,887 (%) 
Inpatient 
Rehabilitation 
11,022(%) 
Occiput 82(6.5%) 154(3.4%) 
L Scapula 33(2.6%) 104(2.3%) 
R Scapula 23(1.8%) 103(2.2%) 
L elbow 8(0.6%) 53(1.1%) 
R elbow 8(0.6%) 49(1%) 
L ribs 5(0.4%) 20(0.4%) 
R ribs 4(0.3%) 23(0.5%) 
Spine 13(1%) 85(1.8%) 
L iliac crest 5(0.4%) 39(0.8%) 
R iliac crest 5(0.4%) 32(0.7%) 
Sacral 585(46.8%) 1659(36.8%) 
L ischium 47(3.7%) 209(4.6%) 
R ischium 47(3.7%) 232(5.1%) 
L trochanter  11(0.8%) 70(1.5%) 
R trochanter 5(0.4%) 62(1.3%) 
Genital 13(1%) 147(3.2%) 
L knee 11(0.8%) 34(0.7%) 
R knee 8(0.6%) 44(0.9%) 
L malleolus 8(0.6%) 66(1.4%) 
R malleolus 12(0.9%) 52(1.1%) 
L heel 98(7.8%) 398(8.8%) 
R heel 92(7.3%) 350(7.7%) 
L foot 34(2.7%) 121(2.6%) 
R foot 29(2.3%) 125(2.7%) 
L unclassified 16(1.2%) 102(2.2%) 
R unclassified 21(1.6%) 78(1.7%) 
C unclassified 25(2%) 90(1.9%) 
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Table 32. 2 X 2 Contingency table, Frequency distribution in the four groups - SCIMS population- Acute 
Care Setting, n=3887 
Risk Pressure Ulcer 
Present Absent 
Pneumonia 451 739 
No Pneumonia 361 2336 
 
Table 33. Demographics (Means and SEM) - SCIMS population- Inpatient Rehabilitation 
Demographics Total 
N=11022(%) 
Pneumonia 
with PU 
n=875(%) 
PU no 
pneumonia 
n=1987(%) 
Pneumonia 
no PU 
n= 1169(%) 
No PU & no 
pneumonia 
n=6991(%) 
p 
value 
Age (years) 
Mean ± SEM 
 
34.39±0.76 35.01± 0.54 33.58±0.36 35.25±0.49 34.4±0.19 0.004*
* 
ASIA A=790(7.2%
) 
B=260(2.4%
) 
C=322(3%) 
D=408(3.7%
) 
U=9242(84
%) 
A=21(2.8%) 
B=5(0.6%) 
C=6(0.7%) 
D=1(0.1%) 
U=842(96.2%
) 
 
A=218(11%) 
B=57(2.9%) 
C=42(2.1%) 
D=26(1.3%) 
U=1644(82.7%) 
A=27(2.3%) 
B=5(0.4%) 
C=11(0.9%) 
D=1(0.1%) 
U=1125(96.2
%) 
A=524(7.5%) 
B=193(2.8%) 
C=263(3.8%) 
D=380(5.4%) 
U=5631(80.5%) 
<0.01*
* 
Mechanical 
Ventilation 
 
N=7632(69.2
%) 
Y=1992(18.1
%) 
U=1398(12.7
%) 
N= 
311(35.5%) 
Y= 
483(55.2%) 
U= 81(9.3%) 
 
N=1366(68.7%) 
Y=360(18.1%) 
U=261(13.1%) 
N=595(50.9
%) 
Y=440(37.6
%) 
U=134(11.5
%) 
N=5360(76.7%) 
Y=709(10.1%) 
U=922(13.2%) 
<0.01*
* 
Gender M=8916(81
%)  F=2160 
(19%) 
M=748     
F=127 
M=1692             
F=295 
M=928         
F=241 
M=5548          
F=1443 
<0.01*
* 
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Table 34. 2 X 2 Contingency table, Frequency distribution in the four groups - SCIMS population- Inpatient 
Rehabilitation (n=11,022) 
Risk Pressure Ulcer 
Present Absent 
Pneumonia 875 1169 
No Pneumonia 1987 6991 
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5.4 DISCUSSION 
The results of these studies investigated the association between presence of pneumonia and 
formation of PUs in acute care through inpatient rehabilitation in RERC on SCI population as a 
preliminary analysis and confirmed the findings in a larger population, SCIMS; in both the acute 
care and inpatient setting. The hypothesis that there are significant differences in the formation 
of pressure ulcers in individuals with pneumonia as compared to individuals who do not have 
pneumonia is retained based on the results of these studies in both RERC on SCI and SCIMS 
population. The individuals with pneumonia have a moderate degree of association for the 
formation of PUs. 
Eighty-six individuals in the RERC on SCI population were followed from the acute care 
hospitalization through inpatient rehabilitation. The individuals who had pneumonia had an 
association with the occurrence of PUs within three weeks after diagnosis of pneumonia than 
those who did not have pneumonia. The risk to develop PUs in individuals with pneumonia in 
this population was twice as compared to the individuals who did not have pneumonia.   
To confirm the results of this preliminary analysis attained in the RERC on SCI 
population, the data were obtained for the same variables from the SCIMS database during the 
time period 2000 to 2005. The results of the SCIMS population in acute care and inpatient 
rehabilitation confirmed the results of the RERC on SCI population. Data analyzed for 3,887 
individuals in the acute care SCIMS population showed significant association for the formation 
of PUs in individuals who had pneumonia as compared to individuals who did not have 
pneumonia. The risk of developing PUs for these individuals who had presence of pneumonia in 
SCIMS acute care population was thrice as compared to individuals who did not have 
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pneumonia. The analysis was repeated for 11,022 individuals in the SCIMS inpatient population 
and provided similar results. The risk of developing PUs for individuals who had presence of 
pneumonia in SCIMS inpatient population was twice as much as individuals who did not have 
pneumonia. In the SCIMS population, individuals in the acute care population were at a greater 
risk to develop pneumonia than the inpatient population.  
The cervical or thoracic level of spinal cord injuries leads to respiratory compromise. 
This critical care management is imperative during the acute care immediately after spinal cord 
injury. The respiratory compromise and impaired airway secretion clearance predisposes the 
individual to pneumonia and/ or other pulmonary conditions.  This airway compromise is 
managed with the help of mechanical ventilators to improve the pulmonary function. Studies 
have shown that the use of mechanical ventilators during acute care for more than 24 hours 
increases the risk to develop nosocomial infections. Hence individuals in acute care unit who are 
on mechanical ventilation were prone to ventilator associated pneumonia [254]. This can explain 
the increased risk to develop PUs in acute care as compared to inpatient SCIMS population. The 
data for mechanical ventilation for the acute care in SCIMS is was not collected. Majority of 
individuals in the inpatient SCIMS population who had presence of both PU and pneumonia 
were on mechanical ventilation. Literature shows the supine or semi-recumbent positioning of 
the individuals on ventilators increases the risk for the formation of PUs [63, 255]. The use of 
these external ventilators in individuals with pneumonia may limit mobility of the individuals, 
increase the pressure on their bony prominences and decrease the oxygenation [256, 257]. This 
could probably explain the increased association of PUs in individuals with pneumonia in acute 
care and inpatient rehabilitation in both the RERC on SCI and SCIMS population.  
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Literature that addresses risk factors for the development of PUs generally considers all 
the medical comorbidities as one factor while assessing the potential risks [257]. Pulmonary 
embolism, deep vein thrombosis, pneumonia or atelectasis and kidney stones were some of the 
clinical factors reported by previous studies to be associated with the formation of PUs [15, 56]. 
The finding in our study is supported by previous studies that indicated association of pulmonary 
disease with the formation of PUs [19, 56]. Among the pulmonary conditions one study showed 
association between chronic obstructive pulmonary disease and formation of PUs [232]. 
Although previous studies attributed pulmonary as one of the clinical factors towards developing 
a PUs, pneumonia was not found to be a significant risk factor [22, 258]. Even though studies 
have linked pulmonary disease as a possible risk factor to develop PU their pathology is not fully 
understood. An intrinsic response associated with the presence of pneumonia may leave 
individuals with SCI immunocompromised. This predisposes them to secondary complications 
such as infections, thus causing skin breakdown. 
Ventilation perfusion ratio is the ratio of amount of air to the amount of blood reaching 
the alveoli. During the normal process of gaseous exchange, the lungs allow the oxygen from the 
inhaled air into the blood and transfer the carbon dioxide from the blood to the exhaled air [259]. 
Pneumonia is an inflammatory condition of the lung due to the infection in the alveoli. In 
individuals with pneumonia, the gas exchange functions of the lungs decline. This is initially 
localized to one lung during the early stage of the disease that causes an overall reduction in the 
alveolar ventilation. The impaired ventilation in these individuals causes an imbalance in the 
ventilation perfusion ratio. This leads to decrease in oxygen (hypoxia) and increased carbon 
dioxide (hypercapnia) in the blood. [260]. The oxygenated blood supplies oxygen and nutrients 
to the tissues. Impaired circulation due to decreased oxygen in the blood causes the tissues to 
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starve. Also, oxygen is essential for healing and repair and previous literature decreased oxygen 
in the tissue to be one of the causes of PUs [261, 262]. Studies have shown decreased oxygen to 
be a predictor for the formation of PUs [263]. This could probably explain why individuals with 
pneumonia have had increased formation of pressure ulcers as compared to individuals with no 
pneumonia. In individuals with SCI, it is essential prevent medical conditions such as pneumonia 
that affect the tissue oxygenation to implement precautionary measures that can help decrease 
the risk of occurrence of PUs.   
5.4.1 Limitations  
Given that this is an existing database, there are potential limitations in both the RERC on SCI 
and SCIMS studies. The research designs for the RERC on SCI study was secondary analysis 
and for the SCIMS study was retrospective. Hence the inherent limitations of the secondary data 
analysis should be kept in mind. In SCIMS study, the variables of interest were collected during 
the 2000-2005 time period. The longitudinal changes that have taken place in the patient-care, 
co-morbidities and patient demographics cannot be ignored. We hypothesize the association 
between presence of pneumonia and pressure ulcers in these individuals may be due to an 
intrinsic and not an extrinsic mechanism and hence this probably should not be a concern. Also, 
due to the changing focus of model systems database the measuring of the severity of injury was 
changed from Frankel’s grade to AIS in 1993. To analyze the injury severity, the Frankel’s grade 
was converted to AIS. The AIS uses sacral spring to define the incomplete injury as compared to 
Frankel’s that uses preservation of sensation at least 3 levels below the injury level. There could 
have been potential misclassification in AISA A and B.  
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The time-points for the comorbidities were not defined in the SCIMS population. Hence 
we could only see if the individuals had presence or absence of the comorbidities (pneumonia 
and pressure ulcer) and were not able comment on their causal relationship. In the RERC on SCI 
population, the sequence and timing of pneumonia and PU was considered. Individuals who had 
formation of PU within three weeks of diagnosis of pneumonia were considered in the group of 
interest whereas in the SCIMS population any individual who had presence of both pneumonia 
and PU were considered in the group of interest. Also, the data analyzed for this study for the 
RERC on SCI population was on individuals who were flowed from acute care through inpatient 
rehabilitation. The data were analyzed separately for the acute care setting and impatient setting 
for the SCIMS population. Hence both the RERC and SCI and SCIMS populations were not 
completely homogenous.  
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5.5 CONCLUSION AND FUTURE WORK 
The findings suggest an association between the presence of pneumonia and formation of 
pressure ulcer. The results indicate that a higher proportion of pressure ulcers occur in 
individuals with SCI having pneumonia. Thus, surveillance and prevention measures for pressure 
ulcers should be even more rigorous in those individuals. The association between presence of 
pneumonia and presence of PU could be because of restriction of mobility after pneumonia, 
decreased oxygenation or imbalance in the inflammatory response after presence of pneumonia. 
To investigate if the presence of pressure ulcers in individuals with pneumonia is linked through 
inflammation, a follow up study was performed (Chapter 6). Further studies should be conducted 
to test if the incidence of PU in individuals with pneumonia can be attributed to decreased 
oxygenation or mobility restriction.  
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6.0  INFLAMMATORY MEDIATORS ASSOCIATED WITH PRESSURE ULCER 
DEVELOPMENT IN INDIVIDUALS WITH TRAUMATIC SPINAL CORD INJURY 
AND PNEUMONIA 
6.1 INTRODUCTION 
Spinal cord injury is a devastating neurologic disorder that has profound impact from physical, 
psychological and socioeconomic perspectives [44]. Increase in age and severity of injury are 
associated with rise in long-term complications after traumatic SCI [79]. The second leading 
cause of death in individuals with SCI is septicemia (88.6%); usually associated with urinary 
tract infections (UTI’s), pneumonia, and/or presence of pressure ulcers [45]. Pressure ulcers 
(PUs) are the most frequent secondary complication in individuals with SCI from the time of 
acute hospitalization through community reintegration. PUs affect quality of life, length of stay 
during hospitalization and increases the mortality and morbidity [1, 7, 12, 48, 49].  
Around 200 risk factors are associated with the formation of PUs in individuals with SCI 
[8]. Many risk factors have been associated with the formation of pressure ulcers. Medical 
complications such as cardiac or renal disease were associated with the risk of developing PUs 
[8]. Individuals likely to develop PUs were those who have SCI of traumatic origin [17], males 
[18], have a history of smoking, alcohol or drug use [10], have medical comorbidities such as 
diabetes mellitus [19, 20], decreased oxygenation or hypotension [16], infections such as 
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pneumonia, urinary tract infections, osteomyelitis, and other bacterial infections [8, 21], those on 
mechanical ventilators[22] and use of steroids [16]. Moisture and/or urinary and fecal 
incontinence, hypo/hyperthermia, friction, shear, were reported to be the extrinsic risk factors 
associated with formation of PUs in individuals in acute care and intensive care unit (ICU) [16, 
19, 51-55]. Decreased nutrition or low serum albumin levels, decreased mobility and sensation, 
and impaired cognitive function contribute towards the intrinsic risk factors for the development 
of PUs in individuals with SCI [19, 20].  The SCI Quality Enhancement Research Initiative 
(QUERI) projects points out the importance and challenge in identification of all the risk factors 
in individuals with SCI and implementing corresponding preventive techniques in the clinical 
practice [34].  
Pneumonia is an inflammatory condition of the lung, specifically inflammation of the 
alveoli (microscopic air sacs in the lungs) or when the lungs are filled with fluid (called 
consolidation and exudation). There are many causes for the occurrence of pneumonia, infection 
being the most common. The infecting agents can be bacteria, viruses, fungi, or parasites [57, 
58]. Pneumonia is the most frequent respiratory complication (66.9% cases) that occurs weeks 
after the SCI [45, 59, 60]. Around 30% of individuals with SCI develop pneumonia during the 
time of hospitalization [50]. Of all the secondary conditions after SCI, pneumonia is one of the 
most frequent causes of death [46, 47]. Overall 5% to 20% of individuals with SCI develop 
pneumonia during initial rehabilitation. Studies have shown pneumonia to be associated with 
atelectasis in these subjects that alters the pattern of respiration. Prior anesthesia increases the 
risk of developing pneumonia [61]. The incidence of ventilator associated pneumonia increases 
within days of intubation for individuals on mechanical ventilation [63].  
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Subjects with high-level traumatic SCI are usually dependent on mechanical ventilation, 
and report an increase in incidence of pneumonia within days of intubation [22, 63]. Significant 
correlations between individuals with SCI having PUs and pneumonia (or atelectasis) were 
observed after 1, 2 and 5 years of injury [37]. The diaphragm is the main inspiratory muscle of 
respiration and is supplied by the phrenic nerve that originates from third and extends to fifth 
cervical nerve (C3-C5). The muscles of respiration such as the diaphragm, abdominals and 
intercostal are affected with progressively higher level of SCIs, resulting in a higher incidence of 
pneumonia in individuals with tetraplegia than paraplegia [61]. Individuals with complete 
tetraplegia have altered lung volumes and ineffective cough, and these individuals present with a 
restrictive ventilatory pattern. The alteration in lung volumes decreases the lung compliance and 
increases the cost of energy, predisposing the individual to respiratory fatigue. Therefore, higher-
level SCIs (tetraplegics at C3-C5) may produce complete respiratory paralysis [62].  
The synthesis of the inflammatory biomarkers increases in individuals with the presence 
of PUs [5], and also in individuals having respiratory infections such as pneumonia [39].  
However, an apparent association linked through inflammation has not yet been explored. 
Presence of pneumonia activates an acute inflammatory response to counteract the infection, 
which when not in balance may result in secondary complications such as PUs. TNF-α was one 
of the early mediators in the inflammatory process and induces activation of pro- and anti-
inflammatory mediators and is responsible for the protective response in pneumonia. Cytokines 
such as IL-1β, IL-6, and IL-8 were correlated with TNF-α in subjects having pneumonia [40]. 
The inflammatory response in individuals with SCI may be different during the inception of 
pneumonia and days after the presence of pneumonia; as previous studies have shown temporal 
changes in the inflammatory response from onset of pneumonia [40]. Increased concentrations of 
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IL-1 and IL-10 were also found to be associated in individuals with pneumonia [3, 39]. These 
differences in the inflammatory response may help explain the formation of PUs in these 
individuals. The aim of this study was to explore and identify the change in the inflammatory 
mediators in urine and plasma, before and after the presence of pneumonia associated with 
formation of PUs in individuals with SCI during acute care hospitalization and inpatient 
rehabilitation. We hypothesized that differences in inflammatory mediators measured before and 
after the presence of pneumonia of TNF-α, IL-1β, IL-6, IL-8 and IL-10 will indicate increased 
risk for the formation of PUs. 
6.2 METHODS 
6.2.1 Research Design 
The RERC database was used here in a secondary analysis to examine the variables and to 
explore the relationship among the clinical and demographic variables and PU outcome [80]. 
6.2.2 Inclusion and Exclusion criteria 
The inclusion and exclusion for RERC on SCI are mentioned in Chapter 2, Section 2.2.2. For 
this particular study the inclusion criteria included: 
1. Individuals with SCI recruited from the RERC on SCI population from acute care 
through inpatient rehabilitation.  
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2. For those who developed pressure ulcers, only those who developed pneumonia before 
or coinciding with the development of PU.  
3. Having inflammatory mediators collected within a week before and within a week 
after pneumonia. 
6.2.1  Data Collection and Processing of Urine and Plasma Samples 
The data collection for RERC on SCI is mentioned in Chapter 2, Section 2.2.3. The processing of 
urine and plasma samples and inflammatory mediator measurement are mentioned in Chapter 3, 
Section 3.2.4.  
6.2.2 Procedure  
The first PU was noted for the individuals with presence of pneumonia in acute care and 
inpatient rehabilitation. The time point closest to diagnosis of pneumonia; within a week before 
and after the presence of pneumonia, of the inflammatory mediators in plasma and urine was 
noted. Some inflammatory mediators such as TNF-α, IL-1β, IL-1, IL-6, IL-8 and IL-10 were 
previously identified in the literature in individuals with presence of pneumonia [3, 39, 40]. 
Additionally, predictors for analysis were included after reviewing the data collected for this 
study, and expert opinion. The outcome in this study was formation of first pressure ulcer. The 
differences of plasma (and urine) inflammatory mediators (t1- t2) between the first time point 
within a week before the onset of pneumonia (t1) and the first time point within a week after the 
onset of pneumonia (t2) were the independent variables for this study.  
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6.2.3 Data Analysis 
Two separate analyses were performed to identify the significant inflammatory mediators in 
plasma and urine. All data were analyzed using Statistical Package for Social Sciences (SPSS) 
version 20.0. Descriptive statistics using means, frequencies, and standard error of mean was 
performed for individuals included in the study to identify plasma and urine inflammatory 
mediators.  
Mann-Whitney U test 
The demographics of the two groups of subjects (those who developed PUs and those who did 
not develop PU) were compared using a Mann-Whitney U test (two-tailed); with continuous-
level variables such as age and ISS.  
Mann-Whitney U statistic is for the two groups are[88]  
U𝑃𝑈 = n𝑃𝑈n𝑁𝑂 𝑃𝑈 + n𝑃𝑈 (n𝑃𝑈 + 1)2 − R𝑃𝑈 
• U= Mann-Whitney U statistic 
• nPU is sample size of group 1 (individuals with PU) 
• nNO PU is sample size of group 1 (individuals with no PU) 
• RPU is sum of the ranks for age (or ISS) in PU group 
The Mann-Whitney U statistic (U) is the smaller of the two values calculated for UPU and UNO PU. 
The Mann-Whitney U follows a z distribution[88]. 
𝑧 = 𝑈 − 𝑛𝑃𝑈𝑛𝑃𝑈2
𝑛𝑃𝑈𝑛𝑃𝑈(𝑛𝑃𝑈 + 𝑛𝑃𝑈 + 1)12  
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Our hypotheses are:  
H0 (Null Hypothesis): The mean ranks of age (and ISS) between the two groups (individuals with 
PUs and individuals with no PUs) are expected to be the same, (or) Calculated z is between -1.96 
and 1.96 
H1 (Alternate Hypothesis): There is a difference between the ranks of age (and ISS) in the two 
groups (individuals with PUs and individuals with no PUs), (or) z < -1.96 or z > 1.96.  
The significance level was set at α = 0.05.  
Chi-Square Test 
It is a nonparametric test that is performed on nominal (gender male/female) and ordinal (ASIA 
scale score, A, B, C, D and E) data. The Chi-square statistic (two-tailed) was performed to test 
differences between the level of injury (and gender) in the two groups (those who developed PUs 
and those who did not develop PU). The chi-square statistic is[80]:  
𝜒2 = � (𝑓0−𝑓𝑒)2
𝑓𝑒
 
• fo is observed frequency of ASIA (or gender) 
• fe is expected frequency (or gender) 
Our hypotheses are:  
H0 (Null Hypothesis): The severity of injury measured by ASIA scale score (or gender) and 
individuals who developed PUs are not related. 
H1 (Alternate Hypothesis): The severity of injury measured by ASIA scale score (or gender) and 
individuals who developed PUs are related. 
The significance level was set at α = 0.05.  
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    Normalization of data 6.2.3.1
The ranges and scales for the concentrations of inflammatory mediators varied among the 
different substances making assessments of their effects difficult using the absolute values. For 
this reason, the responses for the differences of plasma (and urine) inflammatory mediators 
between the two time points (t1- t2) were transformed into percentages of the range for all each 
cytokine. This normalization technique allowed comparison between multiple inflammatory 
mediators on a common scale.  
    Logistic Regression  6.2.3.2
The logistic regression coefficients and the interpretation of these are described in Section 
2.2.5.2 and 2.2.5.3.  
Univariate Logistic Regression 
A univariate logistic regression analysis was conducted to assess individual risk factors ability to 
predict the probability of the outcome (PU, yes/no). The model is[80, 88]: 
𝐥𝐨𝐠𝐢𝐭 (𝐘) = 𝟏
𝟏 + 𝒆−(𝜷𝟎+𝜷𝟏𝑿𝟏) =  𝛃𝟎 +  𝛃𝟏𝐗𝟏 
• β0 is a constant 
• β1 is the coefficient of the individual predictor variable. 
• X1 is the inflammatory mediator (predictor) in question 
Our hypotheses are:  
H0 (Null Hypothesis): β1 = 0  
H1 (Alternate Hypothesis): β1 ≠ 0 
The significance level was set at α = 0.05. 
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Multivariate Logistic Regression 
The results from the univariate logistic regression analysis was used to identify important 
covariates that were moderately associated with the outcome (p<0.25) was used to build a 
multivariate logistic regression model [264]. One covariate at a time was included in the model 
and the importance of each variable was analyzed using Wald statistic. The variables that did not 
contribute to the importance of the model were deleted. Variables that were not initially included 
in the multivariate logistic regression model were added one by one to identify confounding 
variables. The outcome for the model was occurrence first pressure ulcer (yes/no). The model 
is[88]: 
𝐥𝐨𝐠𝐢𝐭 (𝐘) = 𝟏
𝟏 + 𝒆−(𝜷𝟎+𝜷𝟏𝑿𝟏+𝛃𝟐𝐗𝟐+⋯.𝛃𝐤𝐗𝐤) =  𝛃𝟎 + 𝛃𝟏𝐗𝟏 + 𝛃𝟐𝐗𝟐 + ⋯… + 𝛃𝐤𝐗𝒌 
• β1, β2…. βk are the regression coefficients for the independent variables of the regression 
equation.  
• X1, X2…Xk are the independent variables (risk factors in question).  
Our hypotheses are:  
H0 (Null Hypothesis): β1= β2=…. = βk (or) βi = 0  
H1 (Alternate Hypothesis): β1 ≠ 0 (or) βi ≠ 0 
The significance level was set at α = 0.05. 
    Hosmer-Lemeshow goodness of fit 6.2.3.3
The Hosmer-Lemeshow test statistic was computed; this statistic is explained in Section 2.2.5.4.  
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    Area under the Receiver Operating Characteristic (ROC) curve 6.2.3.4
The area under the ROC with the plasma inflammatory mediators will be computed and plotted. 
The area under the ROC curve and classification is explained in Section 2.2.5.5. The 
inflammatory mediators in urine were be analyzed similarly.  
6.3 RESULTS 
6.3.1 Plasma Analysis 
    Demographics 6.3.1.1
The demographics and characteristics of individuals with PU and no PU in acute care through 
inpatient rehabilitation are listed in Table 35. 
    Age and Gender 6.3.1.2
The Mann-Whitney U test detected no significant difference in ages between the two groups. 
Majority of individuals in both the groups were males. The Chi-square test detected no 
significant differences in gender distribution between the two groups. 
(a) Injury Severity 
The severity of injury is for the two groups in Table 35. There were no significant differences in 
the severity of injury ASIA and ISS between the two groups.  
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    Univariate analysis 6.3.1.3
Table 36 shows the univariate logistic regression analysis for the 23 inflammatory mediators in 
plasma. The PU outcome was dichotomized into 2 levels (0= No PU and 1=PU). The individual 
plasma mediators were not significant.  
    Correlational Analysis  6.3.1.4
A correlational analysis performed between the inflammatory mediators in plasma and formation 
of PU produced no significant results. The normalized difference between the inflammatory 
mediators before and after the presence of pneumonia in plasma (t1-t2) was not correlated with 
the formation of first PU in this population (Table 37).  
 
Table 35. Comparison of demographic population in subjects with PUs and subjects without PU 
Demographics All Subjects 
N=16 
 Subjects with 
PU 
n= 8 
Subjects with 
no PU  
n=8 
P value 
Age (years) 
Mean ± SEM 
 
37.6±4.4 35.6±6.2 39.6±6.5 0.598 
Gender 
# of subjects (%) 
M=12 
F=4 
M=6 
F=2 
M=6 
F=2 
1.00 
ASIA 
# of subjects (%) 
A=9 
B=3 
C=3 
D=0 
U=1 
A=6 
B=0 
C=1 
D=0 
U=1 
A=3 
B=3 
C=2 
D=0 
U=0 
0.149 
Injury Severity 
Score (ISS) 
Mean ± SEM 
33.8±5 36.6±6.2 31±8 0.461 
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Table 36. Univariate Regression between PU and plasma and urine inflammatory mediators  
Variables 
 
p value  
plasma_normalized 
p value  
urine_normalized 
IL-β 0.846 0.967 
IL-1RA 0.469 0.173 
IL-2 0.669 0.905 
IL-6 0.273 0.517 
IL-10 0.579 0.573 
TNF-α 0.118 0.437 
Eotaxin 0.264 0.719 
GM-CSF 0.720 0.616 
IFN-α 0.071 0.733 
IFN-γ 0.398 0.477 
IL-4 0.577 0.445 
IL-5 0.531 0.598 
IL-7 0.685 0.603 
IL-8 0.503 0.528 
IL-13 0.863 0.908 
IL-15 0.463 0.271 
IL-17 0.425 0.999 
IP-10 0.512 0.365 
MCP-1 0.881 0.330 
MIP1-α 0.425 0.738 
MIP1-β 0.652 0.341 
MIG 0.398 0.278 
NO2-/NO3- 0.436 0.988 
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Table 37. Correlations between occurrence of first PU and plasma inflammatory mediators (N=16) 
Outcome 
Plasma 
Inflammatory 
Mediators 
Point-biserial 
correlation 
coefficient 
Sig. (2-tailed) 
PU 
Eotaxin 0.31 0.243 
GM-CSF 0.257 0.336 
IFN-α 0.298 0.262 
IFN-G -0.222 0.409 
IL-1RA -0.217 0.418 
IL-1β 0.049 0.858 
IL-2 0.109 0.688 
IL-4 0.145 0.593 
IL-5 -0.168 0.533 
IL-6 0.301 0.258 
IL-7 -0.102 0.706 
IL-8 -0.171 0.526 
IL-10 -0.14 0.604 
IL-13 0.043 0.874 
IL-15 0.186 0.49 
IL-17 0.256 0.338 
IP-10 0.172 0.524 
MCP-1 -0.037 0.89 
MIP-1α -0.205 0.446 
MIP-1β -0.114 0.675 
TNF-α 0.292 0.272 
MIG -0.235 0.381 
NO2-/NO3- -0.236 0.38 
 
  
Note: The dependent variable in this analysis is formation of pressure ulcer  
0= did not have pressure ulcer and 1= had occurrence of pressure ulcer  
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   Multivariate Logistic Regression for Plasma Biomarkers- Model building strategy  6.3.1.5
A multivariate logistic regression was performed with pressure ulcer as outcome (PU present and 
no PU). The PU outcome was dichotomized into 2 levels (0= No PU and 1=PU). Table 38 shows 
the results of the best-fit multivariate logistic regression using the variables included in the 
model. All assumptions were met. There was a significant prediction of PU outcome by 
inflammatory mediators in plasma included in the final model, χ2 (3) =11.986, p=0.007. There 
was significant prediction of pressure ulcer occurrence by IFN-α (p= 0.049). The odds to develop 
PU increased 9.4 times, with a unit increase in the plasma concentration of IFN-α, after diagnosis 
with pneumonia. Although there was no significant prediction of PU outcome by IL-7 (p=0.2) 
and MIP-1α (p=0.2) they were included in the final multivariate model since they accounted to 
be confounding variables and the model fit increases with the inclusion of these variables.  
   Hosmer-Lemeshow test statistic 6.3.1.6
There was no significant differences between the observed and predicted group membership, 
Hosmer-Lemeshow χ2 (6) =8.081, p= 0.23. This means that there is a good overall fit of the 
multivariate logistic regression model and that there is no misspecification of the predictors.  
    Area under the Receiver Operating Characteristic (ROC) curve 6.3.1.7
The area under the curve for the plasma inflammatory mediators included in the multivariate 
logistic regression model is 0.938 (Figure 23) with 95% confidence interval (0.82, 1.000). Also, 
the area under the curve is significantly different from 0.5 since p <0.001 (Table 39).  
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Table 38. Multivariate Logistic Regression of the difference in plasma predictors before and after pneumonia 
(t1—t2) 
Independent 
Variables 
B SE Wald Sig (p) Exp(B) 
IFN- α 2.237 1.14 3.88 0.04* 9.36 
IL-7 -0.06 0.04 1.88 0.17 0.94 
MIP-1α 
 
-0.54 0.05 1.38 0.24 0.94 
Constant 
 
-4.69 4.55 1.06 0.3 0.009 
Model χ2    = 11.99, p=0.007** 
Pseudo R2  = 0.703 
n                 = 16 
 
 
Note: The dependent variable in this analysis is formation of pressure ulcer in acute care or inpatient 
rehabilitation, so that 0= did not have pressure ulcer and 1= had a formation of pressure ulcer  
*p< 0.05 
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Figure 23. ROC Curve for Multivariate Logistic Regression Model for plasma biomarkers in individuals with 
pneumonia 
 
Table 39. Area under the Curve for Multivariate Logistic Regression Model for plasma predictors in 
individuals with pneumonia 
 
Area 
 
Std. Error  
 
Sig  
Asymptotic 95% Confidence Interval 
Upper Bound Lower Bound 
0.938 0.059 0.003** 0.882 1.000 
  Test Variable (s): Predicted probability 
 
Note: *p< 0.05,  
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6.3.2 Urine Analysis 
    Demographics 6.3.2.1
The demographics and characteristics of individuals with PU and no PU in acute care through 
inpatient rehabilitation are listed in Table 40. 
    Age and Gender 6.3.2.2
The mean age for individuals with no formation of PU was 37 years and for the individuals with 
PU 36 years. Mann-Whitney U test detected no significant difference in ages between the two 
groups. Majority of individuals in both the groups were males. Chi-square test detected no 
significant differences in gender distribution between the two groups. 
(a) Injury Severity 
The severity of injury is for the two groups in Table 40. There were no significant differences in 
the severity of injury ASIA and ISS between the two groups. 
    Univariate Logistic Regression 6.3.2.3
Table 36 shows the univariate logistic regression analysis for the 23 inflammatory mediators in 
urine. The PU outcome was dichotomized into 2 levels (0= No PU and 1=PU). None of the 
individual urine inflammatory mediators were significant in the univariate analysis.  
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    Correlational Analysis  6.3.2.4
A correlational analysis performed between the inflammatory mediators in urine and formation 
of PU produced no significant results. The difference between the inflammatory mediators 
before and after the presence of pneumonia in plasma was not correlated with the formation of 
first PU in this population (Table 41).  
 
Table 40. Comparison of Demographic population in subjects with PU and subjects without PU 
Demographics All subjects 
N=15 
 Subjects with 
PU 
n=8 
Subjects with 
no PU  
n=7 
P value 
Age (years) 
Mean ± SEM 
 
36.4±4.5 35.6±6.2 37.2±7 0.816 
Gender 
# of subjects (%) 
M=11 
F=4 
 
M=6 
F=2 
 
M=5 
F=2 
 
0.876 
ASIA 
# of subjects (%) 
A=9 
B=3 
C=2 
D=0 
U=1 
 
A=6 
B=0 
C=1 
D=0 
U=1 
 
A=3 
B=3 
C=1 
D=0 
U=0 
 
0.175 
Injury Severity 
Score (ISS) 
Mean ± SEM 
35.7±5 36.6±6.2 34.6±8.3 0.727 
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Table 41. Correlations between occurrence of first PU and urine inflammatory mediators (N=15) 
Outcome 
Urine 
Inflammatory 
Mediators 
Point-biserial 
correlation 
coefficient 
Sig.  
(2-tailed) 
PU 
Eotaxin 0.094 0.739 
GM-CSF 0.131 0.641 
IFN-α 0.089 0.753 
IFN-G 0.276 0.319 
IL-1RA 0.325 0.237 
IL-1β 0.011 0.97 
IL-2 -0.031 0.913 
IL-4 -0.264 0.341 
IL-5 -0.143 0.611 
IL-6 0.359 0.189 
IL-7 -0.137 0.627 
IL-8 -0.171 0.542 
IL-10 -0.29 0.295 
IL-13 -0.03 0.915 
IL-15 0.353 0.197 
IL-17 0.372 0.172 
IP-10 0.252 0.364 
MCP-1 0.289 0.296 
MIP-1α 0.087 0.758 
MIP-1β 0.263 0.343 
TNF-α 0.268 0.335 
MIG 0.446 0.096 
NO2-/NO3- 0.004 0.989 
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    Multivariate Logistic Regression for Urine Biomarkers- Model building strategy 6.3.2.5
Table 42 shows the results of the multivariate logistic regression using the variables included in 
the model. Multivariate logistic regression was performed with pressure ulcer as outcome (PU 
present and no PU). The PU outcome was dichotomized into 2 levels (0= No PU and 1=PU) and 
three predictors: IL-1RA, IL-2 and IFN-α. All assumptions for logistic regression were met. 
There was a significant prediction of PU outcome by all inflammatory mediators in urine 
included in the final model, χ2 (7) = 13.87, p=0.003. There was some prediction of pressure ulcer 
occurrence by IL-1RA (p= 0.073). The risk to develop PU increased 9.9 times with increased 
urine concentrations of IL-1RA after pneumonia. There was no significant prediction of pressure 
ulcer occurrence by IL-2 (p=0.1), and IFN-α (p=0.1).  
    Hosmer-Lemeshow test statistic 6.3.2.6
There was no significant differences between the observed and predicted group membership, 
Hosmer-Lemeshow χ2 (6) =3.109, p= 0.795. This means that there is a good overall fit of the 
multivariate logistic regression model and that there is no misspecification of the predictors.  
    Area under the Receiver Operating Characteristic (ROC) curve 6.3.2.7
The area under the curve for the urine inflammatory mediators included in the multivariate 
logistic regression model is 0.946 (Figure 24) with 95% confidence interval (0.83, 1.000). Also, 
the area under the curve is significantly different from 0.5 since p value is <0.001 (Table 43).  
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Table 42. Multivariate Logistic Regression of the difference in urine predictors before and after pneumonia 
(t1-t2) 
INDEPENDENT 
VARIABLES 
B SE WALD SIG (P) EXP(B) 
IL-1RA 2.297 1.279 3.225 0.07 9.94 
IL-2 -0.479 0.327 2.147 0.14 0.62 
IFN-α -0.39 0.251 2.424 0.12 0.67 
Constant 
 
24.14 19.85 1.479 0.22 3.0410 
Model χ2    = 13.87, p= 0.003 
Pseudo R2   = 0.806 
n                 = 15 
 
 
Note: The dependent variable in this analysis is formation of pressure ulcer in acute care or inpatient 
rehabilitation, so that 0= did not have pressure ulcer and 1= had a formation of pressure ulcer  
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Figure 24. ROC Curve for Multivariate Logistic Regression Model for urine biomarkers in individuals with 
pneumonia 
 
 
Table 43. Area under the Curve for Multivariate Logistic Regression Model for urine predictors in 
individuals with pneumonia 
 
Area 
 
Std. Error  
 
Sig  
Asymptotic 95% Confidence Interval 
Upper Bound Lower Bound 
0.946 0.06 0.004** 0.829 1.000 
  Test Variable (s): Predicted probability 
 
Note: *p< 0.05,  
 
 193 
 
6.4 DISCUSSION 
The aim of the current study was to investigate if in individuals with pneumonia the formation of 
PUs could be linked through inflammation. We hypothesized that the formation of PU in these 
individuals would be associated with differential presence of the inflammatory mediators. The 
findings of this study showed increase in the plasma synthesis of IFN-α and urine synthesis of 
IL-1RA associated with the formation of first PU in individuals with SCI and pneumonia. An 
association between presence of pneumonia and formation of PU in both RERC on SCI 
population and SCIMS populations was shown in Chapter 5.0 . Prior studies indicate that plasma 
inflammatory mediators to play an important role in the pneumonia [265-269] and pressure ulcer 
[4, 32, 74]. This is a first study to investigate the inflammatory mediators in plasma associated 
with formation of PUs in individuals with PUs after formation of pneumonia.  
In this study, the odds of developing PUs in individuals with SCI and pneumonia increase 
by nine times with a unit increase plasma concentrations of IFN-α.  IFN-α belongs to the Type 1 
interferon group. IFN-α activates the immune cells during infection, by stimulating the T 
lymphocytes and macrophages. Interferons are a part of the innate immune system and known to 
participate in the first line of defense against the pathogens before the specific immune system 
responds. They benefit the host by resisting infection and inflammation initiated after trauma. 
They are produced when the host is subjected to a viral infection or any other pathogen binding 
to the viral cell to induce an antiviral state. [238]. Interferon therapy is used to stop or slow the 
growth of tumor cells, leukemia, melanoma, sarcoma, carcinoma [239], hepatitis [240], and thus 
protect the immune system. During a physiological response, the timely interactions of the 
specific cytokine and the receptor help to control the inflammation and thus prevent secondary 
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complications that may occur after a traumatic SCI. Interferons also have an ability to up 
regulate other cytokine responses [238]. Although there is not much evidence about the role of 
IFN-α in individuals with SCI, type I interferons have been reported to contribute to promote 
functional activity after SCI as they inhibit the astrocytes that are responsible in the secondary 
cellular response after SCI [241].  Increased concentrations of IFN-α has been also been shown 
to be associated development and exacerbation of pneumonia [270-272]. While the role of IFN-α 
in individuals with SCI having pressure ulcers remains not elucidated, we hypothesize that the 
increase in plasma concentrations of IFN-α after pneumonia generates an imbalance in the 
inflammatory response in the immune system and thus predispose these individuals with 
formation of PUs.  
Although urine is a useful portal for measuring the excretion of inflammatory mediators, 
not much evidence is reported on imbalance in the urine synthesis of inflammatory mediators in 
the literature in subjects with pneumonia and PU. Increased concentrations of urinary leukotriene 
were associated with pneumonia [273]. This is a first study to explore the inflammatory 
mediators in urine associated with formation of PUs in individuals with PUs after formation of 
pneumonia.  
The odds to develop PU in individuals with SCI and pneumonia increase by ten times 
with a percent increase in the urine concentrations of IL-1RA. IL-1RA belongs to the 
interleukin-1 cytokine family, secreted by neutrophils is involved in wound healing and 
inflammation[115]. It is an anti-inflammatory cytokine and inhibits the synthesis of IL-1 [165]. 
Increased plasma and/or urine levels of IL-1RA were associated with sepsis [166], rheumatic 
diseases and osteoporotic fractures [167, 168], and schizophrenia [169]. IL-1RA had been used 
as a therapeutic intervention is individuals, cancer [170]  and neuropathy [171]. Increase in the 
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plasma concentrations of IL-1RA were noted in individuals subjected to trauma and during 
infections [165]. IL-1RA was identified as one of the early markers for mechanically induced 
epidermal damage [71]. Although IL-1RA is used to treat individuals with pneumonia by 
blocking IL-1 and other pro-inflammatory mediators, studies show increase in the IL-1RA 
blockage increases mortality[274]. Studies also indicate elevation of anti-inflammatory cytokines 
such as IL-1RA in plasma at the time of admission in individuals with community associated 
pneumonia[275]. In this study the increased urine concentrations of IL-1RA were associated 
with the formation of first PU after the presence of pneumonia in individuals with TSCI. IL-1RA 
maintains homeostasis throughout the acute inflammatory response after SCI, by maintaining a 
balance between the pro and anti-inflammatory mediators (IL-1 and IL-1RA); it thus influences 
the host immune response to the traumatic event [172].  
The model building strategy in this study was developed using the results from the 
univariate analysis since the predictor variables were highly collinear with one another. This 
model building technique avoided large standard errors, effects of multicollinearity, and error 
messages from the fitting program as compared to the stepwise logistic regression technique 
because of multicollinearity and redundancy of the predictor variables.  
Additional large scale studies are necessary to confirm, explore and further clarify the 
role of these inflammatory mediators in individuals with SCI and pneumonia in the pathogenesis 
of pressure ulceration.  
 
 196 
 
6.4.1 Limitations 
The analysis for this study was performed from an existing database hence, potential limitations 
needs to be addressed. The sample size in this study was relatively small. The number of subjects 
for this proposed aim in the existing database is 16 for the plasma inflammatory predictors and 
15 for the urine inflammatory predictors. Given the small number of observations and large 
number of predictor variables the collinearity between the predictor variables was considerably 
large. Adding multiple predictors increased the chances of Type II error; hence univariate 
analysis was used in the model building strategy. Given the small sample size, and large number 
of independent variables the one-way interactions between the variables were not included in the 
model building procedure. It would be interesting to study the one-way interactions between the 
predictor variables along with the main effects.  
This study analyzed the concentrations of the mediators between the two time points 
(difference between the mediators before and after pneumonia). Since temporal time points were 
not studied we may have failed to capture some of the inflammatory mediators. Given the limited 
sample size we included individuals with presence of pneumonia coinciding and preceding with 
the first pressure ulceration. In this process the inflammatory pattern right before the formation 
of pneumonia may have been missed.  
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6.5 CONCLUSION 
This study explored the relationship between inflammation and pressure ulcers in individuals 
with SCI diagnosed with pneumonia. Increased plasma concentrations of IFN-α and increased 
urine concentrations of IL-1RA were shown to be associated with PU formation in individuals 
with SCI and pneumonia. The results of this study suggest that inflammation may play a role in 
formation of PUs in individuals with SCI and pneumonia. Future studies are required to 
investigate the further potential of these mediators in the pathogenesis of PUs in this population. 
Although further investigation is essential, this study suggests that urine and plasma biological 
fluids can aid the diagnosis of pressure ulceration in individuals with SCI and pneumonia.  
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7.0  SUMMARY AND OUTLOOK 
An increased incidence of pressure ulcers (PUs) is observed in individuals with spinal cord 
injury (SCI) during hospitalization. Although many clinical factors are associated with the 
formation of PUs, very few studies have investigated the associated risk factors during acute care 
hospitalization and inpatient rehabilitation. Traumatic SCI induces an increased synthesis of pro-
inflammatory and anti-inflammatory mediators at the site of injury. These mediators spill out 
into blood circulation due to the disrupted blood-spinal cord barrier.  Any imbalance in secretion 
and concentrations of these inflammatory markers predisposes the individual to secondary 
complications such as pneumonia, urinary tract infections (UTIs) and other infections. 
Individuals with SCI, especially higher-level injuries, dependent on mechanical ventilation are 
predisposed to acquire pneumonia. The body’s immune system counteracts these infections by 
synthesizing pro-inflammatory cytokines such as IL-1 and TNF-α, and anti-inflammatory 
cytokines such as IL-10 and IL-1RA to reduce injury. Decreased or excessive inflammatory 
response to counteract the effects after SCI results in inadequate or maladaptive response, which 
predisposes the body to secondary injury and dysfunction (Figure 25).  
In this dissertation the demographic, medical comorbidities and inflammatory factors 
associated with the risk of formation of PUs in individuals with newly traumatic SCI were 
studied. This research study also explored the relationship between presence of pneumonia and 
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development of PU, linked through inflammation. A secondary analysis was performed on the 
data collected for the RERC on SCI Center from acute care hospitalization through inpatient 
rehabilitation. The following specific aims were examined and corresponding hypotheses tested: 
 
Figure 25.  Inflammatory responses post trauma (TR Billar, unpublished) 
 
Specific aim 1 (Chapter 2): 
The aim was to identify the demographic factors and medical comorbidities associated with 
formation of the first pressure ulcer. The factors to be included were identified through a 
literature review, expert opinion and by reviewing the data collected on medical and 
demographic information for individuals enrolled in the RERC on the SCI. A total of 104 
individuals with traumatic SCI were followed in acute care hospitalization and inpatient 
rehabilitation. Thirty-eight percent of individuals developed at least one PU in these settings. 
After performing a univariate logistic regression analysis; age, gender, severity of spinal cord 
injury graded by the ASIA impairment scale (AIS), and medical comorbidities viz., pneumonia, 
UTI, steroids and diabetes were included in a multivariate logistic regression model. The 
outcome measure for the study was formation of the first pressure ulcer. There was a significant 
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prediction of PU outcome by the clinical and demographic factors included in the multivariate 
model. Increased severity of spinal cord injury was associated with formation of first PU. 
Subjects with ASIA A were five times more likely to develop a pressure ulcer as compared to 
subjects with ASIA B, and Subjects with ASIA A were six times more likely to develop a 
pressure ulcer as compared to subjects with ASIA C. Although pneumonia was not significant in 
the multivariate the model, this was the only medical comorbidity that predicted occurrence of 
PU in the univariate analysis.  
 
Specific Aim 2 (Chapter 3): 
Inflammatory response following SCI may be detrimental and can predispose the individual to 
secondary complications and comorbidities. The inflammatory mediators in plasma and urine 
immediately (within four days) after SCI were explored that can aid in predicting the formation 
of pressure ulcers. In this study, twenty-three inflammatory mediators in plasma and urine 
biofluids were assayed using Luminex. Two separate analyses were performed to identify the 
inflammatory mediators in plasma (54 observations) and urine (53 observations). A backward 
stepwise logistic regression model was built to explore the mediators. Decreased plasma 
concentrations of IL-17, IFN-γ IL-1RA, MIP-1β and MIG; and increased plasma concentrations 
of IL-5, GM-CSF and MIP-1α were associated with later development of pressure ulcer. The 
odds to develop PU increased by 1.3 and 1.2 times with a unit increase in the plasma 
concentrations of MIP-1α and GM-CSF, respectively. Decreased urine concentrations of IL-17, 
IL-8, IL-13, MCP-1 and TNF-α; and increased urine concentrations of IL-5, IFN-γ, MIG, IL-6 
and IP-10 were associated with later development of PU. The odds to develop PU increases by 
1.6 and 1.2 times, respectively, with a unit increase in urine concentrations of IFN-γ and MIG 
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within four days after injury. The findings of this study imply the high degree of 
immunoactivation and complex inflammatory cascade, following traumatic SCI, may predispose 
these individual to PUs.  
 
Specific Aim 3 (Chapter 4): 
The aim was to identify significant changes in the concentrations of inflammatory mediators in 
plasma and urine within four days after injury as compared to just before the formation of the 
first PU.  Wilcoxon signed rank test between the baseline measures (within four days of SCI) and 
the earliest time point from within a week before the formation of PUs were performed on 
inflammatory mediators in urine and plasma for individuals with recorded formation of PUs. An 
increase in the plasma concentrations of IP-10 and a decrease in the urine concentrations of IFN-
α were observed just before formation of the first pressure ulcer in individuals with PUs. 
Thereby suggesting these mediators in plasma and urine could help detect imminent pressure 
ulceration.  
 
Specific aim 4 (A) - (1) (Chapter 5): 
The aim was to identify the dependent and pneumonia associated with development of PUs in 
this population. It was motivated by the lack of available literature focusing on the apparent 
association between pneumonia and pressure ulcer formation. Phase 1 of this chapter was a 
preliminary study involving eighty-six subjects in the RERC on SCI population devoted to 
investigate any association between the presence of pneumonia and the formation of PU. The 
individuals were grouped according to sequence and timing of presence of pneumonia and PU 
incidence into four groups: (1) Pneumonia and no PU within three weeks (2) PU and no 
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pneumonia preceding the ulcer (3) Pneumonia coinciding with or preceding the ulcer within 
three weeks and (4) No PU and no pneumonia. Three weeks was chosen to allow the PU ulcer to 
occur within the time course of resolution of pneumonia. Chi-squared test revealed a significant 
association between pneumonia and the development of PUs as compared to no pneumonia. The 
risk to develop PUs in individuals diagnosed with pneumonia was twice as compared to the 
individuals who did not have pneumonia.  
 
Specific aim 4 (A) - (2) (Chapter 5): 
The aim of Phase 2 was to explore the data in a larger population obtained from the SCI Model 
Systems (SCIMS), through the National Spinal Cord Injury Database, to confirm the results 
obtained in the Phase 1 of the study. The chi-squared analysis performed in the SCIMS 
population of 3,887 individuals in acute care hospitalization and 11,022 individuals in the 
inpatient rehabilitation confirmed the association between presence of pneumonia and formation 
of PUs. The risk of developing PUs for these individuals with presence of pneumonia in acute 
care population and inpatient rehabilitation was thrice and twice respectively as compared to 
individuals who did not have pneumonia. Increased severity of SCI results in airway compromise 
and/or pneumonia, which are managed by mechanical ventilation. Decreased movement during 
acute care hospitalization and mechanical ventilation could compromise these individuals with 
SCI to develop PUs.  
 
Specific Aim 4 (B) (Chapter 6): 
These results of Aim 4(A) and 4(B) study thus lead to the development of a mechanistic study on 
the relationship between the two conditions. Inflammatory mediators were known to be 
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associated with the presence of pneumonia. Hence, the aim of Chapter 6 was to investigate if the 
association between pneumonia and PU shown in Chapter 5 could be associated with differential 
presence of the inflammatory mediators in plasma and urine. Twenty-three inflammatory 
mediators in plasma and urine biofluids were assayed using Luminex. The changes in the 
concentrations of the inflammatory mediators before and after diagnosis of pneumonia (t1-t2) 
were posited to predict the formation of first PU. Two separate analyses were performed to 
identify the mediators in plasma (16 observations) and in urine (15 observations). The data on 
the difference between the mediators before and after pneumonia (t1-t2) were normalized. A 
multivariate logistic regression model was built for both plasma and urine predictors from the 
results obtained from the univariate logistic regression analysis. There was a significant 
prediction of PU outcome by the inflammatory mediators in plasma and urine that were included 
in the multivariate model. The results of this study showed that the increased plasma 
concentrations of IFN-α and urine concentrations of IL-1RA after diagnosis with pneumonia 
were associated with the formation of the initial PU in individuals with SCI and pneumonia. 
Increase in a unit of plasma concentration of IFN-α increased the odds of developing PU by nine 
times. Increase in a unit of urine concentration of IL-1RA increased the odds of developing PU 
by ten times. These findings suggest an association between the presence of pneumonia and 
formation of PU could be linked through inflammation.  
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Conclusions and Future Research Implications: 
Pneumonia and increased severity of spinal cord injury were associated with the formation of 
first PU following traumatic SCI. Although the concentrations of plasma inflammatory mediators 
associated with disease and injury is well established, not many studies have explored the urine 
concentrations of these mediators. The results shown in this study strengthen the association of 
the plasma inflammatory mediators with occurrence of PUs in individuals with traumatic SCI. 
The systemic effects of these inflammatory mediators can potentially be diagnostic markers and 
supplement in early detection of pressure ulcers. The study also showed concentrations of urine 
inflammatory mediators associated with formation of PUs.  
  
Near Future Priorities 
The results of this study should be cross-validated in a larger population. The 
inflammatory responses after traumatic SCI are multifaceted; it would therefore be of interest to 
further investigate the temporal evolution associated with the inflammatory mediators via 
principal component analyses and/or factor analyses, to identify the inflammatory patterns 
associated with occurrence of PUs. We also hope to model the effect of time evolution of 
inflammatory mediators on PU and pneumonia outcomes. We also seek to find a multivariate 
logistic regression model that involves relatively 2 (perhaps 3-4 mediators) and their two factor 
interactions that will be useful to predict the pressure ulcers. This would help confirm the 
pathogenesis of PUs. We also will pursue analyzing the association of inflammatory mediators 
with UTI outcomes. 
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Long term Priorities 
From the results obtained in this study the next step would be to explore the mediators’ specific 
to pressure ulceration in different patient cohorts. It will be interesting to study other risk factors 
such as the Braden Scale score at admission, pain and Patient Health Questionnaire-9 (depression 
scale) at admission. An immune response is usually activated immediately following SCI that 
increases the synthesis of pro-inflammatory and anti-inflammatory mediators. Future studies 
capturing the inflammatory mediators activated hours after SCI should be investigated. It is 
postulated that the time of collection of plasma and urine samples plays a critical role and as 
such it is imperative that forthcoming studies should control for time variations in data collection 
between subjects.  The pattern of these mediators should be compared in healing and non-healing 
PUs. Further research is essential to investigate possible intervention strategies and develop an 
objective risk prediction tool to identify individuals at risk to develop pressure ulcers. Additional 
mediators such as the chromatin- associated protein high-mobility group box 1 (HMGB1), which 
is a damage-associated molecular pattern molecules (DAMPs) could be analyzed in these plasma 
and urine samples.  
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